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Abstract 
Ischaemic heart disease (IHD) remains the leading cause of morbidity and mortality 
worldwide. During ischaemia, coronary perfusion is interrupted which triggers 
oxidative stress due to the imbalance between free radical generation and/or inadequate 
antioxidant defense and increased cardiomyocyte apoptosis which contributes to 
ventricular remodelling and deterioration in cardiac function. The primary clinical 
strategy is to quickly restore blood flow to the heart muscle (myocardial reperfusion), 
although this may induce further injury known as myocardial reperfusion injury. During 
ischaemia and reperfusion several processes are activated which include sodium and 
calcium overload, generation of reactive oxygen species (ROS) while myocardial 
antioxidant defence systems are impaired, activation of immediate stress-related gene 
transcription, autophagy and cell death processes, apoptosis and necrosis leading to 
further aggravated cardiac damage.  
 
Advances in treatment strategies have decreased mortality rates although myocardial 
infarction still remains one of the leading global burdens of disease and hence further 
studies are required to identify additional mechanisms involved. Therefore the first aim 
of this thesis was to develop an experimental model of myocardial infarction (MI). This 
was achieved by using the ex-vivo rat heart and inducing MI to determine direct effects 
of treatment without interference by circulatory reflexes. Hearts were isolated from 
anaesthetised male Sprague Dawley (SD) rats and perfused on a Langendorff apparatus. 
Following a stabilisation period, hearts were subjected to regional ischaemia by 
occluding a branch of the left coronary artery (30 minutes) and then releasing the 
occlusion and allowing reperfusion (150 minutes). Increased levels of superoxide and 
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oxidised glutathione (GSSG) with activated cellular pathways autophagy and apoptosis, 
comparable to previous studies validated this model of MI. Although there were 
increased expression levels of autophagy proteins (Beclin-1, Atg5-Agt12 conjugate, 
LC3-II), there was also activation of pro-apoptotic proteins (caspase-3, caspase-9), with 
suppression of anti-apoptotic proteins (B-cell lymphoma-2 (Bcl-2), X-linked inhibitor 
of apoptosis protein (XIAP) and anti-apoptotic repressor protein with a caspase domain 
(ARC)), leading to increased cardiomyocyte apoptosis and aggravated infarct size. 
 
The incidence of IHD in men is twice that of age-matched women, although most 
studies focus on protection by oestrogen, with less attention on androgen receptor (AR) 
mediated actions. Expression levels of mineralocorticoid receptors (MR) have been 
shown to increase in MI and heart failure, which may also contribute to cardiac damage, 
although there have been no previous studies whether there is sexual dimorphism of MR 
expression following myocardial ischaemia-reperfusion (I-R) injury. The second aim 
for this thesis was to determine the role of androgens in the sex differences in cardiac 
damage during MI and whether there are gender differences in expression levels of MR.  
 
Studies were in age-matched male and female SD rats either intact or surgically 
gonadectomised (Gx) ± hormone replacement with testosterone, as androgen 
replacement, or 17-oestradiol as oestrogen replacement via subdermal silastic 
implants; a subset of male rats received dihydrotestosterone. After 21 days, hearts were 
subjected to ex-vivo myocardial I-R. Hearts from intact males had larger infarcts than 
hearts from intact females following I-R; Gx produced the opposite effect, suggesting a 
key role for sex steroid action during MI. Levels of MR did not significantly change 
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during the various treatments suggesting gonadal steroids do not modify MR 
expression. Novel mechanisms were identified for I-R induced aggravated cardiac 
damage in male animals through increased AR and receptor for advanced glycation end 
products (RAGE) expression shifting the balance between autophagy and apoptosis 
towards increased apoptosis. In contrast, myocardial I-R in females produced less 
cardiac damage reflecting enhanced autophagy and decreased apoptosis. RAGE 
expression is the key regulator of this switch since testosterone administration to 
females, aggravated cardiac damage during myocardial I-R which was mediated by 
upregulation of AR and RAGE expression. This may be relevant for postmenopausal 
women receiving testosterone and also provide a platform for tailored therapeutic 
strategies. 
 
Primary treatment strategies for MI are directed to timely restoration of blood flow to 
the ischaemic myocardium using drug therapy (thrombolytics) or catheter procedures 
(percutaneous coronary intervention, PCI), however a high incidence of mortality 
persists and hence additional treatment strategies are needed. Elevated plasma levels of 
aldosterone during PCI for MI are an independent risk factor for mortality therefore 
targeting aldosterone or minarealocorticoid receptors (MR) is an important therapy 
strategy. Our laboratory has previously shown aldosterone aggravated cardiac damage 
during experimental MI, which was mediated via its cognate receptor MR. The next aim 
was to determine whether this aggravated cardiac damage involved genomic signalling 
pathways through the intracellular MR alone or whether there non-genomic pathways 
involved the G protein–coupled receptor 30 (GPR30), which has not been previously 
reported.  
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Aldosterone (Ald) and the membrane impermeable aldosterone-3-
carboxymethoxylamine-TFP ester reacted with an 8-branched PEG amine (Aldo-PEG) 
were used in rat ventricular myoblast cells H9c2 and ex-vivo I-R in rat hearts. Both Ald 
and Aldo-PEG ligand activated extracellular signal-regulated kinase 1/2 (ERK1/2) 
phosphorylation in H9c2 cells, confirming biological activity of the Aldo-PEG ligand 
and comparable to that of the GPR30 selective agonist, G1. The specific GPR30 
antagonist, G36, but not MR antagonist, spironolactone, prevented Ald and Aldo-PEG -
induced ERK1/2 phosphorylation suggesting these rapid non-genomic actions of Ald 
were mediated via GPR30. In contrast, only Ald increased transcript levels of MR-
responsive genes serum/glucocorticoid regulated kinase-1 (Sgk-1) and plasminogen 
activator inhibitor type-1 (PAI-1). In separate ex-vivo I-R studies in rat hearts, Ald (10 
nM) increased infarct size and aggravated apoptosis, whereas Aldo-PEG (10 or 100 nM) 
had no effect. These studies suggest that aldosterone aggravated cardiac damage during 
reperfusion injury requires activation of genomic pathways. 
 
Blockade of MR prevents aldosterone-aggravated cardiac damage and has been shown 
to be an effective treatment strategy in both experimental and clinical studies. Large 
randomised trials have shown MR antagonists (spironolactone or eplerenone) added to 
standard therapy reduced morbidity and mortality in patients with heart failure and heart 
failure post MI, although the mechanisms were not fully defined. In these trials, the 
levels of plasma aldosterone were within the normal range and low doses of MR 
antagonists were used. Therefore the next aim was to identify how MR blockade alone, 
in the absence of other corticosteroids, may prevent cardiac damage during myocardial 
I-R. Dose response studies for MR antagonists, spironolactone and eplerenone showed 
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that low doses of MR antagonists (10 nM spironolactone and 100 nM eplerenone) 
reduced infarct size. Low dose MR antagonists prevented degradation of anti-apoptotic 
protein ARC, which prevented initiation of apoptosis and provides a novel mechanism 
for low-dose MR blockade during I-R. 
 
Since redox signaling during myocardial I-R regulates both apoptosis and stress 
response pathways, the final aim was to determine whether low-dose MR blockade may 
also regulate redox balance and immediate early gene transcription to protect the 
myocardium during I-R. Low-dose spironolactone during I-R decreased superoxide 
levels, maintained redox balance and prevented I-R induced activation of immediate 
early gene transcription. In separate studies, H9c2 cells were exposed to low dose 
spironolactone during oxidant stress simulated using the pro-oxidant agent buthionine 
sulfoximine (BSO). The antioxidant effects of low-dose spironolactone were maintained 
whereas oxidative stress enhanced expression of MR-responsive genes (Sgk-1 and PAI-
1) were prevented, indicating ligand-independent MR regulation. These studies suggest 
that the cardioprotective effects of SPIRO involve both a reduction in ROS formation as 
well as blockade of MR activation. 
 
In summary the results from these studies provide the mechanisms for low dose MR 
antagonists to protect the myocardium during MI. The novel findings in this thesis 
provide direct evidence that these agents have actions beyond preventing ligands access 
to the mineralocorticoid receptor and for including MR antagonists as standard 
treatment regimens in conditions where there is increased oxidative stress and 
apoptosis. 
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1.1 Overview of ischaemic heart disease 
Ischaemic heart disease [IHD; also known as coronary heart disease (CHD)] is the 
leading cause of morbidity and mortality worldwide (Mathers and Loncar, 2006). 
According to a World Health Organisation report, IHD accounts for approximately 7.25 
million (representing 12.8 %) of all deaths (WHO, 2011). In Australia, IHD accounted 
for 22,729 (17%) of all deaths and is responsible for approximately 49% of 
cardiovascular deaths in 2007 (AIHW, 2011). The current best practice for treatment of 
patients with IHD is to re-establish blood flow using primary percutaneous coronary 
intervention (PCI) (Bhatt, 2013), antiplatelet therapy (Boden et al., 2013; Lippi et al., 
2013), coronary artery bypass graft surgery (Doggrell, 2013; O'Gara et al., 2013; Sa et 
al., 2013) and recently stem cell-based therapy (Assmus et al., 2010; Bozdag-Turan et 
al., 2012; Dill et al., 2009; Surder et al., 2010; Turan et al., 2011). These treatments 
allow the restoration of coronary artery blood flow to the myocardium and improve 
cardiac function in patients with IHD. Despite improvements over the last few decades, 
IHD still remains one of leading global burdens of disease (Forouzanfar et al., 2012). 
 
There are a large number of risk factors that may contribute to an even greater medical 
and social burden of IHD in the future. These risk factors include diabetes, hypertension 
(Juarez-Herrera and Jerjes-Sanchez, 2013), coronary artery calcification (Budoff et al., 
2013), smoking, hypercholesterolemia, hyperlipidemia, obesity and physical inactivity 
(Migliaresi et al., 2007; Ram and Trivedi, 2012). Several public health initiatives and 
implementation of  new reperfusion strategies and therapeutics have been effective in  
improving the quality of life for patients with IHD and reducing associated mortality  
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(Borden et al., 2012; Bradley et al., 2012; Darling et al., 2013; Heitzler et al., 2012; Isik 
et al., 2012; Morel et al., 2012; Niles et al., 2010; Purim-Shem-Tov et al., 2012).  
 
1.2 Definition of myocardial ischaemia-reperfusion injury 
Myocardial ischaemic injury occurs when blood supply to the heart muscle is 
interrupted, generally due to occlusion or blockade of coronary arteries, resulting in 
reduced levels of oxygen and nutrients. This leads to cardiac muscle damage and 
cardiomyocyte death, known as myocardial infarction (MI). Acute myocardial 
infarction (AMI) can be the first indication of IHD (Manfroi et al., 2002; Shirani et al., 
1994; Zucker et al., 1997). Rapid restoration of blood flow (reperfusion) is needed for 
myocardial salvage, and improves survival after myocardial ischaemia (Braunwald, 
1989; Miura et al., 2002; Ndrepepa et al., 2010). However, the reperfusion of ischaemic 
tissue itself is deleterious and can exacerbate damage (Hausenloy and Yellon, 2013; 
Yellon and Hausenloy, 2007). This damage is referred to as “ischaemia-reperfusion 
injury” or “reperfusion-induced injury”. Ischaemia-reperfusion (I-R) injury can trigger 
contractile dysfunction and cardiac stunning (Miura et al., 1991), arrhythmias (Tan et 
al., 1998), oxidative stress (Inafuku et al., 2012; Robin et al., 2007), endothelial 
dysfunction and cell death (Gottlieb, 2011; Scarabelli et al., 2002).  
 
1.3 Mechanisms of myocardial I-R injury 
The pathogenic mechanisms contributing to myocardial I-R injury are complex and 
induced by both ischaemia and reperfusion and summarised in Figure 1.1. During 
ischaemia, the O2 supply is reduced, which arrests mitochondrial oxidative 
phosphorylation and thus depletes ATP (Kahles et al., 1979; Reimer et al., 1983). As a 
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result, anaerobic metabolism takes over providing an avenue for continued ATP 
production (Jennings and Reimer, 1991), but producing intracellular acidosis through 
accumulation of lactate, protons, and NAD+. To normalise this accumulation of H+ ions, 
the Na+/H+ exchanger eliminates excess H+ ions, producing in turn a large influx of Na+ 
ions (Murphy and Steenbergen, 2008). The Na+ ions are, in turn, exchanged for Ca2+ by 
the Na+/Ca2+ exchanger (Chen and Li, 2012). Reduction of ATP during ischaemia also 
inactivates Na+/K+ ATPase, reduces active Ca2+ efflux, and limits the reuptake of Ca2+ 
by the endoplasmic reticulum (ER), thereby resulting in Ca2+ overload in the cell 
(Shintani-Ishida et al., 2012). Furthermore, in ischaemia, increased Ca2+ levels induce 
opening of the mitochondrial permeability transition pores (mPTP) leading to 
mitochondrial swelling and ultimately to cardiomyocyte necrosis (Abdallah et al., 2011; 
Assaly et al., 2012; Gorenkova et al., 2013; Ruiz-Meana et al., 2007). Activation of 
mPTP alters mitochondrial membrane potential and induces production of reactive 
oxygen species (ROS); finally the influx of water causes swelling and rupture of the 
mitochondria (Abdallah et al., 2011). In the heart, these cellular changes activate 
number of molecules including proteases, phospholipase, ATPases and endonucleases 
which damage myofibrils and produce hypercontracture and contracture band necrosis 
(Ruiz-Meana et al., 2007). 
 
Although timely reperfusion restores the supply of oxygen and nutrients required for 
aerobic ATP generation and pH normalisation, reperfusion itself leads to further cardiac 
damage  (Yellon and Hausenloy, 2007). At the onset of reperfusion, massive increases 
in mitochondrial Ca2+, oxidative stress and pH normalisation induce opening of the 
mPTP (Abdallah et al., 2011; Assaly et al., 2012; Saotome et al., 2009). The restoration 
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of blood flow also triggers an inflammatory process (Kawaguchi et al., 2011; 
Takahashi, 2011). Different factors, such as generation of ROS, secretion of 
chemokines and cytokines, as well as expression of adhesion molecules on the 
endothelial cell surface promote neutrophil recruitment (Albertine et al., 1994; 
Chandrasekar et al., 2001). In turn, infiltrated neutrophils secrete inflammatory 
molecules and ROS to contribute to tissue damage (Kaminski et al., 2002). 
Furthermore, cytoplasmic Ca2+ overload in the reperfused myocardium is in part due to 
the metabolic disturbance during the ischaemic episode, but is also aggravated at the 
onset of reperfusion by ROS-induced sarcoplasmic reticulum dysfunction and by 
Na+/Ca2+ exchange (Peters and Piper, 2007; Wei et al., 2007). Transient peaks of Ca2+ 
cause uncontrolled contractile activation of the myofibrils, resulting in hypercontracture 
(Ruiz-Meana et al., 2007). 
 
Overall, I-R injury is associated with endothelial dysfunction (Qi et al., 1998), 
complement activation (Yasojima et al., 1998), an inflammatory response (Kawaguchi 
et al., 2011), pH change, Ca2+ overload, opening of the mPTP  and generation of ROS 
(Shintani-Ishida et al., 2012) (Figure 1.1).  Such damage promotes activation of 
autophagy (Dong et al., 2010; Ma et al., 2012b) and cell death pathways including 
apoptosis, necroptosis and necrosis (Gottlieb et al., 1994; McCully et al., 2004; Smith 
and Yellon, 2011), which all contribute to myocardial damage and decreased cardiac 
performance. Thus, understanding the mechanisms involved prepares the way for 
development of novel therapeutic opportunities that not only reduce the extent of injury 
induced by I-R but may also extend the time a tissue could be subjected to ischaemia 
before irreversible injury occurs. 
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Figure 1.1: Mechanisms activated during myocardial ischaemia-reperfusion.  
Reperfused ischaemic myocardium undergoes several biochemical and metabolic 
changes, which include intracellular Ca2+ overload, ROS generation, inflammation, and 
rapid change of pH. All these changes interact with each other and ultimately lead to 
mPTP opening and induction of hypercontracture, activation of autophagy and cell 
death pathways (apoptosis, necrosis and necroptosis). ROS, reactive oxygen species; 
mPTP, mitochondrial permeability transition pore; ATP, adenosine triphosphate. 
(Modified from Kalogeris et al., 2012). 
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1.3.1 Cellular redox regulatory mechanisms during myocardial I-R 
The redox system plays an important role in maintaining cellular homeostasis. Under 
physiologic conditions, cells maintain redox balance through generation and elimination 
of reactive oxygen/nitrogen species (ROS/RNS), for maintaining cell function and 
survival. However, the redox homeostasis is disturbed during I-R injury which increases 
intracellular ROS/RNS levels. Oxidative stress is caused by an imbalance between the 
oxidant and antioxidant systems of the body in favour of the oxidants. ROS or free 
radical production during myocardial I-R is harmful to cells (Sies and Cadenas, 1985) 
and exceeds the capacity of antioxidant defences, triggering cellular dysfunction and 
eventually cell death (Loor et al., 2011; Robin et al., 2007). Moreover, there is evidence 
that oxidative stress occurs in patients with coronary artery disease (CAD) during 
surgical reperfusion, associated with transient LV dysfunction or stunning (Curello et 
al., 1995; Ferrari et al., 1990). Thus regulation of ROS levels is critical in maintaining 
cellular homeostasis. 
 
1.3.1.1 Generation of reactive oxygen species 
In the heart, ROS can be generated from different cell types including cardiomyocytes, 
endothelial cells (ECs), vascular smooth muscle cells (VSMCs), fibroblasts and 
infiltrating inflammatory cells and include superoxide anion radical (dioxide, or O2•-), 
the hydroxyl radical (▪OH), the peroxynitrite anion (ONOO-) and hydrogen peroxide 
(H2O2) (Halliwell and Cross, 1994). During an ischaemic event the presence of residual 
oxygen, Ca2+ overload and opening of the mPTP are associated with ROS generation 
(Feissner et al., 2009; Vanden Hoek et al., 1997a). ROS alter the functional activity of 
the sarcolemmal Ca2+ pump ATPase, decreasing efflux and increasing influx of Ca2+, 
Literature review  Chapter 1 
 
Page | 8  
and finally to cytosolic Ca2+ overload and cell death (Dixon et al., 1990; Matsubara and 
Dhalla, 1996). Moreover, increased mitochondria Ca2+ induces mPTP opening, ROS 
production and organelle disruption (Braunersreuther and Jaquet, 2012).  
 
Reperfusion restores the supply of oxygen and nutrients that are required for salvage of 
myocardium. However, ROS generation occurs very rapidly (within minutes) in post-
ischaemic heart tissue, as examined by electron paramagnetic resonance spectroscopy 
and chemiluminescent techniques (Ambrosio et al., 1991a; Ambrosio et al., 1991b; 
Henry et al., 1990; Zweier et al., 1989). Similarly, reperfusion augments release of ROS 
within the myocardium (Angelos et al., 2006; Ferrari et al., 1990; Ytrehus et al., 1986; 
Zweier et al., 1987; Zweier et al., 1989). Elevated ROS generation induces severe 
damage to lipids, proteins, deoxyribonucleic acid (DNA) and consequently apoptosis 
(Becker, 2004; Yellon and Hausenloy, 2007; Zhao et al., 2004). Further changes occur 
in the mitochondria, such as swelling, membrane instability and cytochrome c release 
from the intra-membrane space, contributes to mitochondrial membrane depolarisation 
and signals cell death (Halestrap et al., 2004). Several mechanisms are responsible for 
the generation of ROS in the reperfused myocardium. These include mitochondrial 
electron transport chain (ETC), xanthine oxidases, NADPH oxidases (NOX), uncoupled 
nitric oxide synthases (NOS), cytochrome P450 or from inflammation cells 
(Braunersreuther and Jaquet, 2012; Raedschelders et al., 2012; Zweier and Talukder, 
2006). Of these, the mitochrondrial electron transport chain and NADPH oxidases are 
important sources of ROS generation in cardiomyocytes. 
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Mitochondrial Electron Transport Chain  
Reduction of molecular O2 by the mitochondrial electron transport chain (ETC) is 
essential for generating most of the biological energy (Cortassa et al., 2009). However, 
electron transfer, and therefore mitochondrial ETC, is impaired during I-R when 
mitochondria are damaged. This results in an electron being gained by molecular O2, 
yielding superoxide (O2•–) (Chen et al., 2008). In myocytes, these reactions occur at 
complexes I (NADH-ubiquinone oxidoreductase) (Ide et al., 1999; Paradies et al., 2004; 
Passarelli et al., 2010; Sgobbo et al., 2007) and complex III (ubiquinol-cytochrome c 
oxidoreductase) (Chen et al., 2003b; Petrosillo et al., 2003) of the mitochondrial ETC. 
Recent studies have provided evidence that mitochondrial complex II (succinate-
ubiquinone oxidoreductase) mediated ROS production also plays an important role in 
heart failure (HF) and reperfused myocardium (Drose et al., 2011; Moreno-Sanchez et 
al., 2013; Mourmoura et al., 2011; Redout et al., 2007). During I-R injury both 
oxidative stress and ROS formation from mitochondrial ETC have been reported by 
using specific inhibitors of the mitochondrial ETC with cyanide, antimycin, and 
rotenone, generating sufficient ROS to disturb contractile function and induce 
cardiomyocyte death (Chen et al., 2006; Lee et al., 2012; Vanden Hoek et al., 1997b). In 
addition, I-R injury causes decreased endogenous mitochondrial antioxidant capacity 
which leads to an imbalance between production versus scavenging and thus increases 
mitochondrial ROS generation (Stowe and Camara, 2009). Furthermore, activation of 
mPTP causes equilibration of H+ across the inner membrane and dissipates the proton 
electrochemical gradient (ΔΨm), leading to ATP depletion, further ROS generation and 
ultimately swelling and rupture of the mitochondria (Baines, 2010; Weiss et al., 2003).  
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NADPH Oxidase 
Five NADPH oxidase (NOX) isoforms have been identified (NOX1 – NOX5), each 
encoded by a separate gene and with distinct tissue distributions (Bedard and Krause, 
2007; Lambeth, 2004). The enzymatic activity of NOX depends on additional small 
protein subunits, which vary according to isoform. NOX1 & NOX4 associate with 
p22phox subunits. NOX2 (also known as p91phox) associates with p47phox, p67phox, p40phox 
and Rac1 or Rac2, while NOX1 associates with Rac1, NOXO1 and NOXA1 
(homologues of p47phox and p67phox respectively). NOX enzymes work as an electron 
transfer chain carrying electrons through the cell membrane to reduce extracellular O2 
into O2•- and using NADPH as an electron donor (Leto et al., 2009). NOX isoforms are 
expressed in multiple cell types including VSMCs (NOX1, NOX2, NOX4) (Hilenski et 
al., 2004; Lassegue et al., 2001; Touyz et al., 2002), ECs (NOX2, NOX4, NOX5) (Ago 
et al., 2004; BelAiba et al., 2007; Gorlach et al., 2000; Jay et al., 2008; Li and Shah, 
2002), adventitial cells and fibroblasts (NOX2, NOX4) (Cucoranu et al., 2005; Pagano 
et al., 1997), and cardiomyocytes (NOX2, NOX4) (Bendall et al., 2002; Byrne et al., 
2003; Hingtgen et al., 2006; Li et al., 2006; Xiao et al., 2002). NOX3 is not expressed in 
cardiovascular cells. 
 
The involvement of NADPH oxidases in post-MI remodelling has been demonstrated in 
both experimental (Fukui et al., 2001) and clinical (Krijnen et al., 2003) studies, with 
elevated myocardial levels of NOX2 and p22phox after MI. More recent studies have 
shown that Nox2-/- or p47phox deficient mice subjected to experimental MI have reduced 
myocyte apoptosis, preventing left ventricular (LV) remodelling and dysfunction and 
improving overall survival compared with wild type controls (Doerries et al., 2007; 
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Looi et al., 2008). Moreover, inhibition of NADPH oxidase with apocynin showed 
decreased oxidative stress and myocyte apoptosis, and improvement of cardiac function 
in heart failure (HF) after MI in rabbits (Qin et al., 2007).  
 
Recent evidence shows that NADPH oxidase and the Rac1 pathway mediate ROS 
production and myocardial contractile dysfunction following acute I-R (Shan et al., 
2010; Talukder et al., 2013). Increased expression of Rac1 and/or NADPH oxidases has 
been reported in animals and humans with MI, HF, diabetes, oxidant stress or  
inflammation (Dwivedi et al., 2010; Fukui et al., 2001; Krijnen et al., 2003; Maack et 
al., 2003; Nagase et al., 2012; Talukder et al., 2013). Disruption of Rac1 signalling 
reduces prolonged myocardial ischaemia-induced Rac1 activity and I-R injury in mice 
(Shan et al., 2010). Taken together, these studies highlight a crucial role of NADPH 
oxidases and Rac1 in acute myocardial I-R injury. In summary, ROS may exert multiple 
actions with all the sources playing some role in ROS mediated damage in I-R injury; 
although exact contribution of each source remains unclear. The precise role of each of 
these ROS generators in the pathology of experimental I-R injury is not clear since a 
particular source may depend upon the experimental protocol used to produce I-R 
injury. 
 
1.3.1.2 Antioxidant defences systems 
During I-R, antioxidant defences (such as glucose-6-phosphate dehydrogenase (G6PD),  
superoxide dismutase (SOD), reduced glutathione and protein SH groups) are decreased 
whereas ROS generating enzymes (such as oxidized glutathione, NADPH oxidase) are 
increased (Ferrari et al., 1985; Krijnen et al., 2003; Usal et al., 1996).  
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G6PD is a critical cytosolic antioxidant enzyme in adult cardiomyocytes (Jain et al., 
2003) and functions as the first and rate-limiting enzyme in the pentose phosphate 
pathway responsible for generation of NADPH in a reaction coupled to the oxidation of 
glucose-6-phosphate (Frederiks et al., 2007; Gupte et al., 2006). Decreased G6PD 
activity lowers NADPH levels and promotes oxidative stress damage (Hecker et al., 
2013b; Jain et al., 2003; Leopold et al., 2001; Leopold et al., 2003). G6PD activity is 
increased in response to a number of stress-induced stimuli, infarcted myocardium and 
failing hearts (Bing et al., 1969; Gupte et al., 2007; Gupte et al., 2006; Stanton et al., 
1991). Studies with G6PD-deficient mice provide evidence for both protective and 
deleterious effects (Hecker et al., 2013a). G6PD deficiency may provide a protective 
effect through decreasing cholesterol synthesis and O2•– production (Matsui et al., 
2006), and thus reduce the risk of CHD and cardiovascular associated death observed in 
humans (Cocco et al., 1998; Meloni et al., 2008). However, recent studies indicate that 
G6PD-deficient mice are more susceptible to ventricular dilation and greater myocardial 
oxidative stress in response to MI or pressure overload-induced HF (Hecker et al., 
2013b). Moreover, mice with G6PD-deficiency displayed increased cardiac dysfunction 
during myocardial I-R, associated with depletion of intracellular glutathione and 
increased oxidative stress (Jain et al., 2004). 
 
The glutathione redox cycle is a major antioxidant defense mechanism against ROS. 
This redox cycle detoxifies ROS by reaction with reduced glutathione (GSH). GSH is a 
radical scavenger that directly neutralizes a variety of reactive molecules, such as 
carbon-centered radicals, superoxide anion and hydroxyl radicals (Dickinson and 
Forman, 2002; Wu et al., 2004). GSH provides the reducing equivalents necessary for 
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the conversion of hydrogen peroxide and lipid peroxides to water and lipid alcohols, 
respectively, thereby preventing degradation to highly toxic free radicals, including 
hydroxyl and peroxy radicals. GSH is also an essential cofactor for inactivation of 
hydroperoxides by glutathione peroxidase, for the conjugation of cytotoxic by-products 
of lipid peroxidation by glutathione-S-transferase, and for the reduction of protein 
mixed disulfides (Bindoli et al., 2008; Fernandes and Holmgren, 2004; Mieyal et al., 
2008; Wu et al., 2004). GSH also has an important role in protecting against oxidation 
of protein sulfhydryl groups (Thomas et al., 1995). During oxidative stress, reduced 
GSH is oxidized to glutathione disulfide (GSSG). The majority of GSSG is reduced 
back to GSH by glutathione reductase and NADPH, an essential cofactor for 
regeneration of GSH from GSSG (Schafer and Buettner, 2001). 
 
The cellular ratio of GSH-to-GSSG under physiological conditions highly favours 
reduced GSH and is decreased during oxidative stress. Thus the levels of GSH, GSSG 
and ratio of GSH-to-GSSG are considered to be sensitive indices of cellular oxidative 
stress (Ho et al., 2008; Verbunt et al., 1995). In isolated rat hearts, myocardial content 
of GSSG is increased during post-ischaemic reperfusion (Verbunt et al., 1995), but not 
during reoxygenation of hypoxic hearts (Darley-Usmar et al., 1989; Park et al., 1991) 
when compared to control levels. Recent studies have shown GSH depletion and 
increased content of GSSG in patients with AMI, indicating these patients experience 
increased oxidative stress (Ho et al., 2008; Usal et al., 1996). Depletion of cardiac GSH 
exacerbates myocardial I-R injury (Leichtweis and Ji, 2001; Singh et al., 1989; Werns et 
al., 1992), whereas exogenous supplementation with GSH protects against such injury 
(Ferrari et al., 1991; Gao et al., 2002; Singh et al., 1989). 
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Pyridine nucleotides include reduced and oxidized nicotinamide adenine dinucleotide 
(NADH/NAP+) and  NADH/NAP+ phosphate (NADPH/NADP+) and are critical 
molecules in energy metabolism, ATP production, Ca2+ homeostasis, anti-oxidation and 
reductive biosynthesis (Belenky et al., 2007; Berger et al., 2004; Pollak et al., 2007). 
NADPH/NADP+ also participate in antioxidant defense in the control of cellular 
oxidative stress and GSH/GSSG redox balance (Ceconi et al., 2000). NAD+ and NADH 
have been used to characterize mitochondrial energy states in isolated hearts and 
myocardial tissue (Di Lisa et al., 2001; Nuutinen, 1984; Stoner et al., 2004). Adult rat 
cardiomyocytes subjected to simulated ischaemia produced substantial reduction in 
NAD+-to-NADH and associated energy-dependent processes including contraction and 
maintenance of ATP (Esumi et al., 1991). NAD+ plays an essential role in mediating 
cell survival by inhibiting apoptosis in response to I-R injury (Hsu et al., 2009; Sukoyan 
et al., 2005). Furthermore, the cellular content of NAD+ has been shown to be regulated 
by multiple mechanisms including nicotinamide phosphoribosyltransferase (Nampt) 
(Revollo et al., 2007). Expression of Nampt in the heart is significantly decreased by 
ischaemia, I-R and pressure overload, leading to significantly decreased NAD+ and ATP 
concentrations (Hsu et al., 2009). 
 
1.3.2 Redox-mediated mechanisms in regulation of cellular processes: 
role of gene transcription 
Redox balance is critical in maintaining cellular homeostasis. Disruption of this balance 
by increased oxidative stress will alter cellular function. In response to oxidative stress, 
cells react by activating expression of several stress-related genes. As shown in Figure 
1.2, this could lead to the synthesis of proteins involved in cellular protection or repair 
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of injury. These stress induced gene products can be distinguished by their specific 
protein structures, functional properties, and their inducing stimuli. Among stress genes, 
the most common and well known are those coding for heat shock proteins (Hsp) 
(Subjeck and Shyy, 1986), proto-oncogenes (immediate early genes) and genes for 
antioxidants (Das et al., 1995). 
 
 
 
Figure 1.2: Schematic of oxidative stress induced expression of transcription 
factors during myocardial ischaemia-reperfusion injury.  
ROS, reactive oxygen species; Hsp, heat shock protein; PGC, peroxisome proliferator 
activated receptor-gamma coactivator; MITO, mitochondrial; +, stimulation; −, 
inhibition. (Modified from Das et al., 1995). 
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Oxidative stress induced by reperfusion injury leads to the expression of heat shock and 
immediate early genes. After 20-30 minutes of reperfusion, accumulation of mRNA for 
hsp90, hsp72 and hsp70 was detectable in ischaemic myocardium (Nishizawa et al., 
1999; Plumier et al., 1996; Schoeniger et al., 1994). Similarly, oxidative stress was 
shown to induce the expression of Hsp27 (Das et al., 1998; Maulik et al., 1993). I-R 
injury also induces the expression of a number of immediate early genes - immediately 
following coronary artery occlusion, mRNAs for c-fos, Egr-1, c-jun and jun-B 
accumulate in the ischaemic region as well as during the reperfusion period (Brand et 
al., 1992; Xu et al., 2008).  
 
Peroxisome proliferator activated receptor-gamma coactivator (PGC)-1α and PGC-1β 
are two key molecules which play important roles in oxidative metabolism, 
mitochondrial biogenesis, as well as ROS generation (Garnier et al., 2003; Huss and 
Kelly, 2005). Both PGC-1α and -1β regulate mitochondrial biogenesis and genes 
encoding enzymes of mitochondrial metabolism and proteins that compose the electron 
transport chain (Fan et al., 2004; Lin et al., 2003; Meirhaeghe et al., 2003; St-Pierre et 
al., 2003). The expression of PGC-1α mRNA was suppressed following acute MI (Sun 
et al., 2007), congestive heart failure (CHF) (Garnier et al., 2003), and pressure 
overload (Huss and Kelly, 2004; Lehman and Kelly, 2002). Conversely, pioglitazone, a 
PGC agonist, attenuated LV remodelling and HF after experimental MI (Shiomi et al., 
2002), while PGC-1β deficient mice exhibited greater degrees of oxidative stress and 
lower rates of glucose metabolism following pressure overload hypertrophy (Riehle et 
al., 2011). Dysfunctional mitochondria in I-R injury are either cleared through 
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autophagy or persist to initiate apoptosis through the intrinsic pathway culminating in 
myocyte death. 
 
1.3.3 Autophagy 
Autophagy is the process for disposal of damaged organelles and non-specific or 
superfluous cytosolic proteins, thereby participating in homeostatic functions in cells 
(Dong et al., 2010). It also provides cells with a survival mechanism in response to 
stressful conditions, such as starvation (nutrient depletion), hypoxia and I-R by 
generating amino acids and fatty acids for maintenance of cell function (Gurusamy and 
Das, 2009; Gurusamy et al., 2009; Hamacher-Brady et al., 2006b). However, 
uncontrolled autophagy may ultimately lead to cell death and aggravate I-R injury 
(Dong et al., 2010; Ma et al., 2012b). 
 
1.3.3.1 Molecular mechanisms involved in autophagy 
Autophagy is tightly regulated and mediated by specific pathways (Figure 1.3). The 
process of autophagy consists of four main phases. Autophagy is initiated by activation 
of class III PI3K-associated Beclin-1 and inhibited by class I PI3Ks through mammalian 
target of rapamycin (mTOR). Beclin-1 bound to anti-apoptotic proteins Bcl-2 or Bcl-xL 
also inhibits autophagy (Cheng et al., 2013; Hamacher-Brady et al., 2006a; Maiuri et al., 
2007; Oberstein et al., 2007). During starvation or stress, mTOR is inactivated and 
initiates formation of a phagophore, which is further facilitated by another complex 
consisting of a class III PI3K associated Beclin-1 (Gottlieb and Mentzer, 2010; He and 
Klionsky, 2009; Levine and Kroemer, 2008). This complex, in turn, recruits autophagy-
related genes (Atg): Atg12, Atg5, and Atg8 (also called LC3), which are essential for 
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the elongation of the membrane and completion of the autophagosome (Figure 1.3). 
p62, a major selective substrate for autophagic degradation, is recruited to the 
autophagosomal membrane through interaction with ubiquitinated substrates and LC3, 
and is degraded during the autophagic process (Bjorkoy et al., 2005; Ichimura et al., 
2008; Pankiv et al., 2007). Atg12-Atg5-Atg16 complex is required for recruitment of 
LC3-II. After autophagosome formation, the remaining membrane-attached LC3-II-
phosphatidylethanol-amine (LC3-II-PE) then fuses with lysosomal protease to create an 
autophagolysosome. The fusion of the autophagosome to the lysosome is mediated by 
the small GTPase Rab7 and the lysosomal-associated membrane protein 2 (LAMP2) 
(Gottlieb and Mentzer, 2010; He and Klionsky, 2009; Levine and Kroemer, 2008; Ma et 
al., 2012b). The contents within this complex are degraded by lysosmal hydrolases and 
in the process can produce ATP (Gurusamy and Das, 2009; Gurusamy et al., 2009; 
Hamacher-Brady et al., 2006b). 
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Figure 1.3: Schematic illustration of the four phases of autophagy.  
PI3K, phosphatidylinositol-3 kinase;  mTOR, mammalian target of rapamycin; Atg, 
autophagy-related gene; Beclin-1, the mammalian homolog of yeast Atg6; LC3, 
Microtubule-associated protein 1 light chain 3; PE, phosphatidylethanol-amine; p62, 
polyubiquitin-binding protein p62 (also called SQSTM1; sequestrome 1); LAMP, 
lysosomal-associated membrane protein; ER, endoplasmic reticulum; PM, plasma 
membrane; Mito, mitochondrial. 
 
1.3.3.2 Regulation of autophagy during myocardial I-R 
Autophagy is induced by a variety of factors during I-R, such as oxidative stress (Dai 
and Rabinovitch, 2011; Dutta et al., 2013; Hariharan et al., 2011), endoplasmic 
reticulum stress, Ca2+ overload (Pan et al., 2013), activation of AMPK and inactivation 
of mTOR (Matsui et al., 2007) and upregulation of Beclin-1 (Ma et al., 2012b). During 
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the ischaemic phase, autophagy is stimulated through an AMPK/mTOR-dependent 
mechanism (Takagi et al., 2007), whereas reperfusion stimulates autophagy through an 
upregulation of Beclin-1-dependent mechanisms rather than by activation of AMPK 
(De Meyer and Martinet, 2009; Ma et al., 2012b; Matsui et al., 2007); induction of 
autophagy and cardiac injury during the reperfusion phase is significantly attenuated in 
Beclin 1+/− mice (Matsui et al., 2007). In Langendorff isolated rabbit hearts, I-R induced 
autophagy (Decker et al., 1980; Decker and Wildenthal, 1980). These studies showed 
that 40 min of ischaemia led to an increase in autophagic vacuoles, and that reperfusion 
after 20 or 40 minutes of ischaemia further enhanced autophagy in the reperfused rabbit 
heart. When ischaemia was extended to 60 minutes, large and possibly dysfunctional 
lysosomes were present during reperfusion, suggesting that the prolonged ischaemia 
impaired autophagic-lysosomal fusion.  
 
Autophagy has been measured in human and pig hearts under chronic myocardial 
ischaemia (Elsasser et al., 2004; Yan et al., 2006; Yan et al., 2005), as well as in mouse 
and rat hearts subjected to acute I-R (Hamacher-Brady et al., 2007; Matsui et al., 2007). 
The extent of autophagy is enhanced during reperfusion compared with ischaemia alone 
in hearts from rabbit and mice (Decker and Wildenthal, 1980; Matsui et al., 2007). 
Autophagy has also been examined in isolated neonatal and adult cardiac myocytes 
subjected to simulated I-R (sI/R) or hypoxia and reoxygenation (H/R), with an increase 
in the number of autophagic vesicles reported (Valentim et al., 2006). Hamacher-Brady 
et al. found that when HL-1 myocytes were subjected to sI/R, autophagic activity was 
inhibited during ischaemia, but re-activated during reperfusion (Hamacher-Brady et al., 
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2006a). Taken together, autophagy is induced by ischaemia and further enhanced after 
reperfusion in the heart (ex vivo and in vivo) and in cultured cardiac myocytes (in vitro).  
Although it is clear that autophagy is enhanced during I-R, the functional significance 
of autophagy (beneficial vs. detrimental) in the heart remains controversial. Several 
studies suggest that up-regulation of autophagy is cardioprotective and attenuates 
myocardial I-R injury (Dosenko et al., 2006; Hamacher-Brady et al., 2006a; Hamacher-
Brady et al., 2006c; McCormick et al., 2012), with inhibition of autophagy worsening 
tissue damage in I-R (Jiang et al., 2010; Qian et al., 2009; Wei et al., 2013). 
Pharmacological induction of autophagy also confers protection against I-R (Gurusamy 
et al., 2010; Sala-Mercado et al., 2010). However, autophagy also leads to detrimental 
effects in I-R (Ma et al., 2012a; Matsui et al., 2008b) (Figure 1.4). Recent experimental 
data also show that the clearance of autophagosomes is impaired in myocardial 
reperfusion injury which is mediated in part by ROS-induced decline in LAMP-2A and 
upregulation of Beclin-1, contributing to increased cardiomyocyte death (Hariharan et 
al., 2011; Ma et al., 2012b). Furthermore, Bcl-2 and Bcl-xL directly interact and 
regulate the autophagy protein inducer Beclin-1 (Cheng et al., 2013; Pattingre et al., 
2005). The BH3 domain of Beclin-1 binds and is inhibited by Bcl-2 or Bcl-xL (Maiuri 
et al., 2007; Oberstein et al., 2007). Dissociation of Beclin-1-Bcl-2/xL complexes 
promotes autophagy (Zalckvar et al., 2009) and ultimately cell death (Luo and 
Rubinsztein, 2010). Thus, Bcl-2/xL not only functions as an anti-apoptotic protein, but 
also as an anti-autophagic protein via its inhibitory interaction with Beclin-1. 
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Figure 1.4: Regulation of autophagy during myocardial ischaemia-reperfusion.  
ER, endoplasmic reticulum; ROS, reactive oxygen species; mPTP, mitochondrial 
permeability transition pore; Bcl-2, B-cell lymphoma 2; Bcl-xL; B-cell lymphoma extra 
large; Beclin-1, the mammalian homolog of yeast autophagy-related gene 6 (Atg6); 
LAMP2, lysosomal-associated membrane protein 2; AMPK, adenosine monophosphate-
activated protein kinase; mTOR, mammalian target of rapamycin; ↑ increased; ↓ 
decreased. 
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1.3.4 Apoptosis 
Apoptotic cell death was first identified by Kerr, Wyllie and Currie early in the 1970s 
and can be initiated by two main mechanisms which are referred to as extrinsic and 
intrinsic pathways of cell death (Kerr et al., 1972; Wyllie et al., 1980). Apoptosis at 
basal level is required for tissue development and cellular homeostasis (Danial and 
Korsmeyer, 2004; Kerr et al., 1972). However, enhanced apoptosis is observed in 
myocardial I-R injury (Fliss and Gattinger, 1996; Gottlieb et al., 1994; Zhao et al., 
2000) and during ventricular remodelling after AMI (Hofstra et al., 2000; Krijnen et al., 
2002; Olivetti et al., 1996; Palojoki et al., 2001; Saraste et al., 1997).  
 
1.3.4.1 Molecular mechanisms involved in apoptosis 
Apoptosis is a mechanism of programmed cell death that results in cell shrinkage and 
condensation of the cytosol and nucleus to eventually form apoptotic bodies (Arbustini 
et al., 2008; Kerr et al., 1972; Saraste and Pulkki, 2000). Since apoptotic bodies are 
surrounded by cell membranes, they can be engulfed and digested by phagocytes 
without inducing an inflammatory process. Apoptosis can be identified by the presence 
of DNA condensation, fragmentation and breakdown of the nucleus substrates (Joselin 
et al., 2006; Sakahira et al., 1999). Figure 1.5 is a schematic of the major apoptotic 
pathways leading to cell death 
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Figure 1.5: Extrinsic (left) and intrinsic (right) mechanisms of apoptosis and the 
cross talk that occurs between these pathways.  
The signalling complexes are induced by death receptor mediated apoptosis or 
necroptosis (programmed necrosis) and by extra-/intra-cellular stimuli mediated 
autophagy, apoptosis or necrosis. TNF, tumour necrosis factor; TNFR1, tumour 
necrosis factor receptor 1; DISC, death-inducing signaling complex; Casp, caspase; 
tBID, truncated BID; ARC, Apoptosis Repressor with Caspase recruitment domain; 
Bcl-2, B-cell lymphoma 2; Bcl-xL; B-cell lymphoma extra large; XIAP, X-linked 
inhibitor of apoptosis; Acinus, ICAD/CAD, inhibitor of caspase-activated DNase/ 
caspase-activated DNase; I-R, ischaemia-reperfusion; MITO, mitochondrial. 
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Extrinsic apoptotic pathway: The extrinsic cell death pathway is activated by death 
receptor ligands such as tumour necrosis factor alpha (TNFα) and Fas ligand (FasL), 
which bind to specific death receptors  (Jeremias et al., 2000; Krown et al., 1996). 
Activation of these receptors results in their trimerization and recruits a number of death 
domain-containing proteins such as FADD and TRADD to the receptor complex 
(Figure 1.5). The death-inducing signalling complex (DISC) and Complex I activate the 
initiator caspase-8 (Dickens et al., 2012; Kim et al., 2000), which in turn, cleaves and 
activates the executioner caspase-3 (Stennicke et al., 1998). The release of an active 
caspase-3 fragment can cleave death substrates such as PARP (poly-ADP ribose 
polymerase) (O'Brien et al., 2001), fodrin (Janicke et al., 1998),  lamin (Rao et al., 
1996), acinus (apoptotic chromatin condensation inducer in the nucleus) (Sahara et al., 
1999) and ICAD/DFF45 (inhibitor of caspase-activated DNase or DNA fragmentation 
factor 45) (Enari et al., 1998; Sakahira et al., 1998). Cleavage of these proteins prevent 
DNA repair and induce DNA fragmentation resulting in increased level of apoptosis. 
  
Intrinsic apoptotic pathway: As shown in Figure 1.5, the intrinsic cell death pathway is 
mediated by intracellular and extracellular stimuli including I-R, UV irradiation, toxic 
compounds (etoposide, staurosporine) or oxidative stress, all of which induce the 
translocation and integration of pro-death members of the Bcl-2 protein family (e.g., 
Bax, Bak) into the outer mitochondrial membrane (Antignani and Youle, 2006; 
Kroemer et al., 2007; Nechushtan et al., 1999). These proteins permeabilize the outer 
membrane, thereby enabling the release of pro-apoptotic proteins from the 
intermembrane space. Bax and Bak proteins stimulate the release of cytochrome c, 
Smac/DIABLO, Omi/HtrA2, and endonuclease-G (endoG) from mitochondria (Arnoult 
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et al., 2003; Kroemer et al., 2007). Cytochrome c, ATP, Apaf-1, and pro-caspase-9 
assemble into the “apoptosome” leading to caspase-9 activation, which can cleave and 
subsequently activate caspase-3 and thus promote nuclear fragmentation (Hu et al., 
1999; Kroemer et al., 2007; Zou et al., 1999).  
 
Crosstalk between extrinsic and intrinsic apoptotic cell death pathways: The extrinsic 
and intrinsic pathways are connected by BID, a direct substrate of caspase-8 (Figure 
1.5). After cleavage of cytosolic BID to truncated BID (tBID), the C-terminus of tBID 
translocates and inserts into the outer mitochondrial membrane and thus transduces 
apoptotic signals from the cytoplasmic membrane to mitochondria (Li et al., 1998). This 
has been associated with the loss of mitochondrial membrane potential, activation of 
Bax and Bak and cytochrome c release and thus cell shrinkage and nuclear 
fragmentation (Figure 1.5) (Korsmeyer et al., 2000; Li et al., 1998; Madesh et al., 
2002). I-R in the rat heart suggested that activation of caspase-9 occurring during 
reperfusion may depend on caspase-8 cleavage of BID, and tBID relocates to 
mitochondria where it induces caspase-9 processing (Scarabelli et al., 2002). This 
shows that although activation of the extrinsic pathway does not directly act in the 
mitochondria it can activate mechanisms within the intrinsic pathway (Figure 1.5). 
 
Counteracting the induction of apoptotic cascades are the anti-apoptotic proteins which 
include Bcl-2/xL, XIAP (X-linked inhibitor of apoptosis protein) and ARC (Apoptosis 
repressor with caspase recruitment domain).  Bcl-2 and Bcl-xL, anti-apoptotic proteins 
at the mitochondrial membrane level, can prevent BID or Bax induced apoptosis by 
stopping these pro-apoptotic proteins from integrating into the outer mitochondrial 
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membrane (Billen et al., 2008; Cheng et al., 2001; Yi et al., 2003). XIAP inhibits 
activation of caspase-9 and -3 (Bratton et al., 2002; Srinivasula et al., 2001), whereas 
ARC antagonises both the extrinsic and the intrinsic death pathways (Nam et al., 2004) 
(Figure 1.5). The change in balance between pro-survival and pro-death proteins 
depends also on the type of apoptotic stimulus (I-R stress, toxic compounds, oxidative 
stress or DNA damage). 
 
1.3.4.2 Regulation of apoptosis during myocardial I-R 
Regulation of apoptosis involves transduction of signalling by apoptotic mediators, both 
pro- and anti-apoptotic proteins. The current study focuses on the role of apoptotic 
mediators during myocardial I-R injury. 
 
Caspases 
Caspases, the main effectors of apoptosis, are a group of cysteine containing proteases 
that specifically cleave proteins at aspartate residues (Alnemri et al., 1996). Caspases 
are constitutively expressed and synthesised as inactive zymogens referred as “pro-
caspases”, containing an N-terminal prodomain and a C-terminal catalytic domain; once 
stimulated mature active fragments, heterotetramers of the smaller cleavage fagments, 
are generated (Nicholson et al., 1995). Caspases are classed according to their function, 
as either upstream (initiator) caspases including caspases-2/-8/-9/-10/-12 or downstream 
(effector, executioner) caspases including caspases-3/-6/-7 (Crow et al., 2004; 
Nicholson et al., 1995). Caspases play critical roles in I-R induced cell death and 
numerous studies have demonstrated increased activity of capase-8, caspase-2, caspase-
9, and caspase-3 in myocardial I-R (Fauconnier et al., 2011; Qin et al., 2004; Scarabelli 
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et al., 2002). Administration of caspase inhibitors such as zVAD-FMK and MX1013 
attenuates apoptosis and cell death in response to I-R in kidney (Daemen et al., 1999), 
liver (Kobayashi et al., 2001), brain (Yang et al., 2003) and heart (Chandrashekhar et 
al., 2004; Yaoita et al., 1998; Yarbrough et al., 2010). Genetic deletion or knockdown of 
specific caspases, both in the extrinsic and intrinsic pathways, also ameliorates I-R 
injury (Contreras et al., 2004; Zhang et al., 2006; Zhang et al., 2010; Zheng et al., 
2006). However, targeting caspase inhibition for reducing I-R injury may not be ideal 
since upstream mitochondria will still be adversely affected (Figure 1.5).  
 
The Bcl-2 family proteins 
The Bcl-2 family of proteins include both pro-apoptotic and anti-apoptotic factors that 
regulate the activation of the intrinsic pathway. Anti-apoptotic factors of the Bcl-2 
family proteins, include Bcl-2, BcL-xL, Bcl-w, inhibit apoptosis by preventing BID or 
Bax activation/mitochondrial translocation and preventing release of cytochrome c from 
mitochondria (Billen et al., 2008; Cheng et al., 2001; Yi et al., 2003). During I-R the 
expression levels of Bcl-2 and Bcl-xL decrease (Lazou et al., 2006; Maulik et al., 1999; 
Zhao et al., 2000). Conversely, overexpression of anti-apoptosis genes, Bcl-2 and Bcl-
xL, block the release of cytochrome c and reduce both myocardial apoptosis and infarct 
size following I-R (Chen et al., 2001; Huang et al., 2003).  
 
Pro-apoptotic Bcl-2 family members function by binding and inactivating anti-apoptotic 
factors and ultimately trigger the release of cytochrome c from mitochondria (Mikhailov 
et al., 2003; Shimizu and Tsujimoto, 2000). BID can also promote the activation of both 
Bax and Bak by competing for Bcl-2 binding (Kim et al., 2009; Ren et al., 2010). 
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Activation, upregulation, translocation, and integration of pro-apoptotic Bcl-2 proteins 
(such as Bax, Bak, Puma, BID and BNIP3) into mitochondrial membranes have been 
reported in ischaemic tissues (Hamacher-Brady et al., 2007; Toth et al., 2006; Webster, 
2006). Bax-, BID-, BNIP3-, or Puma-deficient mice have reduced infarct size, 
confirming a role for these proteins in the progression of I-R injury (Diwan et al., 2007; 
Hochhauser et al., 2003; Toth et al., 2006).  
 
Inhibitors of apoptotic proteins (IAPs) 
IAPs, such as X-linked inhibitor of apoptosis (XIAP), are major endogenous inhibitors 
of apoptosis in cardiomyocytes (Potts et al., 2005). XIAP inhibits apoptosis by binding 
directly to caspases-9 and -3, preventing their processing and activation (Crow et al., 
2004; Deveraux et al., 1997; Riedl et al., 2001). XIAP also prevents the proteolytic 
processing of caspases-3 and -9 by modulating Apaf-1 and cytochrome c-induced 
activation (Deveraux et al., 1998; Potts et al., 2005). Levels of XIAP are reduced in 
response to ischaemia or hypoxia (Lyn et al., 2002; Shilkrut et al., 2003), as well as in 
hearts subjected to I-R (Bhuiyan and Fukunaga, 2008; Liu et al., 2005a; Scarabelli et al., 
2004), suggesting that XIAP is involved in I-R induced cardiomyocyte apoptosis. 
Recent studies have shown that overexpression of XIAP via in vivo gene delivery to 
rabbit hearts decreases expression of cleaved caspase-3, and thus attenuates both 
myocardial apoptosis and infarction following I-R (Kim et al., 2011). 
 
Apoptosis Repressor with Caspase recruitment domain (ARC) 
ARC is an endogenous inhibitor of apoptosis that inhibits both the extrinsic and the 
intrinsic apoptotic pathways (Gustafsson et al., 2004; Koseki et al., 1998; Nam et al., 
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2004). ARC inhibits the extrinsic pathway by direct interaction of the ARC caspase 
recruitment domain (CARD) with the death domains (DD) of Fas and Fas-associated 
protein with death domain (FADD), and with the death effector domain (DED) of 
procaspase-8, thus interfering with DISC formation (Nam et al., 2004). ARC inhibits 
the intrinsic pathway through several mechanisms. These include the direct interaction 
between the CARD of ARC and the C-terminus of Bax, inhibiting death stimulus-
induced Bax conformational activation and translocation to the mitochondria (Nam et 
al., 2004). Direct interaction between the ARC C-terminal domain with the p53 
tetramerization domain inhibits p53 tetramerization (Foo et al., 2007b). This, in turn, 
disables p53 transcriptional and exposes a p53 nuclear export signal that relocates p53 
to the cytoplasm. Furthermore, phosphorylation of ARC at threonine 149 inhibits 
oxidative stress-induced caspase-2 activation, cytochrome c release, and translocation of 
Bax to mitochondria (Zhang and Herman, 2006). 
 
ARC protein levels decrease rapidly in response to hypoxia, I-R and oxidative stress 
(Ekhterae et al., 1999; Nam et al., 2007b; Neuss et al., 2001). The increased degradation 
of ARC protein via the ubiquitin-proteasomal pathway (Nam et al., 2007b) is dependent 
on the p53-induced ubiquitin E3 ligase MDM2 (Foo et al., 2007a). In response to 
hypoxia, ARC protein abundance falls after p53 repression of ARC transcription (Li et 
al., 2008). The activity of ARC is also post-translationally regulated. Dephosphorylation 
of threonine 149 decreases the anti-apoptotic activity of ARC (Li et al., 2002; Murtaza 
et al., 2008; Tan et al., 2008; Yao et al., 2012; Zhang and Herman, 2006). ARC binds 
calcium via its C-terminus and can also suppress Ca2+-mediated apoptosis (Jo et al., 
2004). Recently, it was demonstrated that oxidative stress results in ARC attenuating 
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release of Ca2+ from the sarcoplasmic reticulum and inhibiting Ca2+ elevation in the 
cytoplasm and mitochondria (Lu et al., 2013). Furthermore, Foxo3a, a member of the 
forkhead family of transcription factors, inhibits cardiomyocyte apoptosis by 
maintaining calcium homeostasis through transactivation of ARC (Lu et al., 2013). 
 
ARC plays an important role during MI where rapid proteasomal degradation of 
endogenous ARC protein (Nam et al., 2007b) has been shown to lead to cell death (Nam 
et al., 2004). Accordingly, ARC overexpression leads to improved recovery of 
contractile performance during reperfusion and decrease infarct size (Gustafsson et al., 
2002; Pyo et al., 2008). Conversely, increased cardiomyocyte apoptosis (An et al., 
2009), larger infarcts and exacerbated pathological cardiac remodelling (Donath et al., 
2006) are observed in ARC null mice. Decreased ARC protein levels have been 
measured in heart muscle from patients with heart failure (Donath et al., 2006).  
 
1.3.5 Necrosis 
During MI there is both apoptotic and necrotic myocyte death (Kajstura et al., 1996; 
McCully et al., 2004). In contrast to apoptosis, I-R induced cell necrosis involves 
membrane disintegration and dysregulated ion transport, which leads to the absorption 
of water, cell swelling and eventually membrane rupture (Searle et al., 1982). Release of 
pro-inflammatory mediators and destruction of cellular organelles subsequently recruits 
inflammatory cells (such as neutrophils) to the area of necrosis, initiating inflammation 
and further damage to surrounding tissue (Kajstura et al., 1996; Tavernarakis, 2007; 
Vanlangenakker et al., 2008). Necrosis does not require energy and it has been 
suggested that necrosis is the main type of cell death during ischaemia, whereas 
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apoptosis occurs mainly during reperfusion when the energy supply is restored 
(Kajstura et al., 1996; McCully et al., 2004). 
 
During reperfusion, restoration of oxygen quickly allows ATP levels to recover and 
restore mitochondrial membrane potential. These changes generate ROS and increased 
intracellular Ca2+, which leads to opening of mPTP by cyclophilin D (CyD), and 
mitochondrial swelling ultimately resulting in cellular necrosis (Devalaraja-Narashimha 
et al., 2009; Miura et al., 2009). Involvement of mPTP in cardiac I-R responses has 
been verified in both experimental and clinical studies (Hausenloy et al., 2012; Perrelli 
et al., 2011). Mice with cardiac-specific overexpression of CyD exhibit mitochondrial 
swelling and spontaneous cell death, whereas lack of CyD protected cardiac myocytes 
from Ca2+ overload-induced cell death in vitro (Baines et al., 2005; Nakagawa et al., 
2005). Interestingly, pro-apoptotic protein-induced cytochrome c release did not differ 
between mitochondria from wild-type and knockout CyD mice, suggesting that CyD 
does not have a critical role in apoptosis (Baines et al., 2005; Nakagawa et al., 2005). 
On the other hand, similar mice lacking CyD showed smaller infarct size, improved LV 
function and less mortality following MI (Lim et al., 2011). Although experimental 
studies show cardioprotective effects with cyclosporine A (CsA, a mPTP inhibitor) in 
response to I-R (Boengler et al., 2010), pre-thrombolytic administration of CsA in 
patients with acute anterior ST-segment elevation MI (STEMI) did not reduce infarct 
size or improve morbidity and mortality (Ghaffari et al., 2012). 
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1.3.6 Necroptosis  
Recently, another form of cell death has been described, named “necroptosis’ or 
“programmed necrosis”. As shown in Figure 1.6, necroptosis is a caspase independent 
cell death pathway. The signalling complexes are induced by TNFα stimulation of death 
receptor TNFR1 leading to the formation of complex I at the cytoplasmic membrane 
that includes TNF receptor-associated death domain (TRADD), TNF receptor-
associated factor-2 (TRAF2), and receptor-interacting protein-1 (RIP1). Ubiquitination 
of RIP1 at K377 leads to the recruitment of NF-κB essential modulator (NEMO), a 
regulatory subunit of I kappa B kinase (IKK) complex that in turn activates NF-κB 
pathway. On the other hand, deubiquitination of RIP1 leads to the formation of complex 
II including FADD and caspase-8 to activate a caspase cascade and mediate apoptosis. 
Alternatively, RIP1 interacts with RIP3 and phosphorylation of RIP1 and RIP3 leads to 
the formation of necroptosome and mediates necroptosis (Figure 1.6). 
 
Necroptosis may play an important role in cell death during ischaemia and I-R. 
Necrostatin-1, a highly specific RIP1 inhibitor, reduces infarct volume in a mouse 
model of cerebral ischaemia (Degterev et al., 2005) and also lessens structural and 
functional impairment in a rat model of retinal I-R injury (Rosenbaum et al., 2010). The 
involvement of necroptosis has also demonstrated in kidney I-R where necrostatin-1 
ameliorated functional and morphological changes in kidney damage (Linkermann et 
al., 2012). In contrast to necrostatin-1 treatment, blockade of apoptosis by zVAD (a 
pan-caspase inhibitor) did not prevent tissue damage or the increase in urea and 
creatinine during in vivo renal I-R injury. The protective effect of necrostatin-1 was 
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more pronounced, suggesting the role of necroptosis over apoptosis in the 
pathophysiology of renal I-R injury (Linkermann et al., 2012).  
 
Although no studies have examined the direct role of necroptosis during myocardial I-R 
injury, it has been suggested that a group of serine/threonine kinases called receptor-
interacting proteins (RIPs) are activated and mediate necroptosis during cellular stress 
or death receptor activation (Moquin and Chan, 2010; Smith and Yellon, 2011; 
Vandenabeele et al., 2010). Activation of RIP-1 and -3, in turn, increases ROS 
production, either through activation of NADPH oxidases (Cho et al., 2009; Kim et al., 
2007) or increased mitochondrial oxidant production (Vandenabeele et al., 2010). One 
potential mitochondrial target for RIP-mediated necroptosis is mPTP. The mPTP opens 
in response to excessive production of ROS and Ca2+ overload of the mitochondrial 
matrix (Abdallah et al., 2011; Assaly et al., 2012; Saotome et al., 2009), both of which 
occur during myocardial I-R. This increase in inner membrane permeability dissipates 
the proton electrochemical gradient, leading to ATP depletion, further ROS production, 
and ultimately swelling and rupture of the organelle and cell lysis (Figure 1.6). 
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Figure 1.6: The molecular pathway of necroptosis.  
The signalling complexes are induced by TNFα to mediate cell survival, apoptosis or 
necroptosis. Stimulation of TNFR1 by TNFα leads to the formation of “Complex I”. 
Deubiquitination of RIP1 leads to the formation of “Complex II”. Phosphorylation of 
RIP1 and RIP3 forms “necrotosome” and mediate “necroptosis”. TNF, tumor necrosis 
factor; TNFR1, TNF receptor 1; IKK, I kappa B kinase; TRADD, TNF receptor-
associated death domain; TRAF2, TNF receptor-associated factor-2; RIP, receptor-
interacting protein; FLIP, FLICE-like inhibitory protein; FADD, Fas-associated protein 
with death domain; Pro-casp8; pro-caspase 8; ROS, reactive oxygen species. 
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1.4 Experimental models of myocardial infarction 
Experimental models of MI from small to large animal including sheep, dog, pig, rabbit, 
rat or mouse (Wang et al., 2001; Wong et al., 2011; Zhang et al., 2011; Zornoff et al., 
2009) have been used to identify the mechanisms involved in tissue damage and how 
new treatments intercept these pathways.  Previous studies have shown no significant 
difference between the extent of tissue damage between rat and rabbit models for MI 
(Mihailidou et al., 2009; Wong et al., 2011). Further, infarct size, calculated relative to 
area-at-risk following I-R in rat (Mihailidou et al., 2009), does not differ from other 
species (Schmidt et al., 2010; Wong et al., 2011; Ytrehus et al., 1994). The rat model for 
MI has been widely used to study the (patho)physiological alterations caused by 
occlusion and reperfusion (Fishbein et al., 1978; Selye et al., 1960), including infarct 
size and post infarction remodelling (Goldman and Raya, 1995; Vidavalur et al., 2008; 
Zornoff et al., 2009), and it is for this reason that we chose to perform our studies in 
rats. The progression of changes post- MI include an acute inflammatory response at the 
edge of the infarct area, chronic inflammation, vascularisation and collagenation, cell 
death and formation of necrotic tissue (infarction) (Fishbein et al., 1978). Additionally, 
MI induces myocyte hypertrophy (Anversa et al., 1985; Anversa et al., 1986; Anversa et 
al., 1984).  These features, especially the loss of myocardial cells in the area of injury, 
are also observed in rat hearts after occlusion of blood flow (Mihailidou et al., 2009).  
 
1.4.1 Ex vivo Langendorff isolated heart preparations 
The Langendorff isolated organ technique was established in the 1890s by Oscar 
Langendorff (Langendorff, 1898). This is an ex vivo model that consists of the intact 
heart removed from animal and perfused with blood-like buffer (Krebs-Henseleit buffer, 
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oxygenated solution) via the aorta. This is referred to as a “retrograde perfusion”, as the 
perfusate flows directly into the aorta rather than the normal situation where blood 
enters the aorta from the left ventricles (Bell et al., 2011b; Langendorff, 1898). The 
perfusate is forced through the ostium at the base of the aorta and into the coronary 
arteries. Retrograde perfusion of the coronary arteries can be delivered using either at a 
constant hydrostatic pressure or at a constant flow. Constant flow offers the advantage 
of greater reproducibility, and it is easy to induce various degrees of flow rate 
(Vidavalur et al., 2008).  
 
1.4.2 Advantages and limitations of the ex vivo experimental technique 
Experimental models of MI are usually divided into in vivo and ex vivo models. There 
are advantages and limitations of the ex vivo experimental technique. The isolated heart 
method (ex vivo) provides highly reproducible results. It allows a wide range of 
physiological, morphological and biochemical activity of the heart to be measured in a 
single experiment. Although the hearts are isolated from the body, the method remains 
reasonably close to normal physiology. Another advantage of this model is it allows the 
determination of direct actions of drugs or hormones in the whole heart without 
interference from the peripheral circulation (e.g. circulating hormones, blood cells), 
sympathetic stimulation or peripheral resistance. The model is also very useful for the 
study of dose-response relationships of direct actions of agents (Wong et al2011; 
Mihailidou et al2009) as well as assessing new compounds or drugs (Anderson et al., 
1990).  
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Limitations of isolated heart perfusion include lack of the normal humoral background 
and neuronal regulation of the heart. At very high perfusion flow rate, the retrograde 
flow of perfusate in the aorta may not pass through the ostium into the coronary 
arteries/circulation. The different composition of perfusion buffer compared to 
oxygenated whole blood or red-blood cell enriched solutions produces higher flow rates 
which alter sheer stress along the endothelium of coronary arteries and may lead to 
tissue edema (Döring and Dehnert, 1988). Another limitation is the significantly 
increased possibility of preconditioning during surgical excision of the heart, leading to 
higher oxidative stress and deterioration of contractile function (Ferdinandy et al., 
1999). Despite these limitations, several studies have confirmed that ex vivo results 
correlate well with in vivo studies (Penumathsa et al., 2007; Thirunavukkarasu et al., 
2006). 
 
1.4.3 Regional versus global ischaemia 
Ischaemia can be induced either by stopping perfusate or blood flow (global ischaemia) 
or by occluding a branch of the left coronary artery (regional ischaemia). Clinically, 
regional ischaemia is more important than global ischaemia. Global ischaemia for 25-30 
minutes can cause irreversible necrotic myocyte injury, resulting in substaintial 
increases in creatine kinase (CK) and serve myocardial dysfunction during reperfusion 
(Palmer et al., 2004). The presence or absence of collaterals between coronary vascular 
beds is irrelevant in the study of global ischaemia; however, it is highly relevant to 
regional ischaemia so that consistency is required in placing the snare in regional 
ischaemia. Regional ischaemia in the isolated perfused heart is obtained by ligation of 
one of the branches of the left anterior descending (LAD) coronary artery (Bredee et al., 
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1975; Johns and Olson, 1954; Reimer et al., 1981), reducing the oxygen and nutrient 
supply to the tissue distal to the snare (Liedtke et al., 1975; Neely et al., 1973) and 
cardiac function progressively declines as reperfusion progresses (Bolli and Marban, 
1999; Jennings et al., 1978; Ruiz-Meana et al., 2011). 
 
1.4.4 Duration of ischaemia and reperfusion during myocardial I-R 
For regional ischaemia induced by occlusion of either a branch of the left anterior 
descending or circumflex coronary arteries, the occlusion period varies. Ischaemia for 
30 minutes or less is often used while several studies have shown that 15-40 minutes of 
ischaemia results in potentially reversible cell injury, whereas >40 minutes results in 
cell death (irreversible necrotic injury) (Jennings et al., 1978; Ruiz-Meana et al., 2011). 
In the ex vivo Langendorff perfused heart, an ischaemic period of 30 minutes followed 
by 120-150 minutes of reperfusion produces an infarct area between 17% to 80%, with 
a median infarct size of 42% (Mersmann et al., 2011). This is a significant increase in 
infarct size and apoptosis compared to 60 minutes reperfusion (Mersmann et al., 2011). 
No significant difference in infarct size was observed between 120 to 150 minutes 
reperfusion (Birnbaum et al., 1997; Ferrera et al., 2009; Hausenloy et al., 2003; 
Mihailidou et al., 2009; Schwarz et al., 2000; Wang et al., 2001; Wong et al., 2011; 
Ytrehus et al., 1994).  
 
There is now also growing evidence that there are gender differences in outcomes from 
MI. Whether sex steroid hormones, particularly androgens, regulate the mechanisms 
activated during MI is not defined and further studies are required to determine the 
pathways activated during reperfusion injury differ between males and females. 
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1.5 Gender difference in ischaemic heart disease 
1.5.1 Overview 
Death rates due to IHD are higher in men than age-matched women (Bener et al., 2013; 
Papakonstantinou et al., 2013; Tunstall-Pedoe, 1998; Wingard et al., 1983) suggesting 
sex hormones play an important role. Recent studies highlight distinct gender 
differences in the epidemiology, pathophysiology and prognosis of IHD (Dunlay and 
Roger, 2012; Kostapanos et al., 2013), in that the prevalence of IHD in men is higher 
than in women across all ages (Jacobs, 2009; Kalin and Zumoff, 1990; Roger et al., 
2012). 
 
IHD presents in females approximately 10 years later than in males (Anand et al., 
2008), which decreases with increasing age, especially after the onset of menopause 
(Yusuf et al., 2001), with incidence of MI lower in women (Isaksson et al., 2011; 
Wenger, 2002). Although males have higher STEMI and age-adjusted prevalence of 
IHD compared to females (Heer et al., 2002; Kosuge et al., 2006), younger females 
experience more adverse outcomes after MI and coronary artery bypass grafting surgery 
than do males (Vaccarino et al., 2002), and a higher proportion of females with MI die 
of sudden cardiac arrest before reaching hospital (Roger et al., 2012; Shaw et al., 2006). 
The underlying reasons for the gender differences in IHD incidence have not been fully 
defined and may include genetics, lifestyle differences between genders or levels of 
endogenous sex hormones (Nordlie et al., 2005; Notarangelo et al., 2012; Silander et al., 
2008). Another possible reason for these gender differences may be that most clinical 
trials do not include adequate numbers of women and older males to allow sex-specific 
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analyses, suggesting a possible selection bias (Dunlay and Roger, 2012; Kim et al., 
2010; Xhyheri and Bugiardini, 2010). 
 
1.5.2 Sex hormones and ischaemic heart disease: controversy 
It has been suggested that hormonal differences between men and women may explain 
the gender differences in the incidence of IHD (Kalin and Zumoff, 1990; Perez-Lopez 
et al., 2010). Decline in oestrogen levels in post-menopausal women is associated with 
increased number of coronary deaths (Mosca, 2000; Tunstall-Pedoe, 1998), suggesting 
oestrogens are cardioprotective. Therefore many studies focused on the potential 
cardioprotective effects of oestrogens (Baker et al., 2003; Mendelsohn and Karas, 
1999), with very few studies investigating the role of androgens in IHD. 
 
Hormone replacement therapy (HRT) with oestrogens to post-menopausal women also 
produced conflicting results. While observational studies show improved cardiovascular 
outcomes (Herrington and Klein, 2001; Hodis et al., 2001), prospective randomised 
controlled studies show HRT either had no significant effects (Angerer et al., 2001; 
Cushman et al., 1999; Hodis et al., 2003) or adverse effects (Hulley et al., 1998; Kuller, 
2003; Vickers et al., 2007). Two trials in particular, the Heart and Estrogen/progestin 
Replacement Study (HERS) (Hulley et al., 1998) and the Women’s Health Initiative 
(WHI) study (Kuller, 2003) failed to show cardiovascular benefit as expected from the 
observational studies (Herrington and Klein, 2001), with increased cardiovascular risk 
in the first few years of HRT. The lack of cardiovascular benefit observed in the WHI 
and HERS studies was proposed to be due to the timing of treatment (Machens and 
Schmidt-Gollwitzer, 2003). Cardiovascular benefit was shown when women started 
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HRT at the onset of menopausal symptoms, prior to the development of any significant 
vascular disease (Dubey et al., 2005; Hodis et al., 2001). Recently the Danish 
Osteoporosis Prevention Study (DOPS) shows that 10 years of oestrogen replacement 
may be beneficial, with significantly decreased risk of MI, HF and mortality when HRT 
was started early in postmenopause (Schierbeck et al., 2012). Differences between the 
various trials include the participants recruited. The HERS study was established as a 
secondary prevention trial that targeted women already carrying significant disease risk 
(Hulley et al., 1998), whereas the WHI study was a primary prevention trial and 
included only women with no prior history of CVD (Kuller, 2003). Average age of 
women in the DOPS trial was younger than in the WHI (50 vs 65 years) at the 
commencement of treatment (Kuller, 2003; Schierbeck et al., 2012). In summary, 
endogenous oestrogens may protect younger women against early onset CVD and 
further prospective studies are required for starting oestrogen therapy earlier in post-
menopausal women. 
 
The role of androgens duirng IHD is also conflicting, with the pro-atherogenic effects of 
androgens suggested to contribute to their adverse cardiac effects (Hartgens et al., 2003; 
Hassan et al., 2009; Rockhold, 1993; Sader et al., 2001; Shapiro et al., 1999; Sullivan et 
al., 1998), whereas low levels of endogenous testosterone (T) in men are associated 
with increased CVD events (Akishita et al., 2010; Hak et al., 2002; Malkin et al., 2010). 
Few studies have examined the direct cardiac effects of androgens in males or females 
(Cattabiani et al., 2012; Mathur and Braunstein, 2010; Miller, 2001; Rosano et al., 
2005). Women with polycystic ovary syndrome (PCOS) have elevated levels of 
endogenous androgens and increased CVD risk (Christakou and Diamanti-Kandarakis, 
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2013; Christian et al., 2003; Guzick et al., 1996; Wild et al., 2000), while low 
endogenous testosterone levels in elderly men increased the risk of cardiovascular 
mortality (Laughlin et al., 2008; Wehr et al., 2011). In separate studies acute 
administration of testosterone produced arterial dilation, increased blood flow and 
improved myocardial ischaemia in men with CHD (Rosano et al., 1999; Webb et al., 
1999). The mechanism underlying beneficial effects of testosterone is not clearly 
defined. Since testosterone is coverted to 17β-oestradiol by the enzyme aromatase, it 
may be oestrogen that contributes to the vascular actions of testosterone. The 
dimorphism for sex steroid action may therefore depend upon the balance between 
testosterone and oestrogen (Dai et al., 2012; He et al., 2007; Kocoska-Maras et al., 
2009; Zheng et al., 2012), rather than absolute levels of androgens or oestrogens alone. 
Further studies are needed to confirm the role of androgens in the development or 
prevention of IHD. 
 
1.5.3 Gonadal steroids receptors 
Sex hormones mediate their cardiovascular actions through interaction with their 
specific sex steroid hormone receptors. Both androgen (AR) and oestrogen (E2-R) 
receptors are expressed in male and female hearts (Lizotte et al., 2009; Nordmeyer et 
al., 2004). Understanding whether the expression and regulation of these receptors is 
modified during MI may identify the mechanisms for the gender differences.  
 
1.5.3.1 Oestrogens and oestrogen receptors 
Oestrogens are female sex hormones and synthesized by the ovaries in premenopausal 
women. 17β-oestradiol (E2) is the biologically active oestrogen and oestrone (E1) is a 
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low-potency oestrogen. The conversion of low potency E1 into E2 is metabolized by the 
17β-hydroxysteroid dehydrogenase (17β-HSD) enzyme (Figure 1.7). E2 can exert both 
direct and indirect effects on cells (Miller and Duckles, 2008). E2 bind to the nuclear 
oestrogen receptors (E2-Rα and E2-Rβ) and the cytosolic E2-R-ligand complex 
translocates into the nucleus to regulate transcription. Both E2-Rα and E2-Rβ have been 
shown to be expressed in vascular endothelial cells, VSMCs (Mendelsohn, 2000) and 
cardiomyocytes (Lizotte et al., 2009; Saunders et al., 1997; Savolainen et al., 2001; 
Taylor and Al-Azzawi, 2000; Xu et al., 2003). E2 binds with similar binding affinity to 
both E2-Rα and E2-Rβ (approximately 0.05 to 0.3 nM) (Bologa et al., 2006; Kuiper et 
al., 1998). E2 also binds to a receptor at the plasma membrane. This receptor is either a 
membrane-resident E2-R variant (Haynes et al., 2002; Pedram et al., 2006a; Simoncini 
et al., 2000) or the G protein coupled receptor 30 (GPR30) (Filardo, 2002; Filardo and 
Thomas, 2005; Revankar et al., 2005), which localises to the endoplasmic reticulum 
(Revankar et al., 2005) or the plasma membrane (Filardo and Thomas, 2005). E2-
mediated effects through the activation of membrane-associated E2-R or GPR30 result 
in transactivation of the epidermal growth factor receptor (EGFR) (Filardo, 2002) and 
activating phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase 
(MAPK), NOS and increased levels of second messengers (e.g. cAMP, calcium) 
(Filardo, 2002; Haynes et al., 2000; Levin, 2009; Marino et al., 2006; Moriarty et al., 
2006), which have been shown to be protective. GPR30, however, has very low affinity 
for E2 (~ Kd 10−7 M) and proposed as unlikely to have physiologic relevance as an 
oestrogen receptor (Prossnitz et al., 2008; von Lueder et al., 2013). 
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Figure 1.7: Sex steroid hormones synthesis pathways.  
All steroid hormones are synthesised from the same precursor, cholesterol. The end 
product depends on the complement of enzymes present in the cells and tissues. DHEA, 
dehydroepiandrosterone; P450, cytochrome P450 oxidation enzyme; P450ssc, side 
chain cleavage; P450c17, 17-α-hydroxylase; 3β-HSD, 3β-hydroxysteroid 
dehydrogenase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; P450arom, aromatase; 
5α-RED, 5α-reductase. 
 
Recently, mitochondrial localised E2-R also been demonstrated in a number of cell 
types including primary cardiomyocytes (Chen et al., 2009; Pedram et al., 2006b; Yang 
et al., 2004). The E2-mediated mitochondrial pathway involves the generation of 
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cellular energy (ATP), mitochondrial respiratory complex and ROS generation that play 
important roles in regulating cell activities including cell death (Chen et al., 2009). 
Similarly, Pedram et al. (Pedram et al., 2006b) have shown that E2 inhibits UV-induced 
release cytochrome c, decrease in mitochondrial membrane potential, ROS production, 
and apoptosis in breast cancer cells and endothelial cells. 
 
1.5.3.2 Androgens and androgen receptors 
Androgens are male sex hormones and primarily synthesized in the testes. The principal 
androgen is testosterone (T), with active metabolites E2 and dihydrotestosterone (DHT) 
(Figure 1.7). Cytochrome P450 aromatase converts T to E2 (Diano et al., 1999; Sasano 
et al., 1999), while 5α-reductase enzymes reduce T to DHT, a non-aromatisable 
androgen (Swerdloff and Wang, 1998). DHT is a more potent androgen than T, in that it 
has higher affinity for the androgen receptor (AR) than T (Saartok et al., 1984; Wilson 
et al., 1993; Zhou et al., 1995). The effects of T and DHT are mediated by binding to 
the AR, a member of the steroid receptor superfamily (Mangelsdorf et al., 1995). The 
classical pathway of androgen action involves steroid binding to the AR; the ligand-
receptor complex then translocates into the nucleus to regulate transcription 
(Mangelsdorf et al., 1995; Quigley et al., 1995). AR have been found in ECs, VSMCs 
(Liu et al., 2005b) and cardiac myocytes from multiple species including rat and human 
(Marsh et al., 1998). There appear to be gender differences in AR expression in human 
vasculature, with higher levels in men than in women (Death et al., 2004; McCrohon et 
al., 2000; Sader et al., 2005). 
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1.5.4 Sex hormones in myocardial I-R injury 
Gender differences in cardioprotection have been reported in a few animal studies, 
suggesting that intact females (pre-menopausal) show less cardiac damage following 
ischaemia-reperfusion than males (Bae and Zhang, 2005; Wang et al., 2006). Female 
hearts subjected to global ischaemia followed by reperfusion had smaller infarcts (37%) 
than male hearts (48%) (Bae and Zhang, 2005) and significant improvement in post-
ischaemic recovery of the maximum rate of pressure development and relaxation 
(+/−dP/dt) compared to males (Wang et al., 2006). Under conditions of increased 
contractility or elevated Ca2+, there is reduced I-R injury in female compared to male 
hearts (Cross et al., 2002; Gabel et al., 2005; Kam et al., 2004). Protection may relate to 
the ability of the female heart to reduce Ca2+ loading during I-R, as it is known that 
elevated Ca2+ levels increase during reperfusion injury (Steenbergen et al., 1987). 
Lower levels of β1-adrenergic receptor (β1-AR) expression in intact females may 
provide an explanation for the reduced Ca2+ overload and protect the heart from injury 
(Chen et al., 2003a). In contrast to these findings, other ex vivo and in vivo studies have 
not demonstrated differences between males and females in I-R injury (Cross et al., 
1998; Li and Kloner, 1995; Przyklenk et al., 1995; Schuit et al., 2005). 
 
Gender also appears to be an important determinant of the incidence of cardiomyocyte 
cell death. In clinical studies less cardiomyocytes necrosis and apoptosis was observed 
in the normal and failing hearts of females compared to males (Guerra et al., 1999; 
Mallat et al., 2001; Olivetti et al., 1995). A higher levels of myocyte death in men is 
associated with an earlier onset heart failure (Guerra et al., 1999). Additionally, sex 
differences may occur at the cellular level, in that cells from males show a higher 
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susceptibility to apoptosis than autophagy, while cells from females show a higher 
resistance to apoptosis and susceptibility to autophagy in response to oxidant stress and 
metabolic disturbances (Alvarez et al., 1997; Maselli et al., 2009; Straface et al., 2012; 
Straface et al., 2009). These observations suggest the possibility that female sex 
hormones, such as oestrogen, may have a cardioprotective role while androgens, such as 
testosterone, have a detrimental effect on the development of CHD. 
 
1.5.4.1 Effects of oestrogens during myocardial I-R 
There have been numerous in vitro studies investigating the effects of E2 in multiple 
cell systems, with the collective findings strongly suggesting protective effects of E2. 
These effects include preventing TNF-α activated ERK1/2 signaling and reducing 
apoptosis in human umbilical vein endothelial cells (HUVEC) (Ling et al., 2006), 
reducing H2O2-induced apoptosis (Lu et al., 2007), and increasing levels of the anti-
apoptotic Bcl-2 and Bcl-xL in endothelial cells (Florian and Magder, 2008). Similarly, 
E2 inhibits apoptosis in cardiomyocytes as demonstrated by reduced activity of caspase-
3 and NF-κB transcription factors (Pelzer et al., 2000) and the nuclear accumulation of 
activated Akt (Camper-Kirby et al., 2001), a protein kinase that regulates a broad range 
of responses including cell survival (Kandel and Hay, 1999). Furthermore, in cultured 
neonatal rat cardiomyocytes subjected to in vitro system of hypoxia/reoxygenation to 
simulate I-R injury, E2-activated E2-Rs and suppressed mitochondrial ROS generation 
through PI3K signalling lead to myocyte survival (Kim et al., 2006a). 
 
In contrast, other studies have demonstrated that E2, at physiological concentrations, 
increases apoptosis in human coronary artery endothelial cells by upregulation of Fas 
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and FasL expression (Seli et al., 2006). In human aortic VSMCs, E2-induced apoptosis 
manifests through a non-genomic mechanism mediated by p38 and E2-Rα (Mori-Abe et 
al., 2003). Moreover, physiological concentrations of E2 have dual effects on rat 
VSMCs, simultaneously promoting proliferation of VSMCs and inducing apoptosis 
through up-regulation of Bax via the p38-MAPK pathway (Yang et al., 2007). These 
findings suggest that E2 has additional effects that may counteract the beneficial 
actions. 
 
Myocardial salvage achieved by primary PCI for acute MI is greater in women 
compared with men (Mehilli et al., 2005) with animal studies, showing females  had 
smaller infarct sizes compared with age-matched males (Bae and Zhang, 2005; Johnson 
et al., 2006; Zheng et al., 2011). Furthermore, replacement or treatment of animals with 
E2 prior to in vivo coronary artery ligation reduced I-R injury in both males and females 
as indicated by smaller infarct size (Booth et al., 2003; Booth et al., 2007; Booth et al., 
2005; Das and Sarkar, 2006; Hale et al., 1997; Lee et al., 2004; Li and Kloner, 1995; 
Patten et al., 2004; Sbarouni et al., 1998; van Eickels et al., 2003) and less apoptosis 
(Patten et al., 2004; van Eickels et al., 2003). 
 
Moreover, human myocardial samples from premenopausal females had a greater 
nuclear accumulation of the activated Akt and reduced cardiomyocyte apoptosis 
compared with normal males and postmenopausal females (Camper-Kirby et al., 2001). 
In ex vivo experimental myocardial I-R,  females constitutively expressed a significantly 
lower pro-apoptotic Bax-to-Bcl-2 ratio and higher anti-apoptotic protein ARC than male 
or ovarectomized female rabbits (Bouma et al., 2010). Similarly E2-mediated anti-
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apoptotic effects were observed in ovarectomised female mice in vivo, in which E2 
replacement increased activation of Akt and decreased cardiomyocyte apoptosis after 
MI (Patten et al., 2004).  
 
Although E2 appears cardioprotective during myocardial I-R damage, some adverse 
effects of E2 treatment on ventricular remodelling and mortality have been reported in 
animals with MI (van Eickels et al., 2003; Zhan et al., 2008). The diverse effects of E2 
may be due to differences in the levels of E2, with detrimental effects of high E2 
concentrations but not at physiological levels (Jovanovic et al., 2000; Meng et al., 2011; 
Zhan et al., 2008). For example, supplementing E2 to ovarectomised mice for 8 weeks 
with low-dose E2 (0.42 μg/day), restored plasma levels close to physiological levels and 
improved cardiac function and remodelling following MI; whereas higher moderate (4.2 
μg/day) and very high (18.8 μg/day) doses exacerbated cardiac fibrosis, hypertrophy, 
dysfunction and dilatation (Zhan et al., 2008). 
 
1.5.4.2 Effects of androgens during myocardial I-R 
In comparison with other androgen target organs, the heart can accumulate testosterone 
at higher concentrations (Krieg et al., 1978), and functional AR are present in isolated 
cardiomyocytes (Zhang et al., 1998). However, little information exists regarding the 
role of physiological levels of testosterone in cardiac injury. Testosterone has pro-
inflammatory and/or pro-apoptotic effects in vascular cells, with increased VSMC 
apoptosis in a dose-dependent manner (Bowles et al., 2007). High testosterone levels 
enhance acute myocardial inflammation and increase cardiac rupture, leading to 
deterioration of cardiac function after MI (Cavasin et al., 2006). Blocking AR, by 
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flutamide or removing testosterone by gonadectomy (Gx), decreases myocardial injury 
and improves myocardial function after I-R in adult male rats (Huang et al., 2010; 
Wang et al., 2005; Wang et al., 2009). In comparison with untreated males, Gx male 
and flutamide-treated male hearts had decreased pro-inflammatory cytokines (TNF-α, 
IL-1, IL-6), decreased pro-apoptotic proteins (caspase-3, FasL), increased anti-apoptotic 
protein (Bcl-2), decreased activation of p38 MAPK while increased activation of Akt 
after I-R (Huang et al., 2010; Wang et al., 2005). Acute perfusion of isolated hearts with 
testosterone increased activation of MAPKs and caspase-3 following I-R; however, 
there were no significant differences in the myocardial proinflammatory cytokine 
production (Crisostomo et al., 2006). Consistently, the number of apoptotic cells was 
increased by testosterone in neonatal and adult cardiomyocytes (Kohno et al., 2007; 
Welder et al., 1995; Zaugg et al., 2001). 
 
Several animal studies have shown that exogenous T or DHT treatment aggravate 
cardiac damage during I-R in males and females (Cavasin et al., 2003; Cavasin et al., 
2006; Crisostomo et al., 2006; Huang et al., 2010; Wang et al., 2005; Wang et al., 
2009). Contrary to the adverse effects, a number of studies show neutral (Nam et al., 
2007a; Rubio-Gayosso et al., 2013) or protective effects (Chen et al., 2012a; Kuhar et 
al., 2007; Liu et al., 2012). The variable results may be related to whether low or high 
doses were administered (Cavasin et al., 2003; Chen et al., 2012a; Crisostomo et al., 
2006; Liu et al., 2012) and the route of administration (Stokes et al., 2000). 
Additionally, variability may be a result of whether the androgen used was testosterone, 
which is aromatised to E2, or DHT (Rubio-Gayosso et al., 2013). Metabolism of T to 
E2 diversifies its action as E2 acts through binding and activation of either of the E2-R 
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isoforms, E2-Rα or E2-Rβ, resulting in activation of different set of genes to that 
regulated by T binding its cognate receptor, AR. Indeed, there is increasing evidence 
that the cardioprotective effects of T in male animals is via its aromatisation to E2 (Bell 
et al., 2011a; Chen et al., 2012a; Rubio-Gayosso et al., 2013). However, DHT treatment 
resulted in the opposite effects to T, increasing myocardial damage during I-R in males 
(Rubio-Gayosso et al., 2013).  
 
1.6 Corticosteroids and the mineralocorticoid receptor 
1.6.1 Overview  
To determine the actions of corticosteroids and the mineralcorticoid receptor (MR) 
during MI requires a brief summary of the renin-angiotension-aldosterone system 
(RAAS) which is important in regulating blood pressure and cardiac function. The 
system consists of several important components including renin, angiotensin and 
aldosterone (Figure 1.8). Renin is released from the kidneys into circulation and acts as 
substrate for angiotensinogen that undergoes proteolytic cleavage to form angiotensin I. 
Angiotensin I then cleaves off two amino acids by angiotensin converting enzyme 
(ACE) to form angiotensin II. The formation of angiotensin in blood and tissues, in turn, 
stimulates the release of aldosterone from the adrenal cortex (Mulrow, 1999; Zaman et 
al., 2002). Aldosterone secretion is also stimulated by adrenocorticotropic hormone 
(ACTH), sodium and potassium levels (Merrill et al., 1989; Quinn and Williams, 1988; 
Zaman et al., 2002). Activation of RAAS has been implicated in the pathogenesis of 
CVD including AMI and HF. The hormones in the RAAS, in particular angiotensin II 
and aldosterone, have direct dertrimental effects on the myocardium contributing to 
cardiac remodelling and cardiac failure (Edelmann et al., 2012; Huggins et al., 2003; 
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von Lueder et al., 2013; Weir et al., 2011). Blockade of this system with ACE inhibitors 
or angiotensin receptor blockers (ARB) have shown benefit in MI and HF (Gajarsa and 
Kloner, 2011; Mentz et al., 2012), although they do not suppress plasma levels of 
aldosterone. During prolonged treatment with ACE inhibitors or ARB (Borghi et al., 
1993; Struthers, 1996), plasma levels of aldosterone are increased indicating targeting 
blockade of aldosterone is also required. 
 
 
 
Figure 1.8: Synthesis pathway for the renin-angiotensin-aldosterone system.  
ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; ARB, 
angiotensin receptor blockers; NEP, neutral endopeptidase; AT1R, angiotensin II type 1 
receptor; ACTH, adrenocorticotropic hormone. (Modified from von Lueder et al., 2013 
and Zaman et al., 2002). 
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1.6.2 Corticosteroids 
Both mineralocorticoids (include aldosterone) and glucocorticoids (include cortisol) 
hormones are known as corticosteroids and play an important role in cardiovascular 
pathogenesis including cardiac hypertrophy (Mannic et al., 2013; Ren et al., 2012; 
Tsybouleva et al., 2004),  inflammation and cardiac fibrosis (Lin et al., 2012; Rickard et 
al., 2012; Zhu et al., 2012), left ventricular remodelling post-MI (Hayashi et al., 2001; 
Weir et al., 2011) and HF (Guder et al., 2007). Corticosteroids are synthesised from 
cholesterol within the adrenal cortex (as shown in Figure 1.9). Adrenal glomerulosa 
cells mainly synthesise and secrete the mineralocorticoids, with aldosterone being the 
major mineralocorticoid, while the adrenal fasciculate cells synthesise and secrete the 
glucocorticoids (Yanagibashi et al., 1986). This subspeciality is largely due to the 
complement of biosynthetic enzymes present (Hanukoglu, 1992; Miller and Auchus, 
2011). 
 
At physiological levels these hormones are involved in a wide range of physiological 
processes including immune response, stress response, regulation of inflammation, 
blood electrolyte levels and behaviour (Gupta and Bhatia, 2008). Mineralocorticoids 
(aldosterone) maintain water and electrolyte balance by acting upon the distal tubules 
and collecting ducts of the kidney (Cooper and Hunter, 1994), while glucocorticoids 
(cortisol) regulate metabolic activity, immune function and behaviour (Munck and 
Guyre, 1986). 
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Figure 1.9: Mineralocorticoid (aldosterone) and glucocorticoid (cortisol in human 
and corticosterone in rodents) synthesis pathway.  
Mineralocorticoids and glucocorticoids are synthesised in the adrenal cortex. Adrenal 
glomerulosa cells mainly synthesise and secrete the mineralocorticoid, while the adrenal 
fasciculate cells synthesise and secrete the glucocorticoids. All steroid hormones are 
synthesised from the same precursor, cholesterol. The end product depends on the 
complement of enzymes present in the cells and tissues. P450, cytochrome P450 
oxidation enzyme; P450SCC, side chain cleavage; P450C11, 11-hydroxylase; P450C17, 17-
α-hydroxylase; P450C21, 21-hydroxylase; P450aldo, aldosterone synthase; 3β-HSD, 3β-
hydroxysteroid dehydrogenase; 11β-HSD, 11β-hydroxysteroid dehydrogenase. 
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These hormones exert their biological effects by binding to the mineralocorticoid (MR) 
and glucocorticoid (GR) receptors (Arriza et al., 1987; Weinberger et al., 1985). MR is 
a member of the nuclear receptor superfamily in a closely-related subfamily 3, group C, 
member 2, (NR3C2). MR is closely related to GR/AR/PR (progesterone receptor) 
within this family of hormone receptors, and MR and GR are the most closely related, 
sharing several features in common. The ligand binding domain of MR and GR show 
~57% amino acid identity, consistent with their ability to bind glucocorticoid hormones. 
MR and GR are highly homologous in the DNA-binding domain, sharing an amino acid 
identity of 94%. The N-terminal regions of MR and GR are the most divergent, sharing 
only 15% amino acid identity. Although MR and GR are closely related, MR displays 
~10-fold higher affinity for corticosteroids than GR (0.5 nM vs. 5 nM, respectively for 
corticosterone), and has been shown to predate the evolution of aldosterone (Kassahn et 
al., 2011). MR binds aldosterone and the physiologic glucocorticoids with similar 
affinity (Arriza et al., 1987; Funder et al., 1988; Krozowski and Funder, 1983), but the 
affinity of GR for aldosterone is very much lower [Kd = ~85 nM (GR) vs Kd = ~0.6 nM 
(MR)], and aldosterone does not appear to act via GR at physiological concentrations 
(Gaeggeler et al., 2005). 
 
1.6.3 Structural & functional domain of MR 
To envisage how these hormones might regulate cardiovascular function we need to 
understand the structure-function relationships in the receptor through which they exert 
their effects, the mineralocorticoid receptor (MR). The human MR (hMR) gene 
(NR3C2) is located on the chromosome 4 in the q31.1 region (Fan et al., 1989). It spans 
approximately 450 kb (Morrison et al., 1990; Zennaro et al., 1995), and contains 10 
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exons. The first two exons (1α & 1β) are untranslated; the remaining eight exons encode 
a 984 amino acid protein with molecular weight of 107 kD (Figure 1.10) (Viengchareun 
et al., 2007). The rat MR (rMR) gene is located on chromosome 19q11 and has three 
unstranslated exons (1α, 1β & 1γ), and the eight translated exons encoding a 981 amino 
acid protein (Kwak et al., 1993). Similarly, the mMR gene encodes a 978 amino acid 
protein. 
 
Similar to other nuclear receptors, MR protein contains three main functional domains 
(shown in Figure 1.10): (i) an N-terminal domain (NTD) important for transcriptional 
regulation of specific target genes, (ii) a central DNA-binding domain (DBD) that 
mediates receptor/DNA interactions, and a hinge region linking them to (iii) a carboxy-
terminal ligand binding domain (LBD) important for ligand recognition and binding.   
 
 
Figure 1.10: Structure of the MR.  
The mineralocorticoid receptor consists of three functional domains: (i) N-terminal 
domain (NTD), exon 2; (ii) DNA binding domain (DBD) and a bipartite nuclear 
targeting signal within the hinge region, exons 3-4; (iii) The C- terminal region 
containing the ligand-binding domain (LBD), exons 5-9. AF-1a, activator factor 1a; AF-
1b, activator factor 1b; AF-2; activator factor 2. 
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The NTD of MR is the largest of the steroid receptor family, consisting of 604 amino 
acids (Zennaro et al., 1995). Structure-function studies have demonstrated that the NTD 
is important for the regulation of transcription and to interact with transcriptional co-
activators (Fischer et al., 2010; Tallec et al., 2003). The NTD contains the first 
activation function-1 (AF-1, AF-1a and AF-1b) domain.  The AF-1 domain is located in 
the middle of the MR-NTD (residues 328–382) and is important for transactivation 
(Govindan and Warriar, 1998). Other AF-1 domains are AF-1a and AF-1b which have 
distinct protein regions (residues 1–167 and 445–602 respectively) (Fuse et al., 2000; 
Tallec et al., 2003). These activation function domains recruit coregulators important 
for MR transcriptional activity as well as selectivity (Pascual-Le Tallec and Lombes, 
2005). These coactivators act as adapters that recruit CREB-binding protein/p300/SRC-
1 complexes and promote transcriptional activity of the receptor (McKenna et al., 
1999b).  
 
The DBD is the most highly conserved region across the steroid receptors, with >90% 
identity with that of GR, AR and PR (Viengchareun et al., 2007), recognising specific 
target DNA sequences (hormone response elements: HRE). Structurally, it folds into 
two perpendicular alpha helices and coordinates with two zinc molecules in the classic 
zinc-finger binding domain fold. The zinc fingers contains the “P box” and “D box” 
responsible for tight binding to the minor groove on the DNA double helix and involved 
in receptor homo- and hetero-dimerization (Liu et al., 1995; Pippal and Fuller, 2008). 
MR, GR, AR and PR are known to bind the AGAACA half site, through this domain, 
and thereby alter transcription (Pippal and Fuller, 2008). The flexible hinge or D region, 
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located between DBD and LBD, permits a twist of the DBD relative to the LBD 
(Pawlak et al., 2012), although the function of this region is not clearly defined.  
 
The LBD of the MR is highly conserved across species (80-97% homology) 
(Viengchareun et al., 2007) and is similar to that of the GR in that it binds aldosterone 
and glucocorticoids (cortisol in human and corticosterone in rodents) equally well 
(Arriza et al., 1987). The C-terminal domain is also important for interactions of the MR 
with cofactor proteins and chaperones, such as the heat shock proteins. In the basal 
state, MR are associated with protein chaperones (Hsp90, Hsp70, Hsp40, Hop, p23, FK-
binding proteins) (Faresse et al., 2010), the tumor suppressor gene 101 (Tsg101) 
(Faresse et al., 2012) and the phosphatase calcineurin PP2BAβ (Seiferth et al., 2012). 
Inhibition of Hsp90 with 17-AAG (17-allylamino-17-demethoxygeldanamycin) induced 
MR degradation in ECs by increasing the association between MR and the ubiquitin-
protein ligase CHIP (COOH terminus of Hsp70-interacting protein) (Faresse et al., 
2010). It has been shown that aldosterone-modulated the ubiquitylation state of the 
receptor in ECs by inducing phosphorylation of MR and disruption of MR/Tsg101 
association. These events rapid destabilize of MR and regulate its degradation by the 
ubiquitin proteasome pathway (Faresse et al., 2012). Similarly, treatment with 
aldosterone decreases hMR protein expression in transfected COS-1 cells (Yokota et al., 
2004), effect was blocked by treatment with proteasome inhibitors (ALLnL or MG132). 
 
Other important functions of the LBD include dimerisation and hyper-phosphorylation 
that induce conformational changes required for transactivation (Couette et al., 1996; 
Couette et al., 1998). The LBD also contains the C-terminal activation function 2 (AF-
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2) domain (Pascual-Le Tallec and Lombes, 2005; Pippal and Fuller, 2008; 
Viengchareun et al., 2007). The AF-2 is a hydrophobic groove on the surface of the 
LBD that interacts with coactivators containing an LxxLL motif (Bledsoe et al., 2005; 
Li et al., 2005; Pippal and Fuller, 2008). Ligand-induced functional synergism between 
the AF-1 and AF-2 mediates through their interaction with transcriptional coregulators 
(McKenna et al., 1999a; Rogerson and Fuller, 2003). Although LBD is important for 
ligand binding, the NTD appears to account for ~40-50% of total transactivation and 
represents a key determinant of MR specificity (Lim-Tio et al., 1997; Pascual-Le Tallec 
and Lombes, 2005). 
 
1.6.4 MR expression 
MR is expressed in the epithelial target tissues of the kidney and the colon, as well as 
non-epithelial tissues such as brain and heart (Gomez-Sanchez et al., 2006). In the heart, 
MR are present in cardiomyocytes (Gomez-Sanchez et al., 2006; Lombes et al., 1992; 
Pearce and Funder, 1987), fibroblasts (Lother et al., 2011), VSMCs,  ECs (Kornel, 
1994; Lombes et al., 1992) and macrophages (Rickard et al., 2009). In epithelial target 
tissues, such as the kidney, MR regulates sodium balance in response to aldosterone and 
other factors, including changes in plasma K+ and Na+ concentrations. Epithelial MR 
selectivity for aldosterone is conferred by expression of the enzyme 11 beta-
hydroxysteroid dehydrogenase II (11β-HSD2) that converts cortisol to the inactive 
cortisone which does not bind to MR (Edwards et al., 1988; Funder et al., 1988). 
However, 11β-HSD2 is not expressed in cardiomyocytes (Sheppard and Autelitano, 
2002), therefore endogenous glucocorticoids normally occupy cardiomyocyte MR but 
do not mimic aldosterone, and normally act as MR antagonists (Gomez-Sanchez et al., 
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1990; Sato and Funder, 1996; Young and Funder, 1996).  
 
Under basal conditions, MR are localised to both nuclei and the cytosol of myocytes 
(both H9c2 cells and sections of rat heart, (Gomez-Sanchez et al., 2006), with even 
distribution of unliganded receptors between the nucleus and the cytoplasm in a variety 
of cells (Fejes-Toth et al., 1998; Hernandez-Diaz et al., 2010; Nishi et al., 2001; 
Walther et al., 2005). In addition, studies using fluorescence resonance energy transfer 
and co-immunoprecipitation have reported MR can co-localise with EGFR (Grossmann 
et al., 2010) and caveolin-1 and -3 (Ricchiuti et al., 2011) in the plasma membrane. 
Moreover, aldosterone binding sites have been detected on the plasma membrane of 
human endothelial cells by atomic force microscopy (Wildling et al., 2009). However, 
the characteristics and functional role of such MR membrane sites are not unclear. 
 
MR expression has been found to be upregulated in hearts from patients with congestive 
HF (Yoshida et al., 2005). Similarly, in animal models of experimental MI, levels of 
MR protein were increased in the left ventricle after MI (2-4 weeks) (de Resende et al., 
2006; Milik et al., 2007; Takeda et al., 2007) and were attenuated by chronic treatment 
with spironolactone (Takeda et al., 2007). Interestingly, aldosterone also decreases hMR 
protein expression in transfected COS-1 cells (Yokota et al., 2004), an effect blocked by 
treatment with proteasome inhibitors (ALLnL or MG132). There have been no studies 
to determine myocardial MR expression in short-term or acute MI. 
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1.6.5 Mechanism of action for MR: genomic and non-genomic 
The biological effects of aldosterone in cells are mediated by both genomic and non-
genomic mechanisms (Figure 1.11; Moura and Worcel, 1984). The genomic action of 
aldosterone involves aldosterone binding to the cytosolic MR, and nuclear translocation 
followed by modulation of transcriptional Cytosolic MR are normally attached to multi-
protein chaperones (Hsp90, Hsp70, Hsp40, Hop, Hsp90-binding co-chaperone p23) and 
co-chaperones (FK-binding proteins (FKBP51/52), cyclophilin 40 (Cyp40), serine-
threonine protein phosphatase 5 (PP5), Tpr2). These serve to hold the receptor in a 
conformation that facilitates hormone binding (Echeverria and Picard, 2010). Once 
aldosterone is bound, a conformational change is induced which allows the chaperone 
complexes to dissociate from the receptor and activation of the MR. The aldosterone-
MR complex translocates to the nucleus, undergoes homodimerization and binds to 
hormone response elements (HREs) present in the promoter of responsive genes. This 
results in the complex recruitment of the transcriptional machinery and induces gene 
transcription into mRNA off the DNA sequence (Fuller and Young, 2005). The 
expression of a number of genes is regulated by MR, including the epithelial Na+ 
channel (ENaC) (Asher et al., 1996), serum-regulated kinase 1 (Sgk-1) (Chen et al., 
1999; Naray-Fejes-Toth and Fejes-Toth, 2000), plasminogen activator inhibitor 1 (PAI-
1) (Chun and Pratt, 2005) and Na+/K+-ATPase (Kolla and Litwack, 2000).  
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Figure 1.11: Genomic (right) and non-genomic (left) action of aldosterone.  
MR, mineralocorticoid receptor; GPR30, G protein-coupled receptor 30; EGFR, 
epidermal growth factor receptor; HRE, hormone response elements;  Sgk-1, serum-
regulated kinase 1; PAI-1, plasminogen activator inhibitor 1; ROS, reactive oxygen 
species; TGF- β, transforming growth factor-β; ERK1/2, extracellular signal regulated 
kinase 1/2;  cJNK, c-Jun N-terminal kinase; p38MAPK, p38 mitogen-activated protein 
kinase. 
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The non-genomic effects of aldosterone occur rapidly after stimulation (seconds to 
minutes) and include activation of the second messengers protein kinase C (PKC) 
(Alzamora et al., 2007; Darling et al., 2013; Jennings and Reimer, 1991; Mihailidou et 
al., 2004), Na+/H+ exchange (NHE), extracellular signal regulated kinase 1/2 (ERK1/2) 
(Gekle et al., 2001; Grossmann et al., 2005; Ram and Trivedi, 2012; Surder et al., 
2010), and increases intracellular Ca2+ and pH (Alzamora et al., 2000; Wehling et al., 
1996), and NADPH oxidase-mediated ROS production (Hayashi et al., 2008). Evidence 
for rapid non-genomic aldosterone effects have been studied in different cells and 
tissues including VSMC, skin cells from MR-knockout mice, neonatal rat and isolated 
rabbit cardiomyocytes, trabeculae and coronary arteries. The non-genomic effects of 
aldosterone are not blocked by inhibitors of transcription and protein synthesis (Hayashi 
et al., 2008; Mihailidou et al., 2004) and mediated through MR-dependent and MR-
independent mechanisms (Barbato et al., 2002; Chai et al., 2005; Michea et al., 2005; 
Rossol-Haseroth et al., 2004). 
 
Rapid non-genomic aldosterone effects have also observed clinically in healthy subjects 
was associated with an increase in vascular resistance within first 3-5 minutes (Schmidt 
et al., 1999; Wehling et al., 1998) and changes in cardiac output and cardiac index after 
3 minutes (Wehling et al., 1998). Continuous infusion of aldosterone acutely limits 
forearm blood flow, between 4 and 8 minutes (Schmidt et al., 2003). Perfusion of the 
isolated rat heart with aldosterone induces positive inotropic and vasoconstrictor effects 
within 1-2 minutes which are not blocked by spironolactone (Chai et al., 2005). 
Similarly, aldosterone rapidly (within 2-5 minutes) increases contractility in rat heart 
(Barbato et al., 2002), decreases in coronary blood flow, fractional shortening and 
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lactate extraction rate in non-ischaemic and ischaemic hearts (Fujita et al., 2005). These 
rapid effects of aldosterone were blocked by PKC inhibition but not spironolactone in 
dog heart (Fujita et al., 2005).  
 
Investigations into the mechanisms underlying the rapid effects of aldosterone indicate 
some of these rapid effects are mediated by the G protein-coupled receptor 30 (GPR30 
or GPER1) (Gros et al., 2011b; Ji et al., 1998). GPR30 is located at the cell membrane 
and in the endoplasmic reticulum of transfected cells (Filardo et al., 2007; Revankar et 
al., 2005; Revankar et al., 2007), and is widely expressed in a variety of tissues 
including heart, lung, liver and brain (Deschamps and Murphy, 2009; Jessup et al., 
2010; O'Dowd et al., 1998), and in freshly isolated cardiac myocytes (Deschamps and 
Murphy, 2009), vascular smooth muscle and endothelial cells (Ding et al., 2009). Rapid 
activation of ERK1/2 and apoptosis by aldosterone in vascular smooth muscle cells is 
GPR30-dependent (Gros et al., 2011b). Conversely, activation of GPR30 improves 
functional recovery and decreases inflammation during myocardial I-R in the rat (Weil 
et al., 2010). Although studies suggest GPR30 is a putative membrane receptor 
mediating MR-independent rapid aldosterone signalling, further studies are required to 
determine whether GPR30 mediates the direct actions of aldosterone on the heart. 
 
1.6.6 Effects of MR regulation in the cardiovascular system 
Substantial evidence has suggested that aldosterone directly exerts adverse effects on 
the cardiovascular system. MR effects on the heart include oxidative stress, endothelial 
dysfunction, inflammation, fibrosis and vascular cell apoptosis.  
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1.6.6.1 Oxidative stress 
A number of studies support a specific role of the MR as a mediator of oxidative stress 
and subsequent inflammation (Sun et al., 2002), fibrosis (Bienvenu et al., 2012), 
atherosclerosis (Keidar et al., 2004) and apoptosis (Patni et al., 2007). Indeed, 
aldosterone upregulates various subunits of NADPH oxidase (NOX2, p22phox, 
p40phox, gp91) and induces ROS generation in various cell types (mononuclear, 
VSMCs and neonatal cardiomyocytes) (Ahokas et al., 2005; Calo et al., 2004; Hayashi 
et al., 2008; Schafer et al., 2013; Sun et al., 2002). Aldosterone also decreased G6PD 
expression and impaired endothelial function (Leopold et al., 2007). These effects of 
aldosterone on ROS production and G6PD expression were blocked by anti-oxidants or 
free radical scavenger (tempol), and MR antagonists (Hayashi et al., 2008; Leopold et 
al., 2007). MR blockade improved impaired endothelial function by decreasing 
NAD(P)H oxidase subunit p22phox expression, NAD(P)H oxidase activity and 
superoxide anion generation in chronic HF (Bauersachs et al., 2002) and atherosclerosis 
(Rajagopalan et al., 2002). A recent study demonstrated that MR blockade prevented 
ROS production and vascular p22phox upregulation early after MI (Sartorio et al., 
2007). Furthermore, MR blockade with spironolactone (50 mg/kg/day) was shown to 
improve nephropathy in diabetic hypertensive rats by restoring G6PD activity, 
GSH/GSSG ratio and an overall reduction in oxidative stress (Pessoa et al., 2012) 
 
Although MR are activated during aldosterone excess, they can also be activated in 
states where aldosterone concentrations are in the low-normal range (Matsui et al., 
2008a; Williams et al., 2004). Oxidative stress is recognized as a major contributor to 
cardiac pathology including reperfusion injury (as reported in section 1.4.1). Several 
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reports suggest that oxidative stress enhances MR signal transduction. For instance, MR 
signalling is enhanced in the heart and kidney of obese hypertensive rats with excessive 
salt intake, whereas the antioxidant Tempol suppressed MR activation and reduced 
target organ damage (Matsui et al., 2008a; Nagase et al., 2007). The MR-mediated 
chronotropic, pro-arrhythmogenic response in cultured cardiomyocytes was enhanced 
by oxidative stress (Rossier et al., 2008). Furthermore, glucocorticoids activate 
cardiomyocyte MR during experimental MI, a condition with increased oxidant 
concentrations, and aggravated cardiac damage (Mihailidou et al., 2009). However, the 
exact mechanisms by which oxidant stress induces MR activation have not been clearly 
elucidated.  
 
Recent studies identified a ligand-independent pathway of MR activation by Rac1, a 
Rho family small GTPase, through analysis of RhoGDIα knockout mice (Shibata et al., 
2008). The Rac1-mediated MR activation pathway contributes to the pathogenesis of 
chronic kidney disease (Shibata et al., 2008) and salt-sensitive hypertension (Shibata et 
al., 2011). RacGTPase is a component of NADPH oxidase (Lambeth, 2004).  ROS 
activates Rac1, which in turn, produces ROS via NADPH oxidase activation, leading to 
the formation of a feed-forward loop between Rac1 and ROS (Gonzalez-Santiago et al., 
2006; Ho et al., 2006). In cultured rat cardiomyocytes (H9c2), BSO-evoked oxidative 
stress activates Rac1, which, in turn, causes MR activation, as evidenced by enhanced 
MR-driven transcriptional activity and nuclear accumulation of MR (Nagase et al., 
2012). These enhancing effects of BSO were abrogated by two Rac inhibitors, 
NSC23766 (Shibata et al., 2008) and EHT1864 (Desire et al., 2005), as well as 
expression of dominant-negative Rac1 construct. The effects of Rac1 on MR are 
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blocked by spironolactone (Shibata et al., 2008); however, further studies are needed to 
elucidate the precise mechanisms of MR activation by Rac1. 
 
1.6.6.2 Inflammation, fibrosis and atherosclerosis  
Elevated plasma aldosterone are accompanied by a pro-inflammatory and -fibrogenic 
vascular phenotype (Ahokas et al., 2005; Blasi et al., 2003; Sun et al., 2002) and 
blocked by both spironolactone and anti-oxidants (Sun et al., 2002). In addition, 
aldosterone stimulates collagen synthesis in cardiac fibroblasts (Brilla et al., 1994) 
which ultimately induces cardiac fibrosis (Ahokas et al., 2005). Evidence for 
aldosterone enhancing plaque formation was demonstrated in an animal model of 
atherosclerosis. Aldosterone infusion increased overall aortic plaque area with enhanced 
vascular and macrophage oxidative stress (Keidar et al., 2004).  The MR antagonists 
and aldosterone synthase inhibitors inhibited atherosclerosis and inflammation as well 
as attenuated macrophage oxidative stress in animal models (Gamliel-Lazarovich et al., 
2010; Keidar et al., 2003; Rajagopalan et al., 2002; Suzuki et al., 2006). Furthermore, 
the role of MR in regulating cardiac fibrosis has been demonstrated in mice with 
specific monocyte/macrophage MR deletion, which protects against chronic 
mineralocorticoid/salt-induced cardiac fibrosis and increased systolic blood pressure 
(Rickard et al., 2009). 
 
1.6.6.3 Apoptosis 
Aldosterone is now recognised as an important modulator of myocyte apoptosis (Mano 
et al., 2004). In cultured adult rat ventricular myocytes (De Silva et al., 2009), human 
renal proximal tubular (HK2) cells (Patni et al., 2007) and human mesangial cells in 
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vitro and in vivo (Mathew et al., 2008) aldosterone promotes apoptosis as indicated by 
increasing TUNEL positivity, caspase-3 activation and expression of Bax and p53. 
Moreover, aldosterone decreases Bcl-2 protein expression. Chronic treatment with 
aldosterone induced caspase-3 activity which was prevented by pre-treatment with 
spironolactone in heart and skeletal muscle (Burniston et al., 2005). In in vitro 
aldosterone treatment impairs Akt activation in VSMCs (Hitomi et al., 2007), a pro-
apoptotic effect inhibited by eplerenone and spironolactone (De Silva et al., 2009; 
Mathew et al., 2008). Similarly, antioxidants and free radical scavengers attenuated the 
pro-apoaptotic effects of aldosterone (Mihailidou et al., 2009; Patni et al., 2007). 
 
Anti-apoptotic effects of MR blockade have been demonstrated in both in vitro and in 
vivo systems. In cultured ECs, spironolactone (10 μM) inhibits of caspase-3 activity, 
cytochrome c release and PARP cleavage induced by serum-deprivation, although this 
effect has been suggested to be mediated by an agonist effect of spironolactone via 
progesterone receptor (Williams et al., 2006). Similarly, high-dose (200 mg/kg/day) 
eplerenone attenuated the increase in myocardial expression of the pro-apoptotic BH3 
only protein Bax in a model of pressure overload induced by aortic banding (De Silva et 
al., 2009). Treatment with low dose spironolactone (0.24 mg/day) protects the 
vasculature from aldosterone-induced apoptosis and structural injury via rescuing Akt 
activation, independent of blood pressure effects (Wei et al., 2009). 
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1.6.7 MR regulation during MI: cardiac damage & mechanisms 
involved 
In previous studies from our laboratory, perfusion of rat hearts with corticosteroids 
exacebated infarct area and apoptosis during experimental MI, which were prevented by 
MR but not GR blockade, confirming MR activation aggravates cardiac damage 
(Mihailidou et al., 2009). These preclinical studies are confirmed clinically, with 
elevated plasma aldosterone and cortisol levels in patients presenting for primary PCI 
for ST-segment elevation myocardial infarction (STEMI) and AMI (Beygui et al., 2006; 
Beygui et al., 2009; Palmer et al., 2008) or chronic HF (Guder et al., 2007) having poor 
outcomes.   
 
Involvement of MR in MI was also confirmed in cardiomyocyte-specific MR knockout 
mice which were protected against cardiac remodelling and contractile dysfunction after 
myocardial infarction (Fraccarollo et al., 2011) and chronic pressure overload (Lother et 
al., 2011). In contrast, cardiomyocyte-specific over-expression of MR triggered ROS-
mediated endothelial dysfunction (Favre et al., 2011) and induced a transcriptional 
profile consistent with adverse outcomes in cardiac tissue (Latouche et al., 2010; 
Messaoudi et al., 2013). Similarly, transgenic mice with over-expression of 11β-HSD2 
(the enzyme that converts cortisol into inactive cortisone allowing aldosterone to 
selectively activate MR) in the heart display cardiac hypertrophy, fibrosis and HF which 
can be reversed by eplerenone (Qin et al., 2003).  
 
A role for the cardioprotective effects of MR blockade have been demonstrated in 
animal models of MI both in vitro and in vivo (summarised in Table 1.1 and Table 1.2). 
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Collectively, MR antagonists improved the condition of the heart following MI. MR 
blockade decreased infarct size and incidence of arrhythmia, whilst simultaneously 
improving left ventricular pressure recovery and LV function. The reduction in cardiac 
damage by MR antagonists in these studies vary between 2% to 80% (Table 1.1 and 
1.2), with most studies using high doses (M range) of MR antagonists. Two studies 
have examined the effect of the lower doses of MR antagonists (Barbato et al., 2002; 
Mihailidou et al., 2009). Although Barbato et al. (Barbato et al., 2002) did not measure 
infarct size they reported 10 nM spironolactone markedly increased contractility. In the 
other study using low dose MR blockade, there was significant reduction in reperfusion-
induced infarct size (Mihailidou et al., 2009).  
 
The efficacy of MR blockade to reduce cardiac damage has also been translated 
clinically with several large clinical trials (summarised in Table 1.3) having shown low-
dose MR antagonists, spironolactone and eplerenone, added to standard therapy for HF 
markedly reduced mortality and hospitalization in severe and mild HF, and HF post-MI 
(Pitt et al., 2003; Pitt et al., 1999; Zannad et al., 2011). Importantly, the plasma levels of 
aldosterone in these trials were not eleveated but in the physiological range (0.25 – 0.4 
nmol/l) (Rousseau et al., 2002), which suggest low levels of MR antagonists have 
additional actions, although mechanisms were not fully defined. A recent randomised 
trial has shown a new non-steroidal MR antagonists, BAY 94-8862, is as effective as 
spironolactone in decreasing levels of B-type natriuretic peptide (BNP) and albuminuria 
but lower incidence of hyperkalaemia in patients with HF and reduced left ventricular 
ejection fraction (HFrEF) and moderate chronic kidney disease (CKD) (Pitt et al., 
2013).  
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Animal 
model 
Type & Dose of 
MR antagonist 
Time given 
treatment 
Length of 
treatment Effect on infarct size Other effects Ref. 
Rat 
Ex vivo SP 100 nM 
15 min before 
Isch 
+ 45 min Isch 
+ 3 h Rep ↓ 34% ↑ LVP recovery (Chai et al., 2005) 
Rat 
Ex vivo EPL 1 μM 
15 min before 
Isch 
+ 45 min Isch 
+ 3 h Rep ↓ 22% ↑ LVP recovery (Chai et al., 2006) 
Rat 
Ex vivo
SP 10 nM 
SP 1000 nM 
15 min before 
Isch 
+ 30 min Isch 
+ 2.5 h Rep 
↓ 15% (10 nM) 
↓ 22% (1000 nM) 
↓ apoptosis (TUNEL) with 
both doses  
(Mihailidou et al., 
2009) 
Rat 
Ex vivo 
EPL 1 μM 
EPL 10 μM Hearts 
subjected to 
30 min Isch 
and treatment 
given at 5 min  
before Rep 
+ 2 h Rep ↔ (1 μM) ↓ 73%  (10 μM) 
↑ Akt 
↑ ERK1/2 
(Schmidt et al., 
2010) 
Mouse 
In situ K-can, 1 mg/kg + 2 h Rep ↓ 80% Underlying mechanisms 
studies in isolated rat heart 
(Schmidt et al., 
2010) Rabbit 
In situ K-can, 1 mg/kg + 4 or 72 h Rep 
↓ 31% (4 h) 
↓ 49% (72 h) 
 
Table 1.1: Animal studies examining effects of MR antagonists on cardiac damage and mechanisms involved during ex vivo and in 
situ experimental myocardial ischaemia-reperfusion. SP, spironolactone, EPL, eplerenone; K-can, potassium canrenoate; Isch, ischaemia; Rep, 
reperfusion; LVP, left ventricular pressure; Akt, also known as protein kinase B (PKB); ERK1/2, extracellular signal-regulated protein kinase 1/2. ↓ 
decreased, ↑ increased, ↔, no effect 
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Animal 
model 
Type & Dose of 
MR antagonist 
Time given 
treatment 
Length of 
treatment Effect on infarct size Other effects Ref. 
Rat SP, 100 mg/kg/d After MI 2 weeks ↓ 2% 
↑ LV function 
↓ fibrosis 
↓ apoptosis (TUNEL) 
↓ MR & 11β-HSD2 mRNAs 
(Takeda et al., 
2007) 
Rat EPL, 100 mg/kg/d 3 days post MI 4 weeks 
↓ 16 % (in male) 
↓ 31% (in female) 
↑ LV function 
- Male: restored 4% up-regulated genes 
- Female: restored 44% up-regulated genes 
(Kanashiro-
Takeuchi et al., 
2009) 
Rat EPL, 150 mg/kg twice daily 
24 h after 
MI 
3, 7 or 28 
days 
↑ 14% (day 3), ↓ 9% 
(day 7), ↑ 6% (day 28) 
↓ fibrosis after 28 days (Delyani et al., 2001) 
Rat EPL, 100 mg/kg/d After MI 7 days ↔ 
↓ thinning & dilatation of infracted wall 
↑ neovessel formation 
↑ LV function 
(Fraccarollo et 
al., 2008) 
Rat EPL, 100 mg/kg/d After MI 4 weeks ↓ 5% 
↑ LV haemodynamics 
↓ fibrosis 
↓ mRNAs: AP-1, NF-κB, MCP-1, PAI-1, 
ANP, BNP 
(Enomoto et al., 
2005) 
Rat SP, 100 mg/kg/d After MI 4 weeks ↑ 11% (SP) ↓ AP-1, NF-κB ↓ mRNAs: collagen I/III, APN, BPN 
(Matsumoto et 
al., 2004) 
Rat SP, 80 mg/kg/d 8 days after MI 7 & 90 days 
↓ 2% (day 7) 
↑ 2% (day 90) 
↑ LV haemodynamics 
↓ ROS, collagen density 
↓ LV hypertrophy 
(Mulder et al., 
2008) 
 
Table 1.2: Animal studies examining effects of MR antagonists on cardiac damage and mechanisms involved during in vivo 
experimental myocardial infarction (MI). SP, spironolactone, EPL, eplerenone; LV, left ventricular; AP-1, activator protein 1; NF-κB,  nuclear 
factor kB; MCP-1, monocyte chemoattractant protein 1; PAI-1, plasminogen activator inhibitor 1; ANP,  atrial natriuretic peptide; BNP, brain 
natriuretic peptide; ROS, reactive oxygen species. ↓ decreased, ↑ increased, ↔, no effect   
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Randomised 
Controlled 
Clinical Studies
Injury 
disease 
Standard 
therapy 
Type and dose of 
MR antagonist 
Primary end 
point 
All cause 
mortality 
Hospitalisation 
for HF Ref. 
RALES Severe HF ACE-I, diuretic Spironolactone 25-50 mg/day Mortality ↓ 30% ↓ 33% (Pitt et al., 1999) 
EPHESUS Post-MI, HF 
ACE-I/ARB, β-
blocker, diuretic 
Eplerenone 
25-50 mg/day 
All cause of CV, 
or hosp. for HF ↓ 15% ↓ 23% (Pitt et al., 2003) 
EMPHASIS-HF Mild HF ACE-I/ARB, β-blocker, diuretic 
Eplerenone 
25-50 mg/day 
CV death or 
hosp. for HF ↓ 34% ↓ 42% 
(Zannad et al., 
2011) 
Aldo-DHF Diastolic HF 
ACE-I/ARB, β-
blocker, diuretic 
Spironolactone 
25 mg/day 
LVD function, 
peak VO2 
- - (Edelmann et al., 2013) 
REMINDER STEMI ACE-I/ARB, β-blocker 
Eplerenone 
Up to 50 mg/day 
Mortality, or 
hosp. for HF Unknown Unknown 
ClinicalTrials.gov  
ID: NCT01176968 
TOPCAT Clinical HF 
ACE-I/ARB, β-
blocker, diuretic 
Spironolactone 
15-45 mg/day 
CV death or 
hosp. for HF Ongoing study Ongoing study 
ClinicalTrials.gov  
ID: NCT00094302 
ALBATROSS 
STEMI or 
high risk 
STEMI 
ACE-I/ARB, β-
blocker, diuretic 
Acute bolus of K-
canrenoate, then 
spironolactone 
25 mg/day 
Death, or 
worsened HF, or 
arrhythmias 
Ongoing study Ongoing study ClinicalTrials.gov  ID: NCT01059136 
 
Table 1.3: Clinical MR blockade trials in MI and HF.  
RALES, Randomized Aldactone Evaluation Study; EPHESUS , Eplerenone Post acute myocardial infarction Heart failure Efficacy and SUrvival Study; 
EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure;  Aldo-DHF, Aldosterone Receptor Blockade in 
Diastolic Heart Failure; REMINDER, Impact of Eplerenone on Cardiovascular Outcomes in Patients Post Myocardial Infarction; TOPCAT, Trial of 
Aldosterone Antagonist Therapy in Adults with Preserved Ejection Fraction Congestive Heart Failure; ALBATROSS, Aldosterone Lethal Effects 
Blocked in AMI Treated with or without Reperfusion to Improve Outcome and Survival at Six Months Follow-up; MR, mineralocorticoid receptor; HF, 
heart failure; MI, myocardial infarction; STEMI, ST-segment elevation MI; CV, cardiovascular; LVD, left ventricular diastolic; peak VO2, maximal 
exercise capacity; ACE-I, angiotension converting enzyme inhibitor; ARB, angiotension receptor blocker. 
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Although mechanisms for the cardioprotective effects of moderate-to-high doses of MR 
blockade during myocardial I-R are summarised in table 1.1 and 1.2, further studies are 
required to identify the mechanisms activated by low doses of MR blockade. Oxidative 
stress and apoptosis have been implicated in the pathogenesis of vascular injury and 
remodelling after I-R, leading to development of MI, however little is known whether 
low doses of MR blockade may intercept oxidative stress and apoptosis during I-R.  
 
1.7 Hypotheses and Aims 
This chapter provided the currently defined mechanisms of myocardial I-R injury, the 
role of androgens and oestrogens during I-R injury and the effects of aldosterone and 
regulation of MR during myocardial I-R damage. Several questions have arisen which 
have led to the hypothesis for this thesis. 
 
Hypotheses: 
Physiological levels of androgens modulate myocardial damage during MI in both 
males and females and need to be considered in treatment strategies. Targeting MR with 
low-dose MR antagonists will salvage myocardium by maintaining redox balance, 
preventing oxidative stress and apoptosis, leading to reduced cardiac damage during 
myocardial I-R injury. 
 
Specific aims: 
1. To validate an experimental model of MI and timing of treatment;  
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2. To detemine the role of androgens in the sex differences in cardiac damage 
during MI by a series of gonadectomy/hormone replacement studies examining 
mechanisms of reperfusion injury in male and female rat hearts; 
3. To determine the mechanisms involved in MR regulation during MI and the 
role of low dose MR blockade. 
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2.1 Animals 
Myocardial ischaemia-reperfusion (I-R) experiments were performed using adult male 
(8-12 weeks, 300-400g) and female (8-12 weeks, 200-300g) Sprague-Dawley (SD) rats. 
All experiments were approved by the Royal North Shore Hospital Animal Care and 
Ethics Committee and were conducted in accordance with the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes. Animals were housed 
in the animal facility under conditions of constant temperature (22°C) and supervised by 
staff of the Kearns Research Facility. All rats were fed standard diet with access to food 
and water ad libitum. 
 
2.2 Myocardial ischaemia-reperfusion model 
Using an animal model allowed us to conduct studies on how I-R injury directly 
impacts biochemistry, antioxidant enzyme systems, gene expression and protein levels 
within the myocardium. Rats were weighed before removal from the Kearns facility and 
anaesthetised using intraperitoneal (IP) injection of Ketamine (60 mg/kg) and Xylazine 
Hydrochloride (10 mg/kg); administration of IP heparin (250 IU) was used to prevent 
intravascular blood clots. Once deep anaesthesia was confirmed using suppression of the 
paw pinch reflex (withdrawal in response to a painful stimulus), a median sternotomy 
incision was made and the heart quickly removed from the thoracic cavity. The heart was 
immersed in ice-cold Krebs-Henseleit buffer (KHB, see Appendix for buffer formulation), 
made fresh on the morning of the experiment, to help clear the blood and reduce injury. 
After two washes in ice-cold KHB, the aorta was attached to a needle cannula (size 18G) 
on the Langendorff apparatus and tied in position with a 2.0 silk suture for retrograde 
perfusion via the aorta with KHB. 
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KHB perfusate was maintained at 37°C by heating in a water bath and continuously 
bubbled with carbogen gas (95% O2 and 5% CO2; BOC Gas, Australia) to oxygenate the 
perfusate and maintain the pH at 7.4. Constant flow perfusion was achieved by using a 
MASTERFLEX pump drive and controller (Cole-Parmer Instrument Co.) to deliver 
perfusates at a constant rate of 3-4 mL/min. Perfusate was passed through a heating-coil 
and bubble trap before reaching the isolated heart to ensure the temperature of perfusate in 
the cannula was at 37°C and to prevent any air bubbles from entering the coronary 
circulation. The isolated heart was kept warm at 37°C within a water-jacketed organ 
chamber, connected to the water bath, to ensure the physiological temperature of the heart 
was maintained.  
 
2.2.1 Induction of regional ischaemia-reperfusion 
For regional ischaemia a 6/0 suture was placed around a prominent branch of the left 
anterior descending (LAD) coronary artery, to occlude flow in the artery. After 10 
minutes of stabilisation and 15 minutes KHB perfusion (control or with treatment), the 
suture was threaded through a 0.5 cm polyethylene tube (OD 2.08 mm) to form a snare. 
Occlusion was achieved by clamping the epicardial surface with hemostat forceps so 
that the tube compressed the artery. Regional ischaemia was induced by tightening the 
snare around the LAD artery for 30 minutes. After release of the snare the heart was 
reperfused for 150 minutes. Cardiac contraction rate was monitored throughout the 
experiment. Sham occlusion was achieved by placing the suture around the artery 
without occluding it. 
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2.2.2 Collection of heart tissue 
At the end of the reperfusion period, the LAD artery was re-occluded. The heart was 
perfused with 1.5 mL of 0.05% (w/v) Monastral blue dye (Sigma-Aldrich) in KHB to 
allow identification of the non-ischaemic area. The heart was then removed from the 
apparatus, immersed in ice-cold KHB and sliced in half. Tissue from mid ventricle to 
apex (distal part) was immediately frozen at -20°C for infarct size analysis. The 
proximal part of the heart was quickly fixed in 10% (v/v) neutral buffered formalin for 
24 hours and then transferred into 70% (v/v) ethanol until tissue processing 
(approximately 1-2 weeks). Tissue was embedded in paraffin and sectioned at 5 µm 
thickness for subsequent immunohistochemical studies. In a separate group of 
experiments, hearts were removed from the cannula at the end of reperfusion. The left 
ventricular (LV) free wall tissue was rapidly isolated and washed with ice cold 
phosphate buffer saline (PBS). Tissue was snap frozen in liquid nitrogen and stored at -
80°C for subsequent biochemical and western blot analysis. 
 
2.3 Measurement of infarct size 
After being frozen at -20°C for at least 2 hours, the heart was removed and sliced into 
three cross-sectional pieces (approximately 1.5 mm thickness). Each slice was weighed 
before staining. The slices were incubated in 1% (w/v) 2,3,5-triphenyl-tetrazolium 
chloride (TTC) (Sigma-Aldrich) in PBS at 37°C for 20 minutes. TTC reacts with 
dehydrogenase enzymes and reduced nicotinamide adenine dinucleotide (NADH) in 
viable tissue, staining it deep red, while infarcted tissue remains unstained or dull 
yellow (Fishbein et al., 1981). A representative heart slice stained with TTC is shown in 
Figure 2.1. The area at risk (AAR; ischaemic but viable myocardium) was stained red 
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by TTC while the infarcted area (IA) remained unstained. Following staining, slices 
were washed three times in PBS to remove excess reagent on the tissue and then 
incubated in 10% (v/v) neutral buffer formalin for 7 days to increase contrast between 
the different zones. Each slice was photographed with a digital camera (COOLPIX 
5900, NIKON, Japan) for examination. Computerised planimetry with an image 
analysis software program (National Institute of Health Image J, NIH Image software) 
was used to measure IA, AAR and the total area (TA) of each heart slice. Slices were 
analysed blind by two independent investigators. Calculation of infarct size was as 
follows: 
1. Infarct weight = (IA/AAR) x (AAR/TA) x slice weight 
Total Infarct weight = ∑ (Infarct weights of slices 1, 2, 3) 
2. AAR weight = (AAR/TA) x slice weight 
Total AAR weight = ∑ (AAR weights of slices 1, 2, 3) 
3. % Infarct size relative to AAR = (Total infarct weight / Total AAR weight) x 100% 
 
 
Figure 2.1: Cross-sectional of a heart slice after staining with TTC 
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2.4 Measurement of apoptosis using TUNEL method 
Immunohistochemical detection of apoptotic cells was achieved using In Situ Cell 
Death Detection Kit, TMR red (Roche Applied Science), which is based on the terminal 
deoxynucleotidyl transferase (TdT) – mediated dUTP nick end labeling (TUNEL) 
method, commonly used for the detection of apoptosis with specific DNA strand breaks 
(Gold et al., 1994; Gorczyca et al., 1993; Negoescu et al., 1998). The biochemical 
hallmark of apoptosis involves cleavage of chromosomal DNA into nucleosomal units, 
resulting in DNA fragmentation (Compton, 1992) which can be labelled by the enzyme 
TdT. TdT catalyses polymerization of nucleotides to free 3'-OH DNA ends and 
mediated biotin-16-dUTP nick-end labelling (TUNEL reaction) (Gavrieli et al., 1992; 
Mochizuki et al., 1994; Portera-Cailliau et al., 1994). Tetramethylrhodamine (TMR, red 
fluorescence) labels nucleotides, which can be detected by fluorescence microscopy. 
 
Serial sections (5 µm) were cut from paraffin-embedded tissue samples (see Section 
2.2.2 for tissue collection). One paraffin section per heart and seven to ten hearts per 
group were used for analysis. The tissue sections were deparaffinised with xylene (2 x 5 
minutes) and rehydrated through serial dilutions of ethanol [absolute (2 x 3 minutes), 
95% (v/v) (1 x 3 minutes), 90% (v/v) (1 x 3 minutes), 80% (v/v) (1 x 3 minutes), 70% 
(v/v) (1 x 5 minutes), diluted in milli-Q water]. Tissue sections were pre-treated with 
the proteolytic enzyme, Proteinase K (20 µg/ml) (Sigma-Aldrich) for 30 minutes at 
37°C. As tissues are fixed in formalin fixative, the enzyme induces conformational 
changes in antigen molecules by forming intermolecular cross linkages (Fox et al., 
1985; French and Edsall, 1945). Proteinase K incubation helps break down the cross-
links and thus exposing the antigenic sites (Hilz et al., 1975). Tissue sections were 
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labelled with the TUNEL reagent for 1.5 hours at 37°C in a humidified chamber, 
washed three times with 1x PBS and counterstained with 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI, 1 μg/mL) for 5 minutes at room temperature. DAPI is a DNA-
specific fluorescent dye that binds strongly to A-T rich regions in the minor groove of 
DNA (Kapuscinski, 1995; Larsen et al., 1989; Williamson and Fennell, 1975) and stains 
all nuclei in the section. Anti-desmin (1:50 dilution; Abcam) antibody was used to 
identify cardiomyocytes, and applied to sections and allowed to incubate overnight at 
4°C before being counterstained with DAPI reagent. The sections were then washed 
with 1x PBS and mounted with anti-fade mounting reagent (Invitrogen). Sections were 
viewed on a fluorescent microscope and images captured at 200x magnification.  
 
An area from the anterior, lateral, septal, posterior and sub-endocardial regions of each 
section was randomly selected for evaluation. TUNEL positive nuclei and total DAPI 
nuclei were counted by image analysis software program (National Institute of Health 
Image J, NIH Image software). The apoptotic index was determined as the ratio of 
TUNEL-positive myocyte nuclei relative to the total number of DAPI nuclei and 
expressed as percentage for different regions of the section. Sections were allocated a 
code and analysed and measurements made by two independent observers. 
 
2.5 Myocardial protein expression 
2.5.1 Immunohistochemistry 
Protein expression in myocardium was identified using immunostaining on sections 
from paraffin embedded tissue (5 μm thickness). This technique also allowed us to 
visualise the localisation of proteins within the tissue. Sections were deparaffinised with 
General methods  Chapter 2 
 
Page | 84  
xylene and rehydrated through graded alcohol dilutions as described above (section 
2.4). Endogenous peroxidase activity was blocked by 1% (v/v) hydrogen peroxide 
solution for 30 minutes at room temperature. Heat-induced epitope retrieval was 
performed by incubating slides in 10 mM sodium citrate buffer (pH 6.0) at 95°C for 
about 15 minutes. The sections were immunostained with single or dual specific 
antibodies against proteins of interest (see Table A1, Appendix for details of primary 
antibodies and concentrations). Following washing with 1 x PBS three times, the 
sections were incubated with specific secondary antibodies. For bright field microscopy, 
antibody reactivity was detected with envision+ polymer reagent (DAKO) and 3,3-
diaminobenzidine (DAB) used as the chromogen (Sigma-Aldrich) before 
counterstaining with haematoxylin. For fluorescence staining, antibody reactivity was 
detected by secondary antibodies conjugated to either Alexa Fluor 488 or Alexa Fluor 
594 (1:200 dilution) (Invitrogen) before counterstaining with DAPI reagent. Sections 
were then washed with 1x PBS and mounted. Images were captured by either bright 
field or fluorescence microscopy (both conventional and confocal). 
 
2.5.2 Protein extraction from heart tissue 
At the end of reperfusion period, LV free wall tissue was snap frozen in liquid nitrogen 
and stored at -80°C until protein extraction. Frozen myocardium was quickly powdered 
in a mortar and pestle, and immediately placed into ice cold RIPA buffer (see Appendix 
for details), at a tissue buffer ratio of 1:4 (w/v). Frozen tissues were homogenised in a 
glass-teflon homogeniser by 10-20 strokes of the pestle. Tissue homogenates were left 
on ice for 1 hour before being sonicated (amplitude: 40%, time: 30 sec, pulse: 2.5 sec, 
rest: 1 sec, temperature: 4°C; SONICS Vibra Cell Amplitude) and centrifuged at 
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16,000xg for 30 minutes at 4°C. The supernatant was collected and stored at -80°C for 
further study.  
 
The protein concentration of the resulting myocardial lysates was measured by the 
Bradford Protein Assay (Bradford, 1976), with bovine serum albumin (BSA) as the 
standard and assayed with all unknown samples on the same microplate (96-well clear 
microplate). This allows for construction of a standard curve and quantitation of the 
unknown sample concentrations. The tissue lysates were diluted in milli-Q water at least 
1:30 dilution before the protein concentration was determined. Protein concentrations 
were expressed as µg/µL protein. 
 
2.5.3 Western Blots 
SDS-Gel Preparation 
Separating gel was made to the desired acrylamide concentration (see Table A2, 
Appendix). Polymerisation of the separating gel was achieved by addition of 
ammonium persulfate (AMPS) and N,N,N’,N’-tetramethylethylenediamine (TEMED) 
and the gel mixture poured into an electrophoresis cassette containing 1.5 mm spacers. 
Separating gel was poured to ~1.5 cm below the level of the glass plates followed by 
addition of water to achieve an even interface. After polymerization of the separating 
gel, the unpolymerized gel and water was removed and a 4% stacking gel poured on top 
of the separating gel. The comb was immediately inserted on top and gel allowed to set.  
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Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein from myocardial lysates was separated using SDS-polyacrylamde gel 
electrophoresis (SDS-PAGE) prior to blotting for protein expression. Gel 
electrophoresis is a powerful technique which separates the protein content of tissue 
lysates according to molecular weights. Electrophorsis of samples by SDS-PAGE are 
separated under denaturing conditions, as SDS is an anionic detergent that binds to, 
solubilises and partially unfolds proteins, conferring a negative charge on the protein 
approximately proportional to its length. As such, mobility of proteins in SDS-PAGE is 
a linear function of the logarithms of their molecular weights (Shapiro et al., 1967). The 
composition of the gel and its pH are also important for protein molecules to migrate on 
the gel under the electrical charge. The concentration of acrylamide and its cross-linking 
determine the pore size of the gel matrix and can be varied between gels depending on 
the sample being analysed. High concentration gels (12% or higher) were used for low 
molecular weight proteins (<25 kDa); higher molecular weight proteins (>25 kDa) 
require a lower percentage gel (<12%). Protein samples containing 30-50 μg of protein 
were diluted in 2x SDS loading buffer (see Appendix for details), boiled for 5 minutes 
at 95°C, loaded onto the 7-12% polyacrylamide gels (Laemmli, 1970) and 
electrophoresed at 100 V in Tris-Glycine running buffer [25 mM Tris, 192 mM glycine 
and 0.1% (w/v) SDS, pH8.3]. Molecular weight markers (Bio-Rad) were run on the gel 
with the samples until complete separation of bands was observed. 
 
Protein transfer and immunodetection of protein expression (Western blot) 
Proteins separated on acrylamide gels were transferred onto polyvinylidene fluoride 
(PVDF) membranes (0.45 µm; Millipore) with a Bio-Rad Mini Trans-Blot Cell 
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Electrophoresis Unit at 24 V [voltage varied depending on how many tanks were being 
transferred (24 V per tank, 36 V per 2 tanks and 48 V per 3 tanks)] and left overnight at 
4°C in transfer buffer [25 mM Tris, 192 mM glycine and 10% (v/v) methanol]. After 
proteins were transferred, PVDF membranes were incubated in blocking buffer [1x 
TBS, 0.1% (v/v) Tween-20 and 5% (w/v) non-fat milk powder] for 1 hour at room 
temperature. Primary antibodies (see Table A1, Appendix) were diluted in blocking 
buffer and membranes were incubated for either 1 hour at room temperature or 
overnight at 4°C. Membranes were washed three times for 10 minutes in TBST [1x TBS 
+ 0.1% (w/v) Tween-20] and then incubated with secondary antibody conjugated with 
horseradish peroxidise (HRP, Dako Cytomation) at 1:3000 dilution in TBST containing 
2% (w/v) skim milk. The membranes were washed three times (10 minutes each) in 
TBST and incubated for 1 minute in Western Lightning Chemiluminescence Reagent 
Plus (PerkinElmer, Melbourne, Australia). Visualisation of the bands was achieved by 
digital imaging with LAS4000 (GE Healthcare Life Sciences). Quantitation of band 
intensities was measured with Image J software Analysis (National Institute of Health 
Image J, NIH Image software). Data are presented as arbitrary units for each protein 
analysed. 
 
2.6 Myocardial gene expression 
2.6.1 Total RNA extraction from heart tissue 
For gene expression studies, total RNA from rat heart tissue was extracted with TRIzol 
reagent (Sigma-Aldrich), a single step reagent for the isolation of total RNA, DNA or 
protein from cells or tissues. The reagent is a monophasic solution of phenol and 
guanidine thiocyanate (Chomczynski and Sacchi, 1987). During sample lysis, the 
General methods  Chapter 2 
 
Page | 88  
reagent maintains the integrity of the RNA while disrupting cells and dissolving cell 
components. Addition of chloroform, followed by centrifugation, separates the solution 
into an aqueous phase and an organic phase. RNA remains exclusively in the aqueous 
phase (Chomczynski, 1993; Chomczynski and Mackey, 1995) and is recovered by 
centrifugation after precipitation with isopropanol. 
 
Total RNA was extracted from individual hearts with TRIzol according to 
maufacturer’s protocol and with RNase free or diethylpyrocarbonate (DEPC)-treated 
products. Homogenisation of the tissue was performed in the Mixer Mill (Retsch 
MM301) with the grinding balls (3 mm Tungsten Carbide beads, DEPC-treated) 
(QIAGEN). Tissue samples were weighed and placed in 2 mL Eppendorff tubes. The 
two grinding balls were then added to the tube before the addition of TRIzol (1 mL 
TRIzol reagent per 100 mg tissue). Tissue homogenisation was started immediately 
following the addition of the TRIzol reagent to prevent degradation of the RNA. The 
supernatant was left to stand at room temperature for 5 minutes to allow complete 
dissociation of nucleoprotein complexes before adding chloroform (200 µL per 1 mL 
TRIzol above), and the mixture shaken vigorously by hand for 15 seconds. Samples 
were incubated at room temperature for 5 minutes before separation into phases by 
centrifugation at 12,000xg for 15 minutes at 4°C. Three layers resulted: an upper clear 
aqueous phase containing RNA, a white interphase containing DNA, and a lower red 
organic phenol/choloroform phase containing proteins. The clear aqueous phase (top 
layer) was transferred to another tube, and RNA precipitated by addition of isopropanol 
(500 µL per 1 mL TRIzol), incubation at room temperature for 10 minutes, and 
centrifugation at 12,000xg for 10 minutes at 4°C. The supernatant was discarded, the 
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RNA pellet washed with 1 mL of the 75% (v/v) ethanol and recovered by centrifugation 
at 7,500xg for 5 minutes at 4°C. The supernatant was removed, the pellet air-dried until 
translucent and 30-50 µL RNase free water added to resuspend the pellet. Total RNA 
was stored at -80°C until use. 
 
2.6.2 RNA quantitation and determination 
The concentration and purity of the samples were assessed using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific) according to the manufacturer’s specifications, 
at 260 nm and 280 nm. The spectral measurement was made on a 2 µL RNA sample 
with sample concentration in ng/uL based on absorbance at 260 nm. The ratio of 
absorbance at 260 and 280 nm (A260/A280) is used to assess the purity of RNA. A ratio 
of ~1.8 – 2.1 is generally accepted as pure for RNA. If the ratio is lower, it indicates the 
presence of proteins, phenol or other contaminants that absorb strongly at or near 280 
nm, or incomplete dissolution of the RNA. 
  
2.6.3 RNA cleanup 
This procedure was carried out to purify samples with low A260/A280 ratio (<1.8). Total 
RNA was purified with RNeasy Mini Kit (QIAGEN, cat #217004) as per the 
manufacturer’s instructions. RNA samples were adjusted to a volume of 100 µL with 
RNase-free water followed by addition of 350 µL Buffer RLT. These tubes were mixed 
well by vortexing before adding in 250 µL of 96-100% (v/v) ethanol, followed by a 
subsequent mixing using pipette. Buffer RLT and ethanol added to the sample to create 
conditions that promote selective binding of RNA to the RNeasy membrane. Each 
sample (700 µL) was immediately transferred to an RNeasy Mini column placed in a 
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supplied 2 mL collection tube. The tube was then closed gently and centrifuged for 15 
seconds at 8000xg. The RNeasy mini column contains membrane, which has the 
binding capacity for RNA and allows contaminants to pass through. After 
centrifugation, the flow through was discarded, while the collection tube was reused. 
The column was then washed with 500 μL of RPE buffer for 15 seconds at 8000xg. 
After discarding the flow through, the washing step was repeated again for 2 minutes at 
8000xg. To eliminate any chance of possible RPE buffer carryover, RNeasy column 
was placed in a new 2 mL collection tube and centrifuged in a microcentrifuge at full 
speed for 1 minute. For the elution step, the column was transferred to a new 1.5 mL 
collection tube and 50 μL of RNase-free water was added directly onto the column. This 
was then centrifuged for 1 minute at 8000xg to elute the RNA into the collection tube. 
The concentration and purity of the samples were assessed as described above (section 
2.6.2). 
 
2.6.4 First strand cDNA synthesis from RNA 
cDNA was synthesised from 2.5 µg total RNA by the Superscript III First-Strand 
Synthesis System and oligo (dT)20 as primer (Invitrogen) according to the 
manufacturer’s protocols. The extracted RNA was added into 0.2 mL PCR tubes, 
containing 1 μL of 50 μM oligo (dT)20 and 1 μL of annealing buffer. The mixture was 
made up to a total volume of 8 μL with RNase free water, and incubated in the thermal 
cycler at 65°C for 5 minutes, followed by incubation on ice for at least 1 minute. The 
contents of the tube were then collected by brief centrifugation, followed by addition 
the reverse transcriptase mix containing 10 μL of 2X first-strand reaction mix [10 mM 
MgCl2 and 1 mM each dNTP] and 2 μL of SuperScript III/RNaseOUT enzyme mix. 
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The sample was briefly mixed by vortex and collected by centrifugation. The 20 μL 
total reaction was then incubated in the thermal cycler at 50°C for 50 minutes. The 
reactions were terminated by incubation at 85°C for 5 minutes, and then chilled on ice. 
Finally, 30 μL of RNase free water was added to each 20 μL first strand cDNA 
synthesis reaction and mixed well prior to storage at -20°C. The diluted cDNA was then 
used as templates for amplification in reverse transcription polymerase chain reaction 
(RT-PCR) or quantitative real-time RT-PCR (qRT-PCR) using TaqMan Gene 
Expression Assays (Applied Biosystems). 
 
2.7 Studies using H9c2 cells 
The H9c2 rat cardiomyoblast cell line was used as they have characteristics similar to 
primary cardiomyocytes (Hescheler et al., 1991) and offer a reproducible model for the 
study of myocardial hypoxia/reperfusion (Borchi et al., 2009; Granata et al., 2009; Ko et 
al., 2011; Mizukami et al., 2008). H9c2 cells have also been extensively used in diverse 
cell culture studies examining the effects of stress on apoptosis, hypertrophy and 
cardioprotection (Gross et al., 2006; Liu et al., 2008; Qu et al., 2010; Stuck et al., 2008; 
Watkins et al., 2011). 
 
2.7.1 Culture & passage  
H9c2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 
10% (v/v) heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 10 U/mL 
penicillin and 10 μg/mL streptomycin. This is referred to as complete culture medium. 
Cells were grown in 10 cm dishes at 37°C in a humidified atmosphere with 5% (v/v) 
CO2 and 95% (v/v) air. 
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At 80-90% confluence cells were washed with 1x PBS and trypsinised with 1 mL 
TrypLE reagent (Invitrogen) for 5 minutes at 37°C. Complete culture medium was 
added to each dish and mixed with the trypsinised cells to inactivate trypsin. Cells were 
resuspended into 9 mL of culture medium and subcultured into 10 cm dishes at 1:5 to 
1:10 ratios. Media (7 mL) was replaced routinely every 2-3 days. Experiments were 
performed at passage 3-10. 
 
2.7.2 Cell quantification and viability by Trypan Blue 
To maintain the same cell number between experiments, a haemocytometer was used to 
count cells. The viable cell density was determined as the number of trypan blue 
excluding cells in a haemocytometer. The chromopore Trypan Blue is negatively 
charged and does not enter the cell unless the membrane is damaged (Strober, 2001). 
Therefore, all the cells which actively exclude the dye were considered as viable. For 
counting trypsinised cells were suspended in a total of 10 mL and added to trypan blue 
[0.2% (w/v) in PBS] at a 1:5 dilution followed by gentle mixing and incubation for 2-3 
minutes. An aliquot was transferred to the haemocytometer chamber (Weber Scientific 
International, Teddington, UK) and total live cells counted in four x 1 mm2 squares as 
viewed under the microscope (Magnification 4x; Nikon, Japan). Viable cellsappeared as 
bright dots under microscopy whereas dead cells absorbed the dye and were coloured 
blue. The viable cell numbers were determined as follows: 
Numbers of cell (per mL) = [average count of the four squares] x [dilution factor] x 104 
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2.7.3 Protein extraction from H9c2 cells 
Some conditions (e.g. hypoxia) can weaken the cell’s attachment to the plate and 
therefore the method for collecting cells was modified accordingly. For weakly adherent 
cells, media and trypsinised cells were collected into 15 mL falcon tubes and 
centrifuged at 1000xg for 5 minutes. Cells were then washed two times with 5 mL ice 
cold 1x PBS by centrifugation, and lysed in lysis buffer [50 mM Tris (pH 8.0), 150 mM 
NaCl, 1% (v/v) Nonidet P-40, 0.02% (w/v) sodium azide, and protease inhibitor 
cocktail] (300 µL lysis buffer per 100 mm dish or 100 µL lysis buffer per 35 mm dish). 
For strongly adherent cells, media was removed from the dish and cells were washed 
two times with 5 mL ice cold 1x PBS (remove PBS as much as possible). Lysis buffer 
was added to the dish and adherent cells were scraped off the dish with plastic cell 
scraper and cell suspensions transferred into 1.5 mL Eppendorff tubes. Cell lysates were 
left on ice for about 30 minutes after being sonicated (duty cycle: 30%, time: 30 sec, 
output control: 1, pulse, temperature: 4°C; Sonifier Cell Disruptor B-30) and then 
centrifuged at 16,000xg for 10 minutes at 4°C. The supernatant was collected and stored 
at -80°C for further study.  
 
2.7.4 Total RNA extraction from H9c2 cells 
Cell collection was performed as described above (section 2.7.4). H9c2 cells were lysed 
in TRIzol reagent (1 mL TRIzol per 100 mm dish or 0.5 mL TRIzol per 60 mm dish) 
and total RNA was extracted as described in section 2.6.1. 
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2.8 Statistical analysis 
All data were analysed with SigmaStat 3.0 software, with the Kolmogorov-Smirnov test 
used to confirm normal distribution. Results are presented as the mean ± standard error 
of the mean. Statistical comparisons were performed by one-way analysis of variance 
(ANOVA) followed by the Holm-Sidak correction post-hoc test to adjust for multiple 
comparisons. In some situations the same control group is used in several comparisons, 
and Dunnett's test was used as the post-hoc test. Unpaired Student’s t-test was used for 
comparing differences between two treatments. The results were considered significant 
if P<0.05. 
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3.1 Introduction 
The Langendorff isolated heart preparation has been used extensively to simulate the 
(patho)physiological of I-R injury (Bell et al., 2011b; Langendorff, 1898; Sievers et al., 
1989). The isolated heart preparation by Langendorff is an ex vivo model that involves 
the intact heart removed from the animal and allows measurement of direct mechanisms 
in the absence of cardiac innervation and other factors that influence the heart in 
response to ischaemia, using Krebs-Henseleit buffer (KHB, oxygenated solution). 
Restricted regional flow of blood in a major coronary vessel causes reduction in the 
oxygen and nutrient supply to myocardial tissues (Liedtke et al., 1975; Neely et al., 
1973), representing “myocardial ischaemia”. The most commonly used technique is 
ligation of the branch of the left anterior descending (LAD) coronary artery (Bredee et 
al., 1975; Johns and Olson, 1954; Reimer et al., 1981). Most investigators maintain 
occlusion for 30 minutes (Mersmann et al., 2011). In the Langendorff perfused rodent 
hearts, infarct size and apoptosis significantly increased in studies using 30 minutes 
ischaemia followed by 120-240 minutes reperfusion (Mersmann et al., 2011; Redel et 
al., 2008; Ruixing et al., 2006; Schwarz et al., 2000; Ytrehus et al., 1994), resulting in a 
consistent infarct size of approximately 42% in the control group (Mersmann et al., 
2011; Redel et al., 2008). Previous studies from our laboratory have used this 
experimental model of MI in both rabbit and rat hearts and found similar changes in 
infarct size and apoptosis (Mihailidou et al., 2009; Wong et al., 2011). 
 
Since I-R leads to damage of cell membranes, Na+ and Ca2+ overload, generation of 
ROS, activation of autophagy and cell death (apoptosis and necrosis) processes, the first 
aim for this thesis was to validate that several of these changes could be detected in our 
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ex-vivo rat model of I-R. Apoptosis plays an important role in the progression of 
myocardial damage and left ventricular remodelling following I-R (Ojha et al., 2008). 
Cardiac apoptosis occurs acutely after I-R in the region of the myocardium with 
decreased blood flow and oxygen supply, and in the border area around the infarcted 
myocardium in humans (Olivetti et al., 1996; Saraste et al., 1997) and animals (Fliss 
and Gattinger, 1996; Gottlieb et al., 1994; Scarabelli et al., 2002; Zhao et al., 2000). 
Although autophagy at basal level can promote cell survival by removing damaged and 
toxic cellular components (Rothermel and Hill, 2008), uncontrolled autophagy may lead 
to cell death (Levine and Yuan, 2005). Autophagy has been shown to be upregulated in 
response to ischaemia and reperfusion. Previous studies observed induction of 
autophagy in Langendorff perfused rabbit hearts subjected to I-R (Decker et al., 1980; 
Decker and Wildenthal, 1980). Further studies described activation of autophagy in the 
infarct zones of hearts subjected to reperfusion injury (Hamacher-Brady et al., 2007; 
Hariharan et al., 2011; Matsui et al., 2007). Increased levels of autophagy proteins (such 
as Beclin-1, Atg5-Atg12 conjugate and LC3-II) indicate that a cell has undergone 
autophagy processing (Kassiotis et al., 2009). Thus the level of I-R injury can also be 
estimated by specific markers of autophagy. 
 
Clinical (Pitt et al. 2003) and experimental (Kanashiro-Takeuchi et al., 2009; Schmidt et 
al., 2010) studies show mineralocorticoid receptor (MR) antagonists significantly 
reduce myocardial damage during MI. In these studies, MR antagonists were 
administered post-MI or after ischaemia was established. Early administration (3-7 days 
post-MI) of MR antagonist eplerenone improved outcomes which were not observed 
when treatment was started after 7 days (Adamopoulos et al., 2009), similar to other 
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treatment strategies for MI. In experimental studies using the ex vivo rodent I-R model, 
MR antagonists perfused 15 minutes prior to ischaemia significantly reduced infarct 
size (Chai et al., 2005; Chai et al., 2006). Therefore part of validating our reperfused rat 
heart model of MI is to determine the effect of timing of administration of MR 
antagonists - prior to ischaemia or at reperfusion - on the extent of infarct size. 
 
3.2 Methods 
Male Sprague-Dawley rats were used for these studies. Experimental details for ex vivo 
ischaemia-reperfusion of the rat heart, measurement of infarct size, apoptosis (TUNEL), 
immunohistochemistry and immunoblotting are described in Chapter 2 (sections 2.2-
2.5). 
 
3.3 Results 
3.3.1 I-R induces increased infarct area 
Myocardial infarct size was assessed by measuring the infarct size/area (IA) and area-at-
risk (AAR) of the myocardium. Injection of the Evans’s Blue dye in the presence of the 
occlusion delineates the perfused myocardium (PM, blue) from the area at risk. 2-3-5-
triphenyl tetrazolium chloride (TTC) stains bright red in the presence of dehydrogenase 
enzymes in viable tissue. As such, incubation of sections from the infarcted hearts in 
TTC delineates viable tissue (V) in the area at risk from infarcted tissue, which remains 
unstained (Figure 3.1A). Minimal damage was observed in hearts subjected to sham I-
R, whereas I-R injury caused significant damage to the heart with 42% of the 
myocardium in the area at risk being non-viable after 150 minutes reperfusion (Figure 
3.1B). 
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Figure 3.1: Myocardial infarct size in hearts subjected to ischaemia (30 minutes) 
followed by reperfusion (150 minutes).  
(A) Representative cross-sections of the heart stained with 2-3-5-triphenyl tetrazolium 
chloride (TTC). (B) The effect of I-R injury on infarct size/area (IA) expressed as 
percentage of area-at-risk (AAR). I-R, ischaemia-reperfusion; PM, perfused 
myocardium; V, viable tissue; IA, infracted area. Values expressed as mean ± SE. 
Numbers below the bar graph indicate the number of animals in each group; *P<0.001. 
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3.3.2 I-R induces increased cardiomyocyte apoptosis 
Apoptosis in reperfused myocardial tissue samples was detected using terminal 
deoxynucleotidyl transferase (TdT) mediated nick end labelling (TUNEL) assay which 
measures DNA fragmentation as DNA strands breaks (Gavrieli et al., 1992). DAPI is a 
minor groove intercalating dye which stains DNA in all cell nuclei, and is required 
when calculating the proportion of apoptotic cells. TUNEL negative nuclei appear red, 
while TUNEL-positive nuclei are bright pink (Figure 3.2A). The apoptotic index 
(percentage of TUNEL-positive myocyte nuclei relative to the total number of DAPI-
stained nuclei) from hearts subjected to sham and I-R injury is shown in Figure 3.2B. 
Consistent with the effect on infarct size, reperfusion injury significantly increased 
number of apoptotic myocytes compared with sham-operated hearts. 
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Figure 3.2: Cardiomyocytes apoptosis detected after ischaemia-reperfusion by 
TUNEL assay. 
(A) Representative photomicrographs of ventricular sections show the proportion of 
TUNEL-positive nuclei (red fluorescence, arrows) relative to DAPI (blue fluorescence) 
stained nuclei. Arrows indicate apoptotic cardiomyocyte nuclei (pink). Bar = 100 µm. 
(B) Quantification of the apoptotic index in reperfused myocardium. Apoptotic index 
expressed as a percentage of TUNEL positive nuclei relative to total DAPI nuclei. 
Apoptotic index quantification was based on average of six fields (anterior, lateral, 
septal, posterior and sub-endocardial regions) per heart and seven hearts per group. I-R, 
ischaemia-reperfusion. Values expressed as mean ± SE. Numbers in parentheses 
indicate the number of animals in each group; *P<0.01. 
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3.3.3 Regulation of apoptosis during I-R 
Caspase-3 is a primary effector enzyme of the apoptotic pathway, mediating cleavage of 
nuclear substrates and DNA fragmentation (Liu et al., 1997; Sahara et al., 1999). When 
activated the intact caspase-3 protein (32 kDa) is cleaved into fragments (17 and 12 
kDa) which associate to form a heterotetramer which is the active enzyme (Tawa et al., 
2004). The tetrameric holoenzyme can be detected using conformation-specific 
antibodies that do not bind to the caspase-3 zymogen. In our ex-vivo model of I-R, 
caspase-3 cleavage was observed after 30 minutes ischaemia and 150 minutes 
reperfusion using an activation specific antibody (Figure 3.3A). Similarly, western blot 
showed that 32 kDa full-length caspase-3 was cleaved to a 17 kDa fragment during I-R 
(Figure 3.3B & 3.3C). The anti-apoptotic protein Bcl-2 is known to be regulated in 
activation of the intrinsic apoptotic pathway (Cory and Adams, 2002). In turn, this 
protein must be degraded for apoptosis to proceed during myocardial I-R injury. 
Compared to the sham group, I-R resulted in an approximately 50% decrease in Bcl-2 
expression (Figure 3.4). Combined, these data show that I-R induced apoptosis via 
caspase-3 activation and Bcl-2 suppression correlates with the induction of TUNEL 
positive nuclei in reperfused tissue. 
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Figure 3.3: Caspase-3 is activated during ischaemia-reperfusion.  
(A) Myocardium stained for active caspase-3. Increased green fluorescence indicates 
cleavage of capase-3. Bar = 100 µm. (B) & (C) Representative immunoblots showing 
processing of pro-caspase-3 in left ventricular free wall homogenates of reperfused 
hearts. Values expressed as mean ± SE. N=3-5 per group; *P<0.05. 
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Figure 3.4: Ischaemia-reperfusion induced decreased anti-apoptotic protein Bcl-2.  
Expression of the anti-apoptotic protein Bcl-2 in left ventricular free wall homogenates 
assessed by western blot. Top: Representative immunoblots showing protein expression 
of Bcl-2 in sham and I-R groups. Below: Bar graphs show densitometric analysis of 
Bcl-2. Values expressed as mean ± SE. N=3-5 per group; *P<0.05. 
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3.3.4 Regulation of autophagy during I-R 
To determine whether autophagy is regulated in our modelof I-R injury, the levels of 
several autophagy marker proteins were measured (Figure 3.5). Beclin-1 plays a key 
role in initiating autophagy and forming of autophagosomal membrane (Hamacher-
Brady et al., 2006a; Liang et al., 1999; Mizushima et al., 2001). Expression levels of 
Beclin-1 were increased in response to myocardial I-R (Figure 3.5A), indicating that 
initiation of autophagy is regulated during myocardial I-R. The process of autophagy 
also requires autophagy specific genes (Atg), in particular Atg5 and Atg12, to regulate 
elongation of autophagosomal membrane and formation of autophagic vesicles 
(Mizushima et al., 2001). Atg5-Atg12 conjugate is required for recruiting LC3-II, a 
specific marker of autophagosomes (Hamacher-Brady et al., 2006a; Kabeya et al., 
2000). The conversion of microtubule-associated protein light chain 3 (LC3)-I into 
LC3-II (LC3-II/LC3-I ratio) associated with the autophagosome and has been 
established as indicators of autophagy progression (Kabeya et al., 2000; Klionsky et al., 
2008). The expression of Atg5-Atg12 conjugate was up-regulated in the infracted hearts 
(Figure 3.5B & 3.5C), which were accompanied by significant increased in LC3-II 
levels and LC3-II/LC3-I ratio (Figure 3.5C), confirming that progression of autophagy 
is activated during myocardial I-R. 
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Figure 3.5: Autophagy is activated during myocardial ischaemia-reperfusion.  
Expression of autophagy protein markers Beclin-1 (A), Atg5-Atg12 conjugate (B), 
LC3-I and LC3-II (C) in hearts subjected to ischaemia (30 minutes) followed by 
reperfusion (150 minutes). Left: Representative immunoblots of Beclin-1, Atg5-Atg12 
conjugate and LC3 in sham and I-R groups. Right: Bar graphs showing densitometric 
analysis of protein changes and quantification of the ratio of LC3-I to LC3-II 
conversion. Values expressed as mean ± SE. N=3-5 per group; *P<0.05. 
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3.3.5 Mineralocorticoid receptor blockade protects against cardiac 
damage during myocardial I-R: timing of treatment 
Using ex-vivo experimental model of I-R, hearts were perfused with the MR antagonist 
spironolactone (in the absence of other corticosteroids), 15 minutes prior to ischaemia 
and on reperfusion and measured the effect on extent of infarct size. Figure 6A shows 
timing of treatment protocols during I-R. We found spironolactone reduced the extent of 
infarct area whether perfused after ischaemia or on reperfusion (Figure 3.6B). 
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Figure 3.6: Myocardial infarct size during treatment with 10 nM spironolactone, 
on reperfusion and 15 minutes before ischaemia.   
(A) Experimental protocol for myocardial ischaemia-reperfusion and timing of 
treatment. (B) Bar graph showing myocardial infarct size/area (IA) expressed as 
percentage of area-at-risk (AAR). Isch, ischaemia; Rep, reperfusion; I-R, ischaemia-
reperfusion; KHB, Krebs-Henseleit buffer; SP, spironolactone. Values express as mean 
± SE. Numbers in parentheses indicate the number of animals in each group; *P<0.05 
vs I-R alone.  
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3.4 Discussion 
These results validate the ex-vivo model of myocardial I-R induced by ligation of LAD 
coronary artery. Isolated rat hearts subjected to regional ischaemia (30 minutes), 
followed by reperfusion (150 minutes) showed significant increased cardiomyocyte 
apoptosis and infarct size. Moreover, the studies in this chapter show that in our rat 
model of reperfusion injury modulate the cellular pathways that activate the processes 
of autophagy and apoptosis, as indicated by the increased expression of autophagy 
proteins (Beclin-1, Atg5-Agt12 conjugate, LC3-II), and by activation of pro-apoptotic 
protein caspase-3 and suppression of anti-apoptotic protein Bcl-2. 
 
Myocardial infarct size following I-R injury is an important determinant of the extent of 
myocardial injury. In the current study  myocardial injury (% IA/AAR) in response to I-
R was approximately 42%, which is consistent with other studies using the ex-vivo 
model of I-R induced myocardial infarction (Brar et al., 2004; Ikeno et al., 2007; Kumar 
et al., 2012; McIntosh et al., 2010; Mihailidou et al., 2009). Similarly, there have been 
studies indicating infarct size of 38-46% in animals undergoing myocardial infarction or 
I-R in vivo (Delyani et al., 2001; Enomoto et al., 2005; Holly et al., 1999; Kanashiro-
Takeuchi et al., 2009; Schmidt et al., 2010; Takeda et al., 2007), which is comparable to 
the extent of infarct found in our hands. 
 
Apoptosis and necrosis are two distinct cell death pathways occur during myocardial 
injury and contribute to myocardial infarct size (McCully et al., 2004). The process of 
necrosis-induced myocardial cell death mainly takes place during the ischaemia period, 
in which opening of the mPTP plays an important role (Abdallah et al., 2011; 
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Nakagawa et al., 2005). In contrast, apoptosis is programmed cell death and controlled 
by the complex interaction between pro-survival and pro-death molecules. In the current 
study apoptosis was carefully assessed by histochemical visualisation of nuclear DNA 
fragments by TUNEL assay and immunoblot of tissue homogenates. Apoptotic index 
(% TUNEL-positive nuclei/ total DAPI nuclei) was found to increase ~ four-fold after I-
R compared with sham (8% vs 2% respectively, Figure 3.2), which is similar to 
previous studies from our laboratory (Mihailidou et al., 2009) and others (Fisher et al., 
2005; Rong et al., 2009; Scarabelli et al., 2001; Scarabelli et al., 1999). Moreover, the 
semi-quantitative data of the TUNEL staining was confirmed by western blot of 
apoptotic proteins. Upregulation of the pro-apoptotic protein caspase-3 and 
downregulation of the anti-apoptotic protein Bcl-2 are known to promote apoptosis in 
hearts following I-R injury. In the current study, the increase in TUNEL positive 
cardiomyocytes with I-R injury was associated with an upregulation of caspase-3 and 
downregulation of Bcl-2, which are comparable to previous studies in different models 
(Holly et al., 1999; Moudgil et al., 2001). 
 
There is growing interest suggesting autophagy plays a crucial role during myocardial I-
R injury. The findings in the current study demonstrate a significant increase in the 
autophagy proteins Beclin-1 and Atg5-Atg12 conjugate as well as the conversion of 
LC3-I to LC3-II in left ventricular homogenates from hearts of rat subjected to 
ischaemia followed by reperfusion and are  supported by other studies in different 
experimental models of myocardial infarction (Kanamori et al., 2011; Matsui et al., 
2007; Valentim et al., 2006; Xiao et al., 2011). Moreover, increased levels of Beclin-1, 
Atg5-Atg12 conjugate and LC3-II indicate cardiomyocytes undergoing autophagy 
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processing and predict an impaired outcome (Kabeya et al., 2000; Kassiotis et al., 2009; 
Ma et al., 2012b).  
 
The studies to determine timing of treatment showed that perfusion with low dose (10 
nM) spironolactone 15 minutes prior to ischaemia reduces I-R injury which is supported  
by previous studies showing similar reduction in the  extent of  infarction (Chai et al., 
2005; Chai et al., 2006). Although cardioprotective actions of MR antagonists have 
been observed when administered at the end of ischaemia (Kanashiro-Takeuchi et al., 
2009; Schmidt et al., 2010), our study showed that MR antagonists administered at 
reperfusion have comparable benefit, which confirm the clinical studies for early 
administration of MR antagonists .    
 
One of the limitations of the present study was that we did not have the facilities to 
evaluate contractility, systolic left ventricular pressure, left ventricular end diastolic 
pressure, cardiac output, echocardiography and heart rate variables, which would 
provide further information about the effects of myocardial I-R injury. In conclusion, 
our experimental ex vivo model of myocardial infarction is reproducible and consistent 
with different models reported in the literature and clinical practice. Cardiac apoptosis 
and autophagy were activated during I-R injury and represent the mechanisms involved 
in the (patho)physiological of IHD. 
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4.1 Introduction 
Gender differences have been observed in presentation and outcomes to IHD (Roger et 
al., 2012). Men have earlier onset and more severe age-specific IHD than women, 
although women have a greater risk of death after MI (Greenland et al., 1991; Roger et 
al., 2012). Mechanisms for these differences are not fully defined partly since younger 
women and older men are insufficiently represented in many studies (Kim et al., 2010), 
with focus on 17β-oestradiol (E2) actions mediated via oestrogen receptors (E2-R), and 
less attention on androgen receptor (AR)-mediated androgen action (Vaccarino et al., 
2011). There are even fewer studies on androgens and cardiovascular risk in women.  
 
A few conflicting studies have assessed the effects of androgens during MI. 
Testosterone (T) adversely affects cardiac remodelling and function following MI 
independent of gender (Bae and Zhang, 2005), whereas dihydrotestosterone (DHT) 
ameliorated post-I-R recovery via enhanced angiogenesis (Beygui et al., 2009). Male 
rats have increased infarct area following I-R (Mihailidou et al., 2009; Wang et al., 
2005), whereas T replacement to male rats reportedly reduced I-R mediated cardiac 
injury (Callies et al., 2003). Low circulating T levels are associated with poorer 
outcomes in HF and decreased survival (Malkin et al., 2010) in men with coronary 
artery disease (CAD); whether these are cause or effect is yet to be determined.  
 
Reported effects of endogenous E2 similarly vary in females, with reduction (Booth and 
Lucchesi, 2008) or no difference (Cross et al., 1998) during I-R. Postmenopausal E2 
administration also provides conflicting results, with adverse cardiovascular effects in 
the Women’s Health Initiative study, but reduced cardiovascular disease (CVD) risk in 
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observational trials and the randomised Danish Osteoporosis Prevention Study 
(Schierbeck et al., 2012). Data on the relationship between E2 and CVD risk in men is 
limited or unreliable, despite higher E2 levels measured in men with CAD (Phillips et 
al., 1983). Few studies have examined endogenous T and CAD in women, with either 
positive (Braunstein, 2007) or no (Barrett-Connor and Goodman-Gruen, 1995) 
correlation between serum levels and CVD reported; all these studies used 
immunoassays which provide inaccurate results at low circulating steroid levels 
(Harwood and Handelsman, 2009).  
 
Myocardial I-R activates release of reactive oxygen species and augmentation of the 
multi-ligand receptor for advanced glycation end products (RAGE) (Bucciarelli et al., 
2006), providing a pro-inflammatory stimulus for cardiac dysfunction. Autophagy, a 
cell survival pathway (Matsui et al., 2007) is also activated and recent studies indicate 
autophagy protects cardiomyocytes from apoptosis (Matsui et al., 2007), while in excess 
it may be detrimental (Ma et al., 2012a). It is not known whether sex steroids regulate 
autophagy during MI, although apoptosis leads to tissue damage (Saraste et al., 1997). 
Male rats have increased apoptosis following myocardial I-R (Mihailidou et al., 2009; 
Wang et al., 2005) and men dying after acute MI have a higher apoptotic rate in the 
peri-infarct region at autopsy than women (Biondi-Zoccai et al., 2005).  
 
Expression levels of mineralocorticoid receptors (MR) may also contribute to cardiac 
damage following MI and HF. MR expression levels were  upregulated in post-mortem 
hearts from men with congestive heart failure (Yoshida et al., 2005) and in male animal 
models of experimental MI, levels of MR protein were increased in the left ventricle  2-
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4 weeks post-MI) (de Resende et al., 2006; Milik et al., 2007; Takeda et al., 2007). 
There are no studies which have examined whether there is sexual dimorphism of MR 
expression in the heart following myocardial I-R injury. The aim of the current study 
was to determine how androgens mediate these sex differences in cardiac damage 
during MI and since the focus of this thesis is regulation of MR during MI, whether 
there are gender differences in expression levels of MR.  
 
4.2 Methods 
Adult age-matched male (300 – 400 g) and female (200 – 300 g) Sprague Dawley rats 
(N=190) were allocated at random for either no surgery (Intact), bilateral gonadectomy 
(Gx) or sham operation (Sham Gx) for these studies. 
 
4.2.1 Gonadectomy surgical procedures 
For the gonadectomy (Gx) or sham operations (Sham Gx) the rats were anaesthetised 
with nitrous oxide and oxygen (2:1 v/v, 3 L/min), and 2% (v/v) isoflurane, maintained 
during the procedures, with additional analgesia provided as required. Female rats were 
subjected to bilateral ovariectomy which involved placing them prone, both flanks 
shaved and area disinfected with 70% ethanol followed by a small skin incision (~1 cm) 
was made in the dorso-lateral area to expose the abdominal muscles and, after ovaries 
on both sides of the abdomen located, tied off and removed. The skin incisions were 
closed with michel clips. For orchidectomy, in males, a small mid-line incision (~1 cm) 
was made in the scrotum, the skin separated and both testes pulled out. The spermatic 
cord was tied and cut, and the incisions closed with michel clips. Iodine was applied to 
the incision sites and the rats allowed to recover. In sham operations, the incisions were 
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made and then closed. Animals were monitored post-operatively during the recovery 
period to ensure that they did not display any signs of pain and administered temgesic 
(0.02 mg/kg, i.m.). Rats were then maintained on standard laboratory chow ad libitum 
and monitored daily.  
 
4.2.2 Treatments 
Silastic hormone implants were inserted subdermally in gonadectomised animals on the 
day of surgery and animals monitored for 21 days. Silastic implants have previously 
been shown to provide sustained, controlled concentrations of steroids (Allan et al., 
2010; Meachem et al., 2007). Testosterone and 17β–oestradiol doses in gonadectomised 
females were adjusted to compare to those in males by using smaller size implants due 
to the lower weight of the females. Male animals were divided into the following 
groups: (1) Sham (N=11), (2) Intact (N=14), (3) Sham Gx (N=6), (4) Gx (N=18), (5) Gx 
+ T (3 cm, N=14), (6) Gx + DHT (1 cm, N=8), (7) Gx + E2 (0.4 cm, N=16). Females 
were divided into the following groups: (1) Sham (N=16), (2) Intact (N=20), (3) Sham 
Gx (N=8) (4) Gx (N=15), (5) Gx + T (2.4 cm, N=13) and (6) Gx + E2 (0.3 cm, N=11). 
Testosterone, 17β-oestradiol and dihydrotestosterone implants were prepared as 
previously described (Allan et al., 2010; Meachem et al., 2007). Surgical Gx and steroid 
replacement were confirmed by measuring serum levels of steroids. Since most steroid 
hormone immunoassays lack sensitivity, specificity, and accuracy at low plasma levels 
(Harwood and Handelsman, 2009; Rosner et al., 2013; Stanczyk et al., 2007), especially 
in rodents (Haisenleder et al., 2011; Handelsman et al., 2011), we used liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) assay. This assay has 
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sensitivity and specificity to accurately determine serum androgen levels in rodent 
samples (Harwood and Handelsman, 2009). 
 
4.2.3 Ex-vivo myocardial ischaemia-reperfusion 
Following 21 days post gonadectomy and hormone treatment, rats were anaesthetised 
with intraperitoneal (IP) injection of ketamine (60 mg/kg) and xylazine hydrochloride (10 
mg/kg) and then received heparin (250 IU, IP). Hearts rapidly isolated and subjected to 
regional I-R procedure as described in Chapter 2 (sections 2.2). At the end of 
reperfusion, infarct size and apoptosis (TUNEL) were measured as described in Chapter 
2 (sections 2.3 – 2.4). Infarct size and apoptosis were measured on the same hearts, with 
a separate group of animals used for protein analysis by immunoblotting. 
 
4.2.4 Western blots 
At the end of reperfusion, left ventricular free wall tissue was snap frozen in liquid 
nitrogen. Protein extraction, SDS-PAGE, electrophoretic transfer of proteins to PVDF 
membrane and immunoblotting were performed as described in Chapter 2 (section 2.5.2 
– 2.5.3). Primary antibodies for Beclin-1 (Cell Signaling), LC3-I/II (Cell Signaling), 
Atg-5 (Sigma-Aldrich), RAGE (Abcam), mTOR, Phospho-mTOR (Cell Signaling), 
AMPK, Phospho-AMPK (Cell Signaling), caspase-3/-9 (Cell Signaling), ARC 
(Apoptosis Repressor with a Caspase recruitment domain, Cayman Chemical), Bcl-xL 
(B-cell lymphoma-extra large, Santa Cruz), XIAP (X-linked inhibitor of apoptosis 
protein, (Cell Signaling), rMR 1-18 1D5 (kindly provided by Prof. Celso Gomez-
Sanchez), ERα, ERβ and AR (Santa Cruz Biotechnology) were used. Bound antibodies 
were detected with HRP-conjugated secondary antibody (1:3000, Dako Cytomation). 
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Membranes were exposed to chemiluminescent substrate (Perkin Elmer, Melbourne, 
Australia) and digital images of the resulting bands captured on a LAS4000 (GE 
Healthcare Life Sciences).  
 
4.2.5 Statistical analysis 
Details for statistical analysis are described in Chapter 2 (sections 2.8). 
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4.3 Results 
Females were approximately 100 grams lighter than male littermates with no 
differences between intact and sham Gx males or females (Table 4.1). Treatment did not 
affect body weight except T-treated Gx males were heavier. In females, Gx increased 
body weight which was restored by E2 but not T administration (Table 4.1). Regional 
ischaemia-reperfusion produced larger infarct size in male than female hearts (Figure 
4.1A), similar to previous reports (Bae and Zhang, 2005), and correlated with increased 
apoptosis measured by TUNEL staining (Figure 4.1B). In females, smaller infarct size 
corresponded with less apoptosis (Figure 4.1B). 
 
 
Treatment Male Body Weight (g) 
Female Body Weight           
(g) 
Intact 350 ± 17 247 ± 5 
Sham Gx 360 ± 11 257 ± 9 
Gx 373 ± 8  318 ± 7* 
Gx + T 397 ± 7*     314 ± 15* 
Gx + DHT 380 ± 6 n/a 
Gx + E2 362 ± 13  237 ± 8 
 
Table 4.1: Body weights of male and female rats in the various treatment groups.  
All values shown are Mean ± SE, N = 8-16 per group; *P<0.05 vs respective sham 
gonadectomy (Sham Gx); Gx, Gonadectomy; E2, 17β-oestradiol; T, Testosterone; 
DHT, Dihydrotestosterone. n/a, not administered 
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Figure 4.1: Sex differences in left ventricular infarct size and apoptosis.  
Myocardial infarct size (A) and apoptotic index (B) in male and female rat hearts 
subjected to 30 minutes ischaemia followed by 150 minutes reperfusion (I-R) or sham 
ischaemia-reperfusion (Sham I-R). Myocardial infarct size/area (IA) is expressed as the 
percentage of the area-at-risk (AAR). Apoptotic index is expressed as the percentage of 
TUNEL-positive nuclei relative to DAPI-stained nuclei in the reperfused myocardium. 
Values expressed as mean ± SE. Numbers in parentheses indicate the number of animals 
in each group; *P<0.05. 
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4.3.1 Role of sex steroids on infarct size 
Sham Gx did not influence infarct size in either male [42 ± 4% (Sham Gx, N=5) versus 
43 ± 1% (intact, N=6)] or female [30 ± 4% (Sham Gx, N=7) versus 36 ± 3% (intact, 
N=7)] hearts. Infarct size was reduced in Gx males (Figure 4.2A) but exacerbated in Gx 
females (Figure 4.2B), with neither having detectable serum T or E2 levels. Treatment 
with T restored infarct size in Gx males, despite lower serum T levels [1.3 ± 0.2 ng/ml 
(Gx +T, N=9) versus 2.8 ± 0.8 ng/ml (Sham Gx, N=4), *P<0.05]. To confirm these 
changes were androgen-specific, we used DHT which unlike T cannot be aromatised to 
E2. Infarct size was similarly aggravated by DHT (Figure 4.2A) at serum levels below 
detection limit (<200 pg/ml). Gx females receiving T had elevated serum T levels [2.1 ± 
0.2 ng/ml (Gx+T, N=6) versus 0.04 ± 0.02 ng/ml (sham Gx, N=4), *P<0.05], with no 
effect on Gx-increased infarct size (Figure 4.2B), whereas E2 reduced infarct size 
(Figure 4.2B) to Sham Gx levels. Treatment with E2 aggravated infarct size in Gx 
males (Figure 4.2A) with plasma E2 levels [27.7 ± 7.0 pg/ml, N=10] well above intact 
male and female levels [E2 <5 pg/ml].  
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Figure 4.2: Effect of gonadectomy and steroid treatment on left ventricular infarct 
size in males and females.  
Myocardial left ventricular infarct size from gonadectomised male (A) and female (B) 
animals (± hormones for 21 days) which were subjected to I-R injury. Myocardial 
infarct size/area (IA) is expressed as the percentage of the area-at-risk (AAR). Sham 
Gx, sham gonadectomy; Gx, gonadectomised; DHT, dihydrotestosterone; T, 
testosterone; E2, 17β-oestradiol. Numbers within the columns indicate the number of 
animals in each group. Values expressed as mean ± SE; *P<0.05 vs Sham Gx. 
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4.3.2 Differential regulation of androgen receptor levels during 
myocardial I-R 
Levels of AR, E2-Rα and E2-Rβ were comparable in male and female left ventricular 
free wall (sham I-R, Figure 4.3B & 4.3D). I-R enhanced AR and E2-Rβ expression in 
the infarct area of male (Figure 4.3A & 4.3B) but only E2-Rβ levels in female (Figure 
4.3C & 4.3D) hearts. E2-Rα expression did not change with I-R (Figure 4.3B & 4.3D). 
Myocardial AR levels were decreased in Gx males (Figure 4.3A & 4.3B) but not 
females (Figure 4.3C & 4.3D) and T treatment restored levels in Gx males (Figure 
4.3B) while elevating them in Gx females (Figure 4.3D). E2 had no effect on AR levels 
in Gx males (Figure 4.3B), but suppressed levels in Gx females (Figure 4.3D). Neither 
E2-Rα nor E2-Rβ levels in either gender were modified by treatment (Figure 4.3B & 
4.3D). 
 
 
 
 
Results  Chapter 4 
 
Page | 125  
 
 
Figure 4.3: Regulation of left ventricular sex steroid receptor expression 
Sex steroid receptor expression in the infarcted area from intact and gonadectomised 
males and females. Representative immunoblots of androgen receptor (AR), oestrogen 
receptors (E2-R) -alpha (E2-Rα) and -beta (E2-Rβ) in homogenates of male (Panel A) 
and female (Panel C) left ventricular free wall. Bar graphs show densitometric analysis 
of protein changes compared to the loading control -actin for males (Panel B) and 
females (Panel D). Gx, gonadectomised; T, testosterone; E2, 17β-oestradiol. Numbers 
in parentheses indicate number of animals per group; *P<0.05 vs Intact.  
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4.3.3 Regulation of autophagy by sex steroids during myocardial I-R 
I-R activated autophagy signalling kinases (AMP-activated protein kinase (AMPK) and 
mammalian target of rapamycin (mTOR)) and autophagosome formation initiated by 
increasing levels of Beclin-1, Atg5-Atg12 conjugate, LC3-II, conversion of LC3-I to 
LC3-II (LC3-II/LC3-I ratio) in both males and females (Figure 4.4). Activated AMPK 
activity during I-R was unaffected by Gx (Figure 4.4Ai & 4.4Bi), nor by T or E2 
treatment, with a trend (P=0.045) for enhanced AMPK activity in Gx females receiving 
T. This study indicated gender-specific regulation of mTOR activity. Gx had no effect 
on I-R induced mTOR activation in male hearts (Figure 4.4Aii), but enhanced mTOR 
activation in female hearts (Figure 4.4Bii). T or E2 treatment had no effect on mTOR 
activity in Gx males (Figure 4.4Aii & 4.4Bii), whereas both treatments restored mTOR 
levels in Gx females.  
Gx decreased Beclin-1 levels in the infarct area of hearts from males and females 
(Figure 4.4Aiii & 4.4Biii). There was a trend in restoring Beclin-1 levels in Gx females 
receiving T or E2 but not Gx males. Formation of autophagic vesicles (denoted by 
formation of Atg5-Atg12 conjugate) and progression of autophagy (LC3-II/LC3-I ratio) 
were decreased in the infarct area by Gx in both genders (Figure 4.4Aiv-v & 4.4Biv-v) 
indicating progression of autophagy was interrupted. T treatment restored Atg5-Atg12 
conjugate levels in both genders (Figure 4.4Aiv & 4.4Biv) while E2 treatment only 
restored Atg5-Atg12 conjugate levels in Gx females (Figure 4.4Biv). Suppressed LC3-
II/LC3-I ratios persisted in Gx males despite T or E2 treatment (Figure 4.4Av), 
indicating autophagy could not progress. In contrast, there was a trend by T and E2 to 
restore LC3-II/LC3-I ratio in Gx females to levels in intact females, indicating 
progression of autophagy. 
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Figure 4.4: Effects of sex steroids on autophagy markers. 
I-R induced expression of autophagy markers Beclin-1, Atg5-Atg12 conjugate and 
LC3-II/I assessed by immunoblotting in homogenates of left ventricular free wall from 
infarct area of intact and Gx males and females (± sex steroids). Top: Representative 
immunoblots of P-AMPK, AMPK, P-mTOR, mTOR, Beclin-1, Atg5-Atg12 conjugate, 
LC3-I, LC3-II, in males (A) and females (B). Below:  Bar graphs are densitometric 
analysis of the levels of (i) P-AMPK/AMPK ratio, (ii) P-mTOR/mTOR ratio, (iii) 
Beclin-1, (iv) Atg5-Atg12 conjugate, and (v) ratio of LC3-I to LC3-II conversion. Gx, 
gonadectomised; T, testosterone; E2, 17β-oestradiol; P-AMPK, phosphorylated AMP-
activated protein kinase (AMPK); P-mTOR, phosphorylated mammalian target of 
rapamycin (mTOR); Atg, autophagy-related gene; Beclin-1, known as Atg6; LC3, 
microtubule-associated protein light chain 3. Numbers in parentheses indicate number 
of animals per group; *P<0.05 vs Intact. 
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4.3.4 Differential regulation of RAGE by sex steroids during 
myocardial I-R 
I-R augmented myocardial RAGE expression in infarcted myocardium from intact 
males (Figure 4.5A), but not females (Figure 4.5B), while Gx had no effect in either 
gender (Figure 4.5A & 4.5B). T treatment suppressed RAGE protein levels in Gx males 
(Figure 4.5A), with the opposite effect in Gx females (increased RAGE levels, Figure 
4.5B). E2 treatment had no significant effect in either gender. 
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Figure 4.5: Effects of sex steroids on RAGE expression 
Expression levels of RAGE in homogenates of left ventricular free wall from the infarct 
area from intact and gonadectomised (± sex steroids) males (A) and females (B) 
following I-R. Top: Representative immunoblots of RAGE; Bellow: Bar graphs show 
densitometric analysis in the various treatment groups. RAGE, receptor for advanced 
glycation end products; I-R, ischaemia-reperfusion, Sham, sham I-R; Gx, 
gonadectomised; T, testosterone; E2, 17β-oestradiol. Numbers in parentheses indicate 
number of animals per group; *P<0.05 vs Intact. 
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4.3.5 Sex differences in regulation of apoptosis during myocardial I-R  
Caspase-9 and -3 processing are measures of the intrinsic pathway of apoptosis and 
were activated (presence of cleaved fragments) by I-R in both males and females 
(Figure 4.6). Consistent with effects on infarct size, Gx suppressed caspase-9 and 
caspase-3 processing in males (Figure 4.6Ai & 4.6Aii), but augmented caspase cleavage 
in females (Figure 4.6Bi & 4.6Bii). Treatment with T or E2 restored caspase processing 
in Gx males (Figure 4.6Ai & 4.6Aii). In females T did not affect Gx-activated caspase 
processing (Figure 4.6Bi & 4.6Bii), whereas it was reversed by E2.   
 
Expression levels of anti-apoptotic proteins, XIAP, Bcl-XL and ARC showed dimorphic 
regulation during I-R. In males, I-R decreased levels of all three anti-apoptotic proteins 
whereas levels were preserved in females (Figure 4.7). Gx enhanced expression of ARC 
and Bcl-XL, but not XIAP, in males which was reversed to levels in intact (non-Gx) 
males by treatment with T but not E2 (Figure 4.7A and 4.7B). In contrast, expression of 
XIAP and Bcl-XL, but not ARC, were suppressed following I-R in Gx females and were 
restored by E2 but not T (Figure 4.7C & 4.7D). 
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Figure 4.6: Effect of sex steroids on caspase-3 and -9 processing during myocardial 
ischaemia-reperfusion  
Appearance of cleaved fragments represents caspase processing. Representative 
immunoblots for caspase-3 and -9 cleaved fragments in homogenates of male (A(i)) and 
female (B(i)) left ventricular free wall from the infarct area during ischaemia-
reperfusion (± gonadectomy and sex steroids). Bar graphs represent densitometric 
analysis in males (A(ii)) and females (B(ii)) with -actin as the loading control. I-R, 
ischaemia-reperfusion; C.Casp-9, cleaved caspase-9; C.Casp-3, cleaved caspase-3; Gx, 
gonadectomised; T, testosterone; E2, 17β-oestradiol. Numbers in parentheses indicate 
number of animals per group; *P<0.05 vs Intact.  
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Figure 4.7: Effects of sex steroids on anti-apoptotic regulators of the intrinsic 
pathway of apoptosis 
Left: Representative immunoblots of anti-apoptotic proteins XIAP, Bcl-xL and ARC in 
homogenates of the left ventricular free wall from infarct area from intact and 
gonadectomised (± sex steroids) males (A) and females (B). Right: Bar graphs show 
densitometric analysis with loading control -actin. I-R, ischaemia-reperfusion; Gx, 
gonadectomised; T, testosterone; E2, 17β-oestradiol; XIAP, X-linked inhibitor of 
apoptosis protein; Bcl-xL, B-cell lymphoma-extra large; ARC, apoptosis repressor with 
caspase recruitment domain; Numbers in parentheses indicate number of animals per 
group; *P<0.05 vs Intact. 
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4.3.6 Regulation of MR levels by sex steroids during myocardial I-R  
MR expression in both male and female hearts is shown in Figure 4.8. Although 
reperfusion injury showed a trend to decrease levels of MR in male rats, this was not 
significant. Removal of endogenous sex steroid hormones (androgens or oestrogens) by 
gonadectomy did not alter the levels of myocardial MR in males or females. Similarly, 
there was no change in MR expression levels during supplementation with T or E2 
(Figure 4.8). 
 
Figure 4.8: Effects of sex steroids on MR protein expression during I-R.  
Expression levels of mineralocorticoid receptor in hearts from intact and 
gonadectomised male and female animals (± hormones for 21 days) subjected to 
ischaemia-reperfusion (I-R). (A) Representative immunoblot of MR in left ventricular 
free wall homogenates of male (left) and female (right) hearts. (B) Bar graphs show 
densitometric analysis of protein changes compared to the loading control β-actin. MR, 
mineralocorticoid receptor; Gx, gonadectomised; T, testosterone; E2, 17β-oestradiol.  
Numbers in parentheses indicate the number of animals in each group. 
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4.4 Discussion 
The different sex steroid actions during myocardial I-R involve the androgen receptor, 
RAGE and an unreported gender dependent shift in the balance between autophagy and 
apoptosis. Both androgens and E2 aggravated infarct size in males. The current study is 
one of the few that has shown cardiac actions of low levels of androgens in males. We 
tried to administer weight adjusted doses of sex steroids, and are unsure why Gx males 
receiving E2 showed marked elevations in serum levels of E2. The results therefore do 
not contribute to whether elevated levels of E2 in males are detrimental. This will need 
to be explored by clinical studies in older men with CAD (Phillips et al., 1983), using 
LC-MS/MS and not immunoassay to measure serum E2 levels.  
 
The studies in this chapter confirm that T directly aggravates I-R induced cardiac 
damage in male animals, since Gx reduced infarct size, whereas cardiac damage was 
restored by T supplementation, despite lower circulating levels, a direct action of T 
rather than conversion to oestradiol since DHT produced similar effects. Administration 
of T to Gx females had no effect on infarct size, in agreement with previous reports 
(Nam et al., 2007a). Increased infarct size following I-R in males may be mediated via 
elevated AR levels since Gx down-regulated AR levels, which were restored by T 
treatment in males; T administration to Gx females augmented levels of AR, which has 
not been previously reported and may be relevant for postmenopausal women receiving 
treatment with T. E2 administration had no effect on cardiac AR expression in Gx 
males, whereas cardiac AR levels were down-regulated in Gx females, reducing infarct 
size and consistent with a previous study (Tivesten et al., 2006).   
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Autophagy markers were activated by reperfusion injury in both males and females as 
previously reported for male animals (Matsui et al., 2007); we show for the first time 
differential gender regulation of mTOR activity. Despite no changes in males, Gx in 
females enhanced mTOR activity, indicating inhibition of autophagy and correlating 
with increased infarct size. Beclin-1 is important in regulating balance between 
autophagy and apoptosis by directly interacting with anti-apoptotic proteins Bcl-2 or 
Bcl-xL (Hamacher-Brady et al., 2006a). Our data for Beclin-1 and Bcl-xL in the 
reperfused hearts show an inverse proportional relationship, suggesting this balance as 
important for regulating autophagy and apoptosis by sex steroids. The autophagy 
specific gene Atg5 is a rate-limiting protein; in males, T alone regulates expression of 
Beclin-1 and Atg5-Atg12 to initiate autophagy, whereas in females both T and E2 have 
a similar effect. This may explain why T given to Gx females did not aggravate infarct 
size despite increased levels of cardiac AR. Progression of autophagy is indicated by 
increases in levels of myocardial LC3-II and LC3-II/LC3-I ratio. Although myocardial 
I-R upregulated LC3-II/LC3-I ratio in intact animals, Gx in both males and females 
prevented conversion of LC3-I to LC3-II, indicated by the low LC3-II/LC3-I ratio, so 
autophagy could not proceed; sex steroids did not restore levels in Gx male animals. 
 
Enhanced RAGE expression during myocardial I-R is dependent on circulating T rather 
than E2 levels in both males and females, differing from a previous report that E2 
increases RAGE transcription and protein expression (Tanaka et al., 2000). In the 
current studies, Gx females receiving T showed enhanced RAGE expression, 
correlating with increased infarct size. In Gx males supplemented with T but low 
circulating T levels, RAGE expression was significantly less than intact males. RAGE 
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stimulation activates pro-apoptotic caspase cascade resulting in cardiomyocyte 
apoptosis (Essick and Sam, 2010). There were no differences between males and 
females in activation of pro-apoptotic proteins caspase-3 and -9, confirming terminal 
apoptotic cell death. Decreased levels of anti-apoptotic proteins XIAP, Bcl-xL and ARC 
during myocardial I-R in males but not females further promote apoptosis. Although 
previous studies show sex differences in cardiomyocyte apoptosis following myocardial 
I-R (Bouma et al., 2010), our study is the first to show androgen-dependent 
downregulation of Bcl-xL, a key factor for the crosstalk between autophagy and 
apoptosis. 
 
Although several studies have suggested that MR signalling is gender-specific 
(Hofmann et al., 2012; Kanashiro-Takeuchi et al., 2009; Kunzel et al., 2012; Rigsby et 
al., 2007), there have been no studies that determine the effect of sex hormones on MR 
expression in the heart. In the current study, MR protein levels remain unchanged 
following ischaemia (30 minutes) and reperfusion (150 minutes) in both male and 
female hearts (Figure 4.8). Although previous studies have found an upregulation of 
MR protein levels in left ventricle of animal models of MI, most of these studies were in 
male animals only and MR levels were measured 2-4 weeks after MI (de Resende et al., 
2006; Milik et al., 2007; Takeda et al., 2007). Moreover, the various treatments with sex 
hormones in our study provided an opportunity to identify differential regulation of MR 
expression during myocardial I-R in male and female animals which has not been 
previously reported. There were no significant changes in levels of MR during the 
various treatments (Figure 4.8); suggesting gonadal steroids do not modify MR 
expression. 
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In conclusion, the results in this chapter show novel and key roles for sex steroid action 
during MI (Figure 4.9). Myocardial I-R in male animals aggravated cardiac damage 
through increased AR and RAGE expression, with a shift in the balance between 
autophagy and apoptosis towards increased apoptosis. In contrast, myocardial I-R in 
females produces less cardiac damage reflecting enhanced autophagy and decreased 
apoptosis. RAGE is a key regulator of this switch, with T administration to females 
activating both AR and RAGE expression, which perhaps is relevant for 
postmenopausal women receiving T. These results therefore provide a platform for new 
potential treatment strategies for reperfusion injury in both females and males. 
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Figure 4.9: Schematic summary of pathways activated during myocardial I-R 
injury in male and female myocardium.  
ROS, reactive oxygen species; RAGE, receptor for advanced glycation end products;  
AR, androgen receptors; ER, estrogen receptor; Bcl-xL, B-cell lymphoma-extra large; 
XIAP, X-linked inhibitor of apoptosis protein; ARC, apoptosis repressor with a caspase 
recruitment domain; Atg, autophagy-related gene; Beclin-1, known as Atg6; LC3, 
microtubule-associated protein light chain 3; AMPK, AMP-activated protein kinase; 
mTOR, mammalian target of rapamycin; ↑, increased; ↓, decreased; ↔, no change. 
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5.1 Introduction 
Similar to other steroid hormones, aldosterone binds to its cognate receptor, the 
mineralocorticoid receptor (MR), which belongs to the nuclear superfamily of receptors 
(Griekspoor et al., 2007). Aldosterone and MR activation also have an important role in 
cardiovascular tissues. Circulating levels of aldosterone have been reported to regulate 
L-type Ca2+ currents in ventricular myocytes (Perrier et al., 2005), regulate intracellular 
Ca2+ movement and activation of the ryanodine receptor (Gomez et al., 2009), while 
mildly elevated aldosterone levels have been found in patients with essential 
hypertension (Genest et al., 1956) and elevated levels trigger hypertrophy, fibrosis and 
remodelling (Brilla et al., 1990; Lin et al., 2012; Tsybouleva et al., 2004; Young et al., 
1994). 
 
Elevated plasma levels of aldosterone in patients presenting for primary percutaneous 
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) 
and acute myocardial infarction (AMI) are associated with significantly worse 
prognosis, including higher death rates, recurrent ischaemia, extended MI and heart 
failure (Beygui et al., 2006; Beygui et al., 2009; Palmer et al., 2008).  Similarly elevated 
plasma aldosterone levels in patients with coronary artery disease (CAD), independently 
correlate with long term mortality and increased risk of acute ischaemic events (Ivanes 
et al., 2012). Whether these pathophysiological actions of aldosterone involve 
interaction between non-genomic and genomic signalling pathways has not been 
defined. 
 
The genomic actions of aldosterone involve aldosterone binding to MR followed by 
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translocation into the nucleus and the hormone-receptor complex modulating 
transcription of various target genes which include induction of epithelial Na+ channel 
(ENaC) (Asher et al., 1996), serum-regulated kinase 1 (Sgk-1) (Bhargava et al., 2004; 
Chen et al., 1999; Naray-Fejes-Toth and Fejes-Toth, 2000), Na+/K+-ATPase (Kolla and 
Litwack, 2000). These effects normally occur after hours and are blocked by MR 
antagonists (spironolactone or eplerenone). In contrast, the rapid extranuclear, non-
genomic effects of aldosterone are not dependent on transcription. These include 
activation of signalling pathways such as extracellular signal regulated kinase 1/2 
(ERK1/2), c-Jun NH2-terminal kinase 10/2 (JNK1/2) (Gekle et al., 2001; Grossmann et 
al., 2005; Rossol-Haseroth et al., 2004) and protein kinase C (PKC) (Alzamora et al., 
2007; Fujita et al., 2005; Mihailidou et al., 2004), as well as increases in intracellular 
Ca2+, pH (Wehling et al., 1996) and NADPH oxidase-mediated ROS production 
(Hayashi et al., 2008). The nongenomic effects of aldosterone are not blocked by 
inhibitors of transcription and protein synthesis, and mediated through MR-dependent 
and MR-independent mechanisms (Chai et al., 2005; Fujita et al., 2005; Schmidt et al., 
1999; Schmidt et al., 2003; Wehling et al., 1998). 
 
Several studies have suggested a potential MR located at the plasma membrane 
(Grossmann et al., 2010; Ricchiuti et al., 2011; Wildling et al., 2009) to mediate the 
non-genomic effects, although identifying this receptor has been elusive until recently. 
Fractionation studies have identified MR in both cytoplasmic and membrane fractions 
(Ricchiuti et al., 2011), while the G protein-coupled receptor 30 (GPR30 or GPER1) has 
been shown to mediate non-genomic aldosterone signalling (Gros et al., 2011b) 
including rapid activation of ERK1/2 and apoptosis in vascular smooth muscle cells 
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(VSMC) (Gros et al., 2011b) and endothelial cells (Gros et al., 2013) as well as VSMC 
contraction (Gros et al., 2011a). Although some studies suggest GPR30 is the putative 
membrane receptor mediating MR-independent rapid aldosterone signalling, the role of 
GPR30 in the pathophysiological actions of aldosterone in the heart has not been 
defined. Based on the results from the previous chapter showing significantly greater 
cardiac damage in males compared with age-matched females following myocardial I-
R, the aim of the current study was to determine the interaction of non-genomic with 
genomic signalling pathways in the cardiac actions of aldosterone in male animals. 
 
5.2 Methods 
5.2.1 Reagents 
Aldosterone (Ald) and other chemical reagents were purchased from Sigma-Aldrich and 
cell culture reagents were from Invitrogen. The GPR30 specific agonist G1 and the 
selective GPR30 antagonist G36 were purchased from Azano Pharmaceuticals, Inc. 
Aldosterone-3-carboxymethoxylamine-PEG amine (Aldo-PEG, molecular weight 
~40,000) was manufactured by Prof. Celso Gomez-Sanchez as described below. Dose-
response studies (0.1-100 nM) were completed from a stock (100 μM) for Ald and 
Aldo-PEG. 
 
Chemical synthesis of Aldo-PEG: Aldosterone-3-CMO was prepared by aldosterone 
(26.5 mg) dissolved in a mixture of methanol (2 mL) and pyrrolidone (13 μL) for 10 
min followed by adding carboxymethoxylamine hemi hydrochloride (10 mg). The 
reaction mixture was left overnight at room temperature (~22°C). The methanol was 
partially evaporated and the product was dissolved in dichloromethane (30 mL), washed 
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with 1N HCl twice followed by 4 times with water. Complete conversion was checked 
by thin layer chromatography (TLC) where a single compound was found. The 
dichloromethane was dried with sodium sulfate, filtered and evaporated. The 
aldosterone-3-CMO-TFP ester was prepared by dissolving aldosterone-3-CMO in 
dimethylformamide (2 mL) and tetrafluorophenol (12 mg) and then added 
diisopropylcarbodiimide (12 μL). The reaction mixture was left overnight at room 
temperature and complete conversion was checked by TLC. Coupling of aldosterone-3-
CMO-TFP ester to methoxy-PEG was achieved as follows: methoxy-PEG (mw: 40,003 
(JenKem, China); 615 mg) dissolved in water (20 mL) were reacted with the 
aldosterone-3-CMO-TFP ester for overnight. The solution was then dialyzed against 4 L 
sodium bicarbonate (50 mM) for overnight, then 3 changes of water over 3 days at 4°C. 
The product was then lyophilized. A small amount was acidified with HCL and 
extracted, washed and tested by ELISA. No free steroid or free amino groups were 
demonstrated in the methoxy-PEG- aldo. 
 
5.2.2 Cell culture and treatment 
Rat cardiomyoblast, H9c2 cells were used. Experimental details for routine cell culture 
and passage of H9c2 cells are described in Chapter 2 (sections 2.7.1 – 2.7.2). Before 
treatment, the cells were washed with PBS and cultured in DMEM containing 10% 
(v/v) dextran-coated charcoal stripped FBS (DCC-FBS) [2.5% (w/v) Norit-A charcoal 
and 0.25% (w/v) DextranT-70] for 36 hours to eliminate any steroid source before 
treatment. H9c2 cells were treated with Ald or Aldo-PEG (0.1, 0.3, 1, 3, 10 and 30 nM) 
in DMEM/DCC-FBS medium for either 20 minutes (for ERK1/2 activation studies) or 4 
hours (for subcellular fractionation and gene expression studies). In a separate 
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experiment, cells were treated with GPR30 agonist, G1 (10, 100, 1000 and 10000 nM) 
for 20 minutes for ERK1/2 activation studies. To confirm the specificity of GPR30, the 
GPR30 antagonist, G36 was used. The suitable dose of G36 was determined by 
stimulating the cells with a constant dose of G1 and increasing concentrations of G36 
(10, 100, 500, 1000 nM) for 20 minutes and protein lysates collected for ERK1/2 
activation studies. To examine whether actions of Ald, Aldo-PEG or G1 were mediated 
via MR or GPR30, H9c2 cells were pre-incubated for 30 minutes with SPIRO (100 nM) 
or G36 (500 nM) prior to addition of Ald, Aldo-PEG or G1 for ERK1/2 activation 
studies.  
 
5.2.3 Measurement of superoxide generation 
Cardiomyocyte superoxide generation was measured using lucigenin-enhanced 
chemiluminescence, as previously described (Laskowski et al., 2006; Peshavariya et al., 
2007). H9c2 cells were seeded into 6-well plates at a density of 4 × 105 cells/well, 
serum-deprived overnight and treated with Ald (10 nM) or Aldo-PEG (10 nM) for 4 
hours. Stimulated cells were collected in Krebs-HEPES buffer [ 130 mM NaCl, 5 mM 
KCl, 1 mM MgCl2, 1.5 mM CaCl2, 1 mM K2HPO4, 11 mM Glucose and 20 mM 
HEPES, pH 7.4, with 1 mg/mL bovine serum albumin (BSA)] containing NADPH (100 
µM) and lucigenin (5 µM) for chemiluminescence measurements. The cell suspensions 
were transferred into a 96 well OptiView plates (PerkinElmer, Inc.) and measured using 
a Veritas Microplate Luminometer (Turner Biosystems, Inc.). Each treatment group was 
performed in triplicate and the photon emissions were recorded every 30 seconds for up 
to 20 readings. Background chemiluminescence in buffer containing lucigenin was 
measured in the absence of cells and subtracted from the average of 20 readings. 
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5.2.4 Subcellular fractionation 
Plasma membrane, cytosolic and nuclear fractions were prepared from 100 mm dishes 
of confluent H9c2 cells. Plasma membrane and cytoplasmic fractions were prepared at 
4°C as previously described (Perez-Reyes et al., 1989) with modifications. Briefly, cells 
were washed with PBS, which was aspirated, and scraped into 5 mL of PBS containing 
protease inhibitor cocktail (Roche Applied Science).  The cells were pelleted by 
centrifugation for 5 minutes at 3,000xg and resuspended into 1 mL of homogenisation 
buffer [50 mM Tris (pH 7.2) and 1 mM EDTA with protease inhibitors]. Cells were 
placed on ice to swell for 5 minutes followed by 20 strokes in a dounce homogeniser 
and centrifugation of the lysate at 750xg for 10 minutes. The supernatant (containing 
cytoplasmic and membrane fractions) was removed and stored on ice. The pellet was 
resuspended in 1 mL of homogenisation buffer, homogenised and centrifuged again. 
The two supernatants were combined and centrifuged at 100,000xg for 60 minutes in a 
Beckman Ti90 rotor. The supernatant from this final centrifugation represents 
cytoplasmic proteins. The pellet was resuspended in homogenisation buffer and 
represents the membrane fraction. 
 
For nuclear extraction, cells were resuspended in 400 µL ice-cold buffer A [10 mM 
HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT and 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF)] and incubated on ice for 20 minutes.  At the 
conclusion of this incubation, 25 µL of 10% (v/v) Nonidet P-40 was added, the tube 
vigorously vortexed (15 seconds) and the homogenate centrifuged at 10,000xg for 30 
secconds. The nuclear pellet was resuspended in buffer B [20 mM HEPES (pH 7.9), 0.4 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and 1 mM PMSF]. Lysates of the 
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nuclear fraction were sonicated and clarified by centrifugation at 10,000xg for 5 
minutes.  
 
5.2.5 Immunofluorescence staining 
Immunostaining was used to identify and localise proteins in sections of reperfused 
myocardium using the protocol described in Chapter 2 (section 2.5.1). Sections 
incubated with anti-MR (1:20) or -GPR30 (1:40) antibodies overnight at 4°C followed 
by Alexa Fluor 594 conjugated concanavalin A (20 µg/mL; Invitrogen) or anti-IgG 
conjugated Alexa Fluor 488 antibody (1:200; Invitrogen) for up to 1 hour.  Sections 
were counterstained with DAPI reagent, mounted and analysed using confocal 
fluorescence microscope (Leica SP5) with a 63x oil objective. 
 
5.2.6 Western blots 
Total protein was extracted from rat heart tissue and H9c2 cells as described in Chapter 
2 (sections 2.5.2 and 2.7.3). Western blots were performed as described in Chapter 2 
(section 2.5.3). The primary antibodies were rMR 1-18 1D5 (kindly donated by Prof. 
Celso Gomez-Sanchez), GPR30 (Santa Cruz Biotechnology, cat# sc-48524), phospho- 
(pT202/pY204) and total p44/42 MAPK (ERK1/2) (Cell Signaling, cat# 9101 & 9102).  
The proteins aquaporin1 (Santa Cruz, cat# sc-20810), α-tubulin (Santa Cruz, cat# sc-
5286) and Histone H1 (clone 1415-1) (NeoMarkers) were used as makers to confirm 
purity of subcellular fractions as they are exclusive to the membrane, cytoplasm and 
nucleus, respectively. Antibody binding was detected using HRP-conjugated secondary 
antibodies (1:3000, Dako Cytomation). Membranes were exposed to chemiluminescent 
substrate (PerkinElmer, Melbourne, Australia) and digital images captured on a 
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LAS4000 (GE Healthcare Life Sciences). 
 
5.2.7 Quantitative real-time RT-PCR (qRT-PCR) 
Following treatment, total RNA was extracted from H9c2 cells using QIAzol lysis 
reagent (Qiagen) according to the protocol provided by the manufacturer and described 
in Chapter 2 (sections 2.6.1 and 2.7.5). The concentration and purity of the RNA 
samples were assessed using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific). The cDNA was synthesised from 2.5 µg total RNA using the Superscript III 
First-Strand Synthesis System and oligo (dT)20 as a primer (Invitrogen) according to the 
manufacturer’s protocols (see section 2.6.4 for more details). cDNA samples were 
stored at -20°C until used for qRT-PCR. The mRNA expression of 
serum/glucocorticoid regulated kinase 1 (Sgk-1) and plasminogen activator inhibitor 
type 1 (PAI-1) were analyzed using TaqMan gene expression assays (Applied 
Biosystems, [Rn00570285_m1] and [Rn01481341_m1], respectively). Glyceraldehyde-
3-phosphate dehydrogenase (Gapdh) [Rn99999916_s1] was used as endogenous 
control. Amplification efficiency curves were performed for all gene expression assays 
prior to sample analysis, with the sample designated as the calibrator, using six point 
dilution series (1, 1:10, 1:100, 1:1000, 1:10000, 1:100000 dilutions). The 7900HT Fast 
Real-Time PCR system (Applied Biosystems) was used to perform qRT-PCR in clear 
96 or 384 well plates. Each cDNA sample was run in triplicate and a no template 
control was included on each plate to check for cross contamination. The qRT-PCR 
reaction mix consisted of following components:  
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Components 96 wells plate 384 wells plate 
Sterile water (µl) 4 0.5 
TaqMan gene expression master mix [2x] (µl) 10 5 
TaqMan gene expression assay [20x] (µl) 1 0.5 
Diluted cDNA sample [1:5 dilutions] (µl) 5 4 
Total reaction volume 20 10 
 
Table 5.1: Preparation of the qRT-PCR reaction cocktail 
 
The real-time PCR program included a holding stage at 50°C for 2 minutes, 95°C for 10 
minutes, and cycling 40 times at [95°C for 15 seconds (melting), and 60°C for 1 minute 
(annealing/extension)]. The Delta–Delta Comparative Threshold (CT) method was 
used to quantify the relative fold change between the samples. Data was analysed using 
RQ Manager Analysis software, version 1.2.1 (Applied Biosystems). 
 
5.2.8 Ex vivo myocardial ischaemia-reperfusion studies 
Adult male (300 – 400 g) Sprague Dawley rats (N = 38) were used to avoid any 
variability associated with fluctuations in female hormonal cycles, and particularly since 
GPR30 is also a highly avid receptor for estrogen (Ding et al., 2009; Filice et al., 2009). 
Myocardial I-R injury was performed as described in Chapter 2 (sections 2.2). Briefly, 
rats were anaesthetised and the hearts rapidly excised and attached to a Langendorff 
apparatus for regional ischaemia for 30 minutes followed by reperfused for 150 
minutes. At the end of reperfusion, infarct area was determined as per Chapter 2 
(section 2.3). Apoptotic cells were visualised by TUNEL staining of paraffin embedded 
heart sections using In Situ Cell Death Detection Kit described in Chapter 2, section 2.4. 
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5.2.9 Statistical analysis 
Details for statistical analysis are described in Chapter 2 (sections 2.8). 
 
5.3 Results 
5.3.1 MR and GPR30 expression in cardiomyocytes 
The large molecular size of PEG yields a hybrid molecule that has similar structure to 
aldosterone (Ald) but is membrane impermeable (Figure 5.1) which allows 
identification of non-genomic Ald signaling pathways separate to the genomic actions. 
 
 
 
Figure 5.1: Structure of Aldosterone-3-carboxymethoxylamine-PEG-amine (M.W.  
40,000) compared to aldosterone (M.W. 360.44). 
 
Immunoblotting confirmed endogenous expression of both MR and GPR30 in H9c2 
cardiomyocytes and rat myocardium (Figure 5.2A). Expression of GPR30 was 
comparable between rat myocardium and H9c2 cells, whereas expression of MR was 
higher in H9c2 cells than left ventricular myocardium. To determine the profile of 
potential receptor activation by Ald and Aldo-PEG, we fractionated H9c2 cells and 
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examined subcellular receptor location. Aquaporin-1, α-tubulin and histone H1 were the 
plasma membrane, cytoplasmic and nuclear protein markers respectively and clearly 
demonstrate the integrity of the lysates used. 
 
In untreated H9c2 cells, MR were primarily cytoplasmic (62 ± 3%, mean ± SE, N=3) 
with 38 ± 3% (N=3) in the nuclear resident pool of MR (even in the presence of DCC-
FBS) (Figure 5.2B). Addition of Ald indicated translocation of MR with the proportion 
of nuclear-resident MR increasing to 77 ± 6% (Figure 5.2B). In contrast, Aldo-PEG did 
not mimic the effect of Ald on MR subcellular localisation confirming the inability of 
Aldo-PEG to enter the cell (Figure 5.2B). GPR30 was localised to the cytoplasmic and 
membrane fractions of H9c2 cells, consistent with previous reports for GPR30 
distribution (Filardo et al., 2007; Revankar et al., 2005; Revankar et al., 2007). In 
contrast to MR, the level of GPR30 protein was similar in non-stimulated and 
stimulated cells, with no change in the sub-cellular distribution of the receptor upon 
addition of Ald or Aldo-PEG (Figure 5.2B).  
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Figure 5.2: Expression and localisation of MR and GPR30 in H9c2 cells 
(A) MR and GPR30 expression in H9c2 cells. Western blot of MR and GPR30 total 
proteins that were extracted from rat heart tissue and H9c2 cardiomyocytes. (B) 
Subcellular fractions/distribution of MR and GPR30 in H9c2 cells. Total protein, 
membrane, cytosolic and nuclear protein fractions were extracted and subjected to 
immunoblot analysis. Aquaporin-1, α-tubulin and histone H1 were used as loading 
controls for membrane, cytosolic, and nuclear extracts, respectively. Cells were 
incubated with Ald (10 nM) or Aldo-PEG (10 nM) for 4 hours. 
 
Subcellular distribution of GPR30 and MR was detected by immonostaining in left 
ventricular myocardial sections from rat hearts subjected to I-R using confocal 
microscopy (Figure 5.3A), with both MR and GPR30 detected in rat myocardium. For 
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these studies Concavalin A (Con A), a lectin that specifically binds to α-mannosyl 
saccharides in the core of integral plasma membrane glycoproteins, was used as a 
plasma membrane marker (Filardo et al., 2007). Con A staining in tissue sections 
highlighted the plasma membrane exclusively (Figure 5.3A & 5.3B, red). MR displayed 
a primarily cytosolic localisation, with a small amount in the nucleus and no co-
localisation with Con A in rat hearts following reperfusion injury (Figure 5.3A).  
Consistent with studies in H9c2 cells, there was an increased proportion of MR in the 
nuclei of injured myocardium exposed to 10 nM Ald but not Aldo-PEG (Figure 5.3A, 
arrow). The overlapping staining of GPR30 and Con A in the membrane shows co-
localisation of GPR30 with the plasma membrane marker and its localisation to the cell 
membrane (Figure 5.3B, yellow). Although GPR30 has been reported to localise to the 
endoplasmic reticulum, which in myocytes is located near and continuous with the outer 
layer of the nuclear envelop, the current study did not find staining in this location and 
only detected in the cytoplasm (Figure 5.3B).  
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Figure 5.3: Expression and localisation of MR and GPR30 in rat heart 
Representative overlay confocal images of ventricular sections from hearts subjected to ischaemia-reperfusion injury. MR (A) and GPR30 
(B) were detected with Alexa 488 (green). Tissue sections were co-stained with Alexa 594 conjugate concanavalin A (Con A, red), which 
specifically binds α-mannosyl saccharides in plasma membrane glycoproteins). Nuclei are stained using DAPI (blue). Scale bar = 10 µm. 
Results  Chapter 5 
 
Page | 154  
5.3.2 Aldo-PEG regulates non-genomic signalling pathways similar to 
aldosterone 
Activation of ERK1/2 signalling, a recognised non-genomic signalling pathway for Ald 
(Gros et al., 2011b; Grossmann et al., 2005) was used to confirm the biological activity 
of Aldo-PEG. Dose-response studies in H9c2 cardiomyocytes showed that both Ald 
(Figure 5.4A) and Aldo-PEG (Figure 5.4B) increased phosphorylation of ERK1/2 after 
20 minutes incubation, with similar kinetics and potency confirming that the modified 
compound was as efficacious as Ald when activating non-genomic signalling.  
 
Previous studies suggest that GPR30 is required for MR-independent action of Ald 
(Gros et al., 2011b). To confirm the involvement of GPR30, we used G1 (GPR30 
agonist) and G36 (GPR30 antagonist). Dose-response studies for G1, using 
concentrations similar to those previously reported (Gros et al., 2013) also increased 
phosphorylation of ERK1/2, with maximal effect at 100 nM (Figure 5.4C) and this dose 
was selected for subsequent studies. To confirm GPR30-mediated responses, the 
GPR30 antagonist G36 was used. Dose-response studies for G36 were completed to 
find an appropriate dose which would inhibit G1-activated ERK1/2 phosphorylation 
(Figure 5.5). Cells were stimulated with a constant dose of G1 (100 nM) and increasing 
concentrations of G36 (10, 100, 500, 1000 nM) were used to identify an optimal dose of 
G36 at 500 nM (Figure 5.5) and this was selected for subsequent studies. 
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Figure 5.4: Aldo, Aldo-PEG and G1 mediated ERK1/2 phosphorylation  
The effects of Ald (A), Aldo-PEG (B) and G1 (C) on phosphorylation of ERK1/2 in 
H9c2 cells were measured by western blot. Cells were incubated with indicated 
concentrations of Ald, Aldo-PEG or G1 for 20 minutes. Left: representative western 
blot of phosphorylated ERK1/2 and total ERK1/2 images. Right: Graphs show 
quantification of phospho-ERK1/2 to total ERK1/2. Ald, aldosterone; ERK1/2, 
extracellular signal-regulated protein kinases 1/2. Values expressed as mean ± SE from 
three independent experiments; *P<0.05 vs no treatment. 
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Figure 5.5: Effects of G36 on G1 mediated ERK1/2 phosphorylation. 
G1 mediated ERK1/2 phosphorylation is inhibited by increasing concentrations of G36. 
H9c2 cells were incubated with G36 (10-1000 nM) for 30 minutes prior to G1 (100 nM) 
addition and protein lysates were collect after 20 minutes. Top: representative western 
blot images of phosphorylated ERK1/2 and total ERK1/2. Below: Graph shows 
quantification of phospho-ERK1/2 to total ERK1/2. ERK1/2, extracellular signal-
regulated protein kinases 1/2. Values expressed as means ± SE from three independent 
experiments; *P<0.05 vs G1. 
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To determine whether the rapid responses of Ald and Aldo-PEG were mediated by MR 
or GPR30, the cells were pretreated with the MR antagonist (SPIRO, 10 nM) or GPR30 
antagonist (G36, 500 nM) and assess the effect Ald- and Aldo-PEG-mediated ERK1/2 
phosphorylation. Following G36 pre-treatment, Ald, Aldo-PEG and G1 acitvated 
ERK1/2 phosphorylation were significantly reduced (Figure 5.6), indicating that these 
actions were mediated by GPR30. In contrast, the effects of Ald, Aldo-PEG and G1 on 
ERK1/2 activation persisted in the presence of SPIRO indicating that these actions were 
not mediated by MR. G36 (500 nM) or SPIRO (10 & 100 nM) treatment had no 
significant effect on baseline ERK1/2 phosphorylation (Figure 5.6). 
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Figure 5.6: Effects of antagonists on Ald, Aldo-PEG and G1 mediated ERK1/2 
phosphorylation. 
H9c2 cells were incubated with SPIRO (10 nM) or G36 (500 nM) for 30 minutes prior 
to Ald (1 nM), Aldo-PEG (1 nM) or G1 (100 nM) addition and protein lysates were 
collect after 20 minutes. Top: representative western blot images of phosphorylated 
ERK1/2 and total ERK1/2. Below: Bar graph shows quantification of phospho-ERK1/2 
to total ERK1/2. Ald, aldosterone; Aldo-PEG, aldosterone-3-carboxymethoxylamine-
PEG amine; SPIRO, spironolactone; ERK1/2, extracellular signal-regulated protein 
kinases 1/2. Values expressed as mean ± SE from four independent experiments; 
*P<0.05 vs control. 
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One of the actions of aldosterone in the cardiovascular system is generation of oxygen 
free radicals (Hayashi et al., 2008; Rude et al., 2005) which contributes to the adverse 
cardiac damage. Generation of superoxide levels was measured in H9c2 cells after 
exposure to Ald or Aldo-PEG. Superoxide production was significantly increased to 
equivalent levels in H9c2 cells treated with Ald or Aldo-PEG (Figure 5.7), correlating 
with the rapid activation of ERK1/2 phosphorylation (Figure 5.7). 
 
 
 
Figure 5.7: Aldosterone and Aldo-PEG mediated superoxide generation 
Superoxide generation measured by lucigenin-enhanced chemiluminescence in H9c2 
cells following treatment with Ald and Aldo-PEG. Cells were incubated with indicated 
concentrations of Ald or Aldo-PEG for 4 hours. Bar graphs show quantification of 
superoxide levels. Ald, aldosterone; Aldo-PEG, aldosterone-3-carboxymethoxylamine-
PEG amine; ERK1/2, extracellular signal-regulated protein kinases 1/2. Values 
expressed as mean ± SE from five independent experiments; *P<0.05 vs No Rx. 
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5.3.3 Aldo-PEG does not activate transcription of aldosterone-
responsive genes 
The ability of Ald and Aldo-PEG to modulate non-genomic signalling was equivalent 
(Figure 5.4, 5.6 & 5.7) and next aim therefore examined whether Aldo-PEG may also 
regulate genomic targets using qRT-PCR from total RNA. Activation of MR results in 
transcriptional control of a wide variety of genes; the two best characterised MR 
response genes are Sgk-1 and PAI-1 (Latouche et al., 2010). MR activation in response 
to treatment with 10 nM Ald for 4 hours significantly increased transcript levels for 
both Sgk-1 (Figure 5.8A) and PAI-1 (Figure 5.8B) compared to vehicle control. These 
activities were prevented by co-incubation with SPIRO (10 nM) confirming genomic 
MR activation. In contrast, Aldo-PEG (1 and 10 nM) had no effect on Sgk-1 and PAI-1 
mRNA levels; suggesting genomic MR responses cannot be elicited from a ligand that 
is cell impermeable. Moreover, these findings discriminate a role for plasma-membrane 
based receptors (such as GPR30) in non-genomic responses (ERK 1/2 activation) and 
genomic responses to Ald. 
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Figure 5.8: MR activation by Ald but not Aldo-PEG regulates Sgk-1 and PAI-1 
gene expression 
Regulation of Sgk-1 (A) and PAI-1 (B) mRNA expression by Ald and Aldo-PEG (1 and 
10 nM) in H9c2 cells was examined by qRT-PCR. H9c2 cells were incubated with 
indicated concentrations of Ald or Aldo-PEG for 4 hours. Sgk-1, serum/glucocorticoid 
regulated kinase 1; PAI-1, plasminogen activator inhibitor-1; Ald, aldosterone; Aldo-
PEG, aldosterone-3-carboxymethoxylamine-PEG amine; SP, spironolactone. Values 
expressed as mean ± SE from four independent experiments; *P<0.05 vs No Rx. 
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5.3.4 Activation of MR genomic signalling pathways mediate 
aldosterone-aggravated cardiac damage 
The studies in H9c2 cells confirm that the cell impermeable Aldo-PEG elicits non-
genomic, but not genomic responses, with equal potency to the classical MR agonist 
Ald. To determine whether there was a role for MR non-genomic signalling in the 
pathophysiological action of Ald, ex vivo experimental model of myocardial infarction 
was used. We found that Ald (10 nM) but not Aldo-PEG (10 and 100 nM), increased 
infarct size (Figure 5.9A) and aggravated myocyte apoptosis (Figure 5.9B). As such, the 
non-genomic actions of Aldo-PEG (most likely working through GPR30) are 
insufficient to mediate the cardiac damaging effects of Ald during infarction. These data 
strongly suggest that the genomic actions downstream of “classical” MR activation 
drive the aggravation of myocardial I-R injury by Ald (increased infarct size and 
apoptosis) which complement the sub-cellular localisation (Figure 5.2 & 5.3) and gene 
expression studies (Figure 5.8). 
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Figure 5.9: Aldo-PEG induces superoxide production but maintains apoptosis and 
infarct size by preventing MR activation 
(A) Myocardial infarct size in hearts subjected to ischaemia followed by reperfusion (I-
R) during treatment with Ald and Aldo-PEG. Infarct area/size (IA) is expressed as 
percentage of area at risk (AAR). (B) Quantification of apoptotic index from treated 
reperfused myocardium. Apoptotic index is expressed as percentage of TUNEL positive 
nuclei relative to total nuclei. Numbers of animals in each group are indicated in 
parentheses within columns. Values expressed as mean ± SE; *P<0.05 vs I-R alone. 
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5.4 Discussion 
Rapid, non-genomic effects of aldosterone in the cardiovascular system are confirmed 
(Alzamora et al., 2003; Alzamora et al., 2000; Gros et al., 2011b; Mihailidou et al., 
1998; Mihailidou et al., 2004; Schmidt et al., 2005; Wehling et al., 1995), and 
interaction with the genomic aldosterone effects towards 
physiological/pathophysiological MR signalling identified, however, how this 
interaction takes place continues to remain unknown. This is partly due to the lack of a 
specific tool to delineate the nongenomic from the genomic actions of aldosterone, 
given that aldosterone activates different signalling pathways. By using the high 
molecular weight hybrid molecule, Aldo-PEG, that does not cross biological 
membranes, our findings provide for the first time strong evidence separating the non-
genomic aldosterone-responsive signalling pathways from genomic actions in the heart. 
The current studies show that although non-genomic actions of increased ROS and 
ERK1/2 phosphorylation, activation of genomic MR signalling is required for the 
pathophysiological action of aldosterone for aggravated cardiac damage during 
reperfusion injury. 
 
There has been intense interest in identifying the plasma membrane MR, although the 
functional role has not been defined. Early studies have used BSA-coupled aldosterone 
(Gekle et al., 1998; Le Moellic et al., 2004) to identify the MR membrane receptor, 
although BSA may dissociate from aldosterone, similar to oestrogen-BSA (Hammes 
and Levin, 2007). Further reports of aldosterone binding sites at the plasma membrane 
were reported by using atomic force microscopy technology in human endothelial cells 
(Wildling et al., 2009), or fluorescence resonance energy transfer in a heterologous 
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expression system using HEK-293 cells (Grossmann et al., 2010), although the exact 
location of the aldosterone binding sites in the plasma membrane or at the cell surface 
could not be confirmed.  
 
Subcellular fractionation studies did not detect any levels of MR in the membrane of 
H9c2 myoblasts or in rat ventricular myocardium by immunofluorescent analysis using 
a specific MR antibody (kindly donated by Prof Gomez-Sanchez) even though recent 
studies show MR in membrane fractions of heart tissue (Ricchiuti et al., 2011). Our 
studies show MR localises in the nucleus and cytoplasm in both H9c2 myoblasts and rat 
ventricular myocardium, similar to previous reports (Gomez-Sanchez et al., 2006). 
Using the PEGylated aldosterone (Aldo-PEG), which is polyethyleneglycol (PEG) 
covalently attached to aldosterone-3-carboxymethoxylamine-TFP ester, provides for the 
opportunity to separate the rapid, non-genomic signalling at the plasma membrane form 
the genomic signaling pathways and how these contribute to the pathophysiological 
cardiac actions of aldosterone. In the absence of ligand, MR were primarily located in 
the cytoplasm of H9c2 cells (Figure 5.2B). Addition of Ald, but not Aldo-PEG, resulted 
in increased expression of MR in the nuclei while MR decreased in the cytoplasm, 
confirming translocation of MR, further confirming that Aldo-PEG was membrane-
impermeable. 
 
Recent studies have reported GPR30 mediates the non-genomic actions of aldosterone 
(Gros et al., 2013; Gros et al., 2011b). GPR30 is ubiquitously expressed (Deschamps 
and Murphy, 2009; Jessup et al., 2010; O'Dowd et al., 1998) but is particularly 
prominent in heart tissue and freshly isolated cardiac myocytes (Deschamps and 
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Murphy, 2009), VSMC and endothelial cells (Ding et al., 2009; Gros et al., 2013). 
Subcellular localisation of GPR30 is controversial due to the specific GPR30 antibody 
used, with both expression at the endoplasmic reticulum (Revankar et al., 2005) and 
plasma membrane reported (Langer et al., 2010). By using subcellular fractionation of 
H9c2 cells we show GPR30 is located in the plasma membrane (Figure 5.2) and 
cytoplasm (Figure 5.2) and this was confirmed by immunostaining of cardiomyocytes in 
rat tissue sections. The lack of immunohistochemical signal near the endoplasmic 
reticulum in our cardiac tissue sections may be due to recognised limitations of the 
GPR30 antibodies for immunohistochemistry (Langer et al., 2010).  
 
The results showing that both Aldo-PEG and Ald activate ERK1/2 phosphorylation in 
the 0.1-1 nM range is in agreement with previous studies in multiple cell types (Ding et 
al., 2009; Gros et al., 2011b; Grossmann et al., 2005; Maggiolini et al., 2004; Revankar 
et al., 2005). Similarly, the lack of effect by spironolactone to prevent ERK1/2 
phosphorylation, confirms that these are MR-independent actions as previously reported 
(Gros et al., 2011b). The involvement of GPR30-mediated ERK1/2 phosphorylation by 
Aldo-PEG and Ald was confirmed by the receptor agonist G1 and antagonist G36 
(Figure 5.4-5.6). Conversely, Aldo-PEG and Ald-mediated ERK1/2 activation persisted 
in the presence of spironolactone. Collectively, these results indicating that GPR30 
activation are the major contributor to the rapid non-genomic action of Aldo in these 
cells.  
 
In contrast, whereas Ald-induced superoxide production has been previously reported 
(Hayashi et al., 2008; Iwashima et al., 2008; Keidar et al., 2004), the novel finding that 
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the cell-impermeable Aldo-PEG activated superoxide production with similar efficacy 
to Ald (Figure 5.7), provides evidence that Ald-induced superoxide production in 
cardiac myocytes is not only regulated by the traditional intracellular MR. Further 
experiments on the effects of G36 and G1 on superoxide production would be necessary 
to confirm the involvement of GPR30 in Ald-induced superoxide production in cardiac 
myocytes. 
 
Having established that the cell impermeable Aldo-PEG was as efficacious as Ald when 
activating non-genomic signalling, we examined whether these pathways may interact 
with genomic signaling such as transcriptional control of two well characterized MR 
responsive genes Sgk-1 and PAI-1, (Latouche et al., 2010). Exposure to 10 nM Ald for 
4 hours significantly increased transcript levels for both Sgk-1 and PAI-1, in agreement 
with previous reports (Chun and Pratt, 2005; Naray-Fejes-Toth and Fejes-Toth, 2000) 
and these activities were prevented by co-incubation with spironolactone (10 nM), 
confirming genomic MR activation. In contrast, Aldo-PEG (1 and 10 nM) had no effect 
on levels of Sgk-1 and PAI-1 mRNA. 
 
Since aldosterone-induced activation of PAI-1 synthesis has been proposed to mediate 
myocardial injury (Chun and Pratt, 2005), Aldo-PEG was used to confirm the cross-talk 
between genomic with non-genomic signalling for aldosterone during experimental MI. 
Ald but not Aldo-PEG, increased infarct size and aggravated myocyte apoptosis, 
indicating that although non-genomic aldosterone actions were activated, these were not 
sufficient alone to aggravate cardiac damage during MI. Previous studies (Weil et al., 
2010) show that GPR30 activation, using the GPR30 agonist G-1, improves myocardial 
Results  Chapter 5 
 
Page | 168  
functional recovery and decreases inflammation in the same model of myocardial I-R. 
Interestingly, GPR30-deficient male mice have impaired left-ventricular cardiac 
function and enlarged left ventricles (Delbeck et al., 2011), while in separate studies, 
GPR30-deficient female mice have hyperglycemia and impaired glucose tolerance, 
reduced body growth and increased blood pressure (Martensson et al., 2009) although 
these studies did not use MR blockade to determine whether MR-regulated signalling 
pathways were activated for these adverse effects. 
  
In conclusion, the findings in this chapter provide for the first time the opportunity to 
examine the non-genomic actions separately from the genomic actions of aldosterone by 
using the membrane impermeable pegylated aldosterone (Aldo-PEG). This molecule 
will provide the opportunityto start to identify the contribution of each to the final 
response. In the heart, activation of GPR30 alone, is not sufficient to trigger the 
deleterious effects on myocardial reperfusion injury but by raising ROS levels may 
amplify the MR-mediated actions of aldosterone during myocardial reperfusion injury. 
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Introduction 
Treatment options for IHD include primary PCI, thrombolytic therapy and coronary 
artery bypass graft surgery (O'Gara et al., 2013); however, additional therapies are 
required since IHD remains a leading burden of disease (Forouzanfar et al., 2012). 
Blockade of MR may be a suitable additional treatment based on both experimental and 
clinical studies. A significant reduction in mortality and hospitalisation was observed 
when MR antagonists were added to standard treatment in three large randomised trials 
in severe HF (RALES) (Pitt et al., 1999), mild HF (EMPHASUS-HF) (Zannad et al., 
2011) and HF after MI (EPHESUS) (Pitt et al., 2001). Interestingly, patients in these 
studies had aldosterone levels within the normal range and the doses of MR antagonists 
were low; however, the mechanisms for this cardioprotection have not been clearly 
defined. Since apoptosis is activated during I-R injury and involved in LV remodeling 
post-MI (Baldi et al., 2002; Fliss and Gattinger, 1996), the hypothesis for the current 
chapter was that MR activation aggravates cell death during I-R injury and that addition 
of MR blockade will prevent apoptosis, leading to reduced cardiac damage during HF 
and MI. The findings in the current chapter confirm this hypothesis by demonstrating, 
for the first time, that activation of MR during I-R injury triggers degradation of the 
anti-apoptotic protein ARC, aggravating injury and myocyte loss. Further novel 
findings are that mechanism for the cardioprotective actions of by low concentrations of 
MR antagonists involve suppression of the intrinsic apoptosis pathway, by preserving 
the levels of ARC leading to reduced infarct area. This chapter has been published as: 
Le TYL, Mardini M, Howell VM, Funder JW, Ashton AW, Mihailidou AS. Low-dose 
spironolactone prevents apoptosis repressor with caspase recruitment domain 
degradation during myocardial infarction. In Hypertension. 2012;59(6):1164-9. 
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The studies presented above demonstrate that ARC is abundant in heart tissue and 
decreases during I-R injury. Perfusion with low dose MR antagonists (SPIRO 10 nM or 
EPL 100 nM) restored ARC expression (Figure 3 & S4 in the manuscript). The next aim 
was to determine the mechanism by which the regulation of ARC stability by MR 
activation may occur. Interaction of ARC with other proteins causes proteosomal 
degradation and decreases protein stability (Foo et al., 2007a; Nam et al., 2007b). The 
hypothesis therefore was that MR may interact with ARC and in situ Proximity Ligation 
Assay (PLA) was used to examine this hypothesis. 
 
Supplemental method: In situ Proximity Ligation Assay 
Proximity Ligation Assay is a highly specific method for detecting protein-protein 
interaction in fixed cells or tissue sections using a complementary pair of 
oligonucleotide-labeled secondary antibodies (PLA probes), which generate a signal 
only when the two probes hybridise (Soderberg et al., 2006; Soderberg et al., 2008). In 
this assay, the two primary antibodies (or two proteins) need to be within 40 nm for a 
signal to be generated. Each interaction site generates a signal which is visualised as an 
individual fluorescent spot. The number of spots was used as an indicator of the degree 
of protein-protein or MR-ARC interaction.  
 
The PLA was performed according to the manufacturer’s instructions (Duolink II 
Fluorescence, OLINK Bioscience), using antibodies against MR and ARC. Sections (5 
μm) from reperfused hearts were deparaffinised, rehydrated and subjected to antigen 
retrieval using the protocol described in Chapter 2 (section 2.5.1). Primary antibodies 
against MR (MR1-18 1D5, mouse, provided by Prof Celso Gomez-Sanchez) and ARC 
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(rabbit, Cayman Chemical) were diluted in 1% (w/v) BSA in TBS/T diluent (1:20 and 
1:50 respectively) and incubated with sections in a humidified chamber overnight at 
4°C. Following three washes in TBS/T, sections were incubated with PLA PLUS anti-
mouse and PLA MINUS anti-rabbit probes for 1 hour at 37°C in a humidified chamber. 
After that, sections were washed in wash buffer A twice for 5 minutes each and exposed 
to ligation solution for 30 minutes at 37°C. Sections were washed in wash buffer A and 
incubated with amplification-polymerase solution for 100 minutes at 37°C. The 
amplification-polymerase solution was then removed, sections washed in wash buffer B 
and dried at room temperature in the dark. Finally, slides were mounted with Duolink 
mounting media with DAPI. Negative controls were performed by omitting one of the 
two primary antibodies. Sections were analyzed using confocal fluorescence microscope 
(Leica SP5) with a 63x oil objective. 
 
Supplemental result: MR-ARC interact based on in situ PLA 
Previous studies demonstrated a close correlation between the protein-protein 
interactions identified by co-immunoprecipitation studies and the in situ PLA method 
(Greenberg et al., 2008; Salmon et al., 2012). Using tissue sections, the interaction 
between MR and ARC was confirmed in uninjured myocardium (Sham, Figure 6.1, red 
fluorescent spots). Complex formation is primarily extra-nuclear/cytoplasmic; however, 
staining patterns do not indicate any specific sub-cellular organelle. This MR-ARC 
interaction was decreased during myocardial I-R injury (I-R, Figure 6.1), which may be 
due to the degradation of ARC in these samples (Figure 3 & S4, manuscript), or due to 
changes in the conformatio of MR by oxidative stress during I-R injury. Consistent with 
SPIRO salvaging ARC levels during I-R injury (Figure 3 and S4) the MR-ARC 
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complex formation was restored to levels in the sham control by treatment with low 
dose SPIRO (Figure 6.1). In this case MR-ARC interactions appeared more in the 
nucleus, although the majority were still cytoplasmic in nature. To our knowledge, these 
results are the first to show complex formation between MR and ARC proteins within 
the myocardium.  
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Figure 6.1: Interaction of MR-ARC by in situ PLA during myocardial I-R.  
Sections of reperfused myocardium were stained with MR and ARC antibodies. Red 
fluorescent spots (arrows) indicate MR-ARC direct interaction. Nuclei were 
counterstained with DAPI (blue).  
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Supplemental discussion 
As shown in these studies, there is regulation of ARC by MR agonists and antagonists 
(Figure 4 and S5, manuscript). ARC is a tissue specific anti-apoptotic repressor protein 
involved in the intrinsic and extrinsic death pathways. Previous studies have 
demonstrated direct interaction of ARC with FADD, Fas and Bax which are key to this 
inhibition (Nam et al., 2004). Similarly, MR-mediated signal transduction requires 
interactions with multiple protein coregulators, including PGC-1α, FLASH, RIP140, 
NF-YC (summarised in Yang and Fuller, 2012). However, the exact mechanisms and 
structural basis of the interaction between ARC and MR has not been characterised in 
such detail.  
 
The key to regulation of ARC expression during MI may be the expression and/or 
activity of the ubiquitin ligase MDM2 (Foo et al., 2007a). Interestingly, MR activation 
by aldosterone, induces MDM2 expression, leading to proliferation of human vascular 
smooth muscle cells (Nakamura et al., 2006) and as shown in the current studies, 
degradation of ARC (Figure 4, manuscript). MDM2 is also the ligase for p53, 
controlling both ubiquitination and degradation of p53 (Foo et al., 2007a). MR 
activation also regulates p53, a transcriptional regulator of the pro-apoptotic protein Bax 
(McCullers and Herman, 1998). The mechanism by which the regulation of ARC 
stability by MR during I-R may involve modulation of the ARC/MDM2/p53 signalling 
pathway or oxidative stress-mediated ARC degradation pathway have yet to be 
completely defined. Further studies are required for examining the interaction between 
MR and ARC. 
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7.1 Introduction 
Reperfusion of ischaemic hearts also induces free radical generation, activation of early 
stress responses in addition to apoptosis (Gottlieb, 2011; Yellon and Hausenloy, 2007), 
which contribute to the ventricular dysfunction and increased infarct area. In the 
previous chapter, the mechanism for reduced cardiac damage by treatment with low-
dose MR antagonists was shown to involve prevention of mitochondrial apoptotic 
signaling which led to reduced cardiomyocyte apoptosis during myocardial infarction 
(MI). One of the triggers for cardiomyocyte apoptosis during MI is increased oxidative 
stress and depletion of endogenous antioxidants (Kim et al., 2006b; Qin et al., 2007; 
von Harsdorf et al., 1999).  
 
Oxidative stress is one of the critical mechanisms contributing to ventricular 
dysfunction following MI (Doerries et al., 2007; Looi et al., 2008; Qin et al., 2007). 
During MI, the myocardial content of oxidised glutathione (GSSG) is increased, 
whereas levels of reduced glutathione (GSH) reduced, leading to decreased GSH/GSSG 
ratio in heart tissue (Hill and Singal, 1996; Lesnefsky et al., 1989; Verbunt et al., 1995). 
These changes in redox balance are primarily due to an increase in ROS in the myocyte 
during I-R; in particular, nicotinamide adenine dinucleotide phosphate (NADPH) 
derived superoxide generation (Talukder et al., 2013). In cardiomyocytes mitochondrial 
metabolism is the major regulator of the ROS production. Peroxisome proliferator 
activated receptor (PPAR)-γ coactivator (PGC)-1α and PGC-1β are key regulators of 
mitochondrial biogenesis, oxidative metabolism and ROS generation (Garnier et al., 
2003; Huss and Kelly, 2005), with MI suppressing expression of PGC-1α mRNA 
reported (Sun et al., 2007).  
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The imbalance between oxidant and antioxidant triggers a range of physiological, 
pathological and adaptive responses which ultimately modulate transcriptional outputs 
and influence cellular processes. I-R injury triggers increased expression number of 
transcription factors, including heat shock proteins (Hsp27, Hsp40, Hsp70, Hsp72, 
Hsp90) (Das et al., 1998; Maulik et al., 1993; Nishizawa et al., 1999; Plumier et al., 
1996; Schoeniger et al., 1994) and immediate-early genes (c-fos, Egr-1, c-jun, jun-B) 
(Brand et al., 1992; Xu et al., 2008). Heat shock proteins (Hsp) are group of chaperones 
which protect cells against a variety of stresses including I-R injury (Benjamin and 
McMillan, 1998; Efthymiou et al., 2004).  
 
In previous studies from our laboratory, activation of MR by aldosterone aggravates the 
extent of cardiac damage during MI (Mihailidou et al., 2009) and this was prevented by 
both the free radical scavenger tempol and MR blockade, suggesting a role for 
myocardial oxidative stress and MR regulation during MI. Indeed MR antagonists 
(spironolactone or eplerenone) showed attenuation of O2•– and NADPH oxidase levels 
in rats with heart failure after MI (Noda et al., 2012; Sartorio et al., 2007) which 
correlated with improved ventricular function (Noda et al., 2012). Interestingly, even at 
low levels of aldosterone, increase in oxidative stress or redox imbalance enhances MR 
signal transduction (Matsui et al., 2008a; Nagase et al., 2012; Rossier et al., 2008) , with  
a ligand-independent pathway of MR activation suggested (Shibata et al., 2008). 
Cultured rat cardiomyocytes (H9c2), treated with buthionine sulfoximine (BSO), an 
inhibitor of glutathione synthesis, to simulate increased oxidative stress showed 
activation of reactive oxygen species (ROS) and Rac1, a small G-protein in the Rho 
family and regulatory component of the plasma membrane NADPH oxidases  
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(Lambeth, 2004). This, in turn, resulted in MR activation, indicated by enhanced 
transcriptional activity and nuclear accumulation (Nagase et al., 2012). Therefore, MR 
is both a regulator and subject to regulation by oxidative stress in the heart. Therefore 
the hypothesis tested in this chapter was that reduction of infarct area below basal level 
by treatment with low-dose MR antagonists involves modulating of redox balance and 
response or interaction with co-repressors and co-activators which have yet to be 
completely defined.  
 
7.2 Methods 
7.2.1 Protocol for collection of left ventricular tissue following ex vivo 
myocardial I-R 
Male Sprague-Dawley rats were used for these studies and experimental details for ex 
vivo I-R of the rat heart are described in Chapter 2 (section 2.2). MR antagonist, 
spironolactone (SPIRO, 10 nM) was perfused for 15 minutes prior to inducing 
ischaemia and continued during reperfusion. Since I-R induced ROS peak within the 
first 15 minutes of reperfusion (Kutala et al., 2006; Petrosillo et al., 2003), left 
ventricular (LV) free wall tissue was collected after 15 minutes of reperfusion (unless 
otherwise specified), and snap frozen for measuring free radicals and other biochemical 
markers.  
 
7.2.2 Measurement of myocardial glutathione levels 
Left ventricular free wall tissue collected 15 minutes after reperfusion was homogenised 
and samples prepared for estimation of oxidised glutathione (GSSG)-to-reduced 
glutathione (GSH) GSSG:GSH ratio as per the manufacturer’s instructions (Cayman 
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Chemical, GSH Assay Kit, cat# 703002). Tissue was homogenized 1:10 (w/v) in MES 
buffer, containing 2-(Nnorpholino) ethanesulphonic acid, phosphate, and EDTA. The 
homogenate was centrifuged twice at 10,000xg for 15 min at 4°C. Supernatant was 
removed and de-proteinated using meta-phosphoric acid at (5% (w/v) final 
concentration) and stored at -20°C until assayed (within 6 months). Myocardial 
concentrations of GSSG and total glutathione (GSSG and GSH) were estimated using 
the glutathione reductase/5,5'-dithiobis-(2-nitrobenzoic acid) recycling assay. Before 
analysis, triethanolamine was added to supernatant (final concentration 200 mM) and 
pH adjusted to pH 7.0. GSSG was measured by derivatizing GSH with 2-vinylpyridine 
(final concentration of 10 mM) during 60 minutes incubation at room temperature. The 
assay was quantified using a Synergy Multi-Mode Microplate Reader (BioTek). The 
absorbance was recorded at 405 nm at 5 minute intervals for 30 minutes. Concentration 
of GSH was calculated by subtracting oxidized (GSSG) from total (GSH + GSSG) 
concentrations. 
 
7.2.3 Measurement of I-R triggered superoxide production 
Superoxide levels in reperfused myocardium were measured using lucigenin-enhanced 
chemiluminescence (Noda et al., 2012; Peshavariya et al., 2007). Left ventricular free 
wall tissue was homogenized in Krebs-HEPES buffer [NaCl (130 mM), KCl (5 mM), 
MgCl2 (1 mM), CaCl2 (1.5 mM), K2HPO4 (1 mM), Glucose (11 mM) and HEPES (20 
mM), pH 7.4] in a 1:10 (w/v) ratio. NADPH (100 μM) as a substrate, and lucigenin (5 
µM) were added to homogenates for chemiluminescence measurements. After 
stabilisation (10 minutes), the homogenates were transferred into a 96 well OptiView 
plates (PerkinElmer, Inc.) and the chemiluminescence measured by a Veritas Microplate 
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Luminometer (Turner Biosystems, Inc.). Samples from each treatment group were 
assayed in triplicate and the photon emissions were recorded every 30 seconds for up to 
10 minutes. Background chemiluminescence in Krebs-HEPES buffer (containing 
lucigenin and NADPH) was measured in the absence of homogenates and subtracted 
from the average of 20 readings.  
 
7.2.4 Measurement of myocardial nicotinamide adenine dinucleotide 
(NAD+ ) 
Concentration of NAD+ was measured by EnzyChrom NAD+/NADH assay (BioAssay 
Systems, cat# ECND-100), according to manufacturer instruction. Approximately 20 
mg tissue was homogenized with 100 μL NAD extraction buffer, incubated at 60°C for 
5 minutes before addition of 20 μL assay buffer and 100 μL of the NADH extraction 
buffer to neutralize the extracts. The homogenate was centrifuged twice at 14,000xg for 
5 minutes. Supernatant was removed and assayed using the Synergy Multi-Mode 
Microplate Reader (BioTek). The absorbance was recorded immediately (for optical 
density at time “zero”, OD0min) at 565 nm and after 15 minutes incubation at room 
temperature (OD15min). The ∆OD values for standard and sample were calculated by 
subtracting OD0min from OD15min and used to determine concentration of NAD+ in the 
sample from the standard curve. 
 
7.2.5 Dose-response for BSO ± SPIRO in H9c2 cells 
Rat cardiomyoblast, H9c2 cells were used for these studies. Experimental details for 
routine cell culture and passage of H9c2 cells are described in Chapter 2 (sections 2.7.1 
– 2.7.2). L-Buthionine-(S,R)-sulfoximine (BSO), a selective inhibitor of γ-
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glutamylcysteine synthetase, was used to induce oxidative stress by depleting GSH. The 
H9c2 cells were seeded into 60 mm culture plates at a density of ~8×105 cells and 
serum-deprived overnight. The effective dose (EC50) of BSO was determined by dose-
response studies for BSO (0.2 - 1000 μM) for 24 hours prior to harvest. In separate 
experiments, H9c2 cells were pre-incubated with 10 nM SPIRO for 30 minutes prior to 
addition of BSO (10 - 1000 μM) and harvested after 24 hours. Following treatment, 
glutathione levels were measured as described in section 7.2.6. 
 
7.2.6 Measurement of glutathione  and superoxide levels in H9c2 cells 
Cellular glutathione content was measured using the same Glutathione assay kit listed in 
section 7.2.2. Following treatment, H9c2 cells were washed twice with PBS and 
collected in 300 µL of MES buffer. The homogenate was then sonicated and centrifuged 
at 10,000xg for 15 minutes at 4°C. Supernatant was removed, de-proteinated and 
assayed as described above (section 7.2.2). 
 
Superoxide generation in H9c2 cells was measured using lucigenin-enhanced 
chemiluminescence, as previously described (Laskowski et al., 2006; Peshavariya et al., 
2007). H9c2 cells were seeded into 6-well plates at a density of ~4×105 cells/well, 
serum-deprived overnight. Cells were then treated with SPIRO (10 & 100 nM) or 
Tempol (100 μM), either alone or in combination with BSO (5 μM). For co-
administration, SPIRO or Tempol was incubated for 30 minutes before BSO addition 
and harvested after 24 hours. Stimulated cells were collected in Krebs-HEPES buffer [ 
130 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.5 mM CaCl2, 1 mM K2HPO4, 11 mM 
Glucose and 20 mM HEPES, pH 7.4, with 1 mg/mL bovine serum albumin (BSA)] 
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containing NADPH (100 µM) and lucigenin (5 µM) for chemiluminescence 
measurements. The cell suspensions were transferred into a 96 well OptiView plates 
(PerkinElmer, Inc.) and measured using a Veritas Microplate Luminometer (Turner 
Biosystems, Inc.). Samples from each treatment group were assayed in triplicate and the 
photon emissions were recorded every 30 seconds over a 10 minutes period. 
Background chemiluminescence in buffer containing lucigenin and NADPH was 
measured in the absence of cells and subtracted from the average of 20 readings. 
 
7.2.7 qRT-PCR: rat heart tissue and H9c2 cells 
Following treatment, total RNA was extracted from rat heart tissue and H9c2 cells using 
TRIzol lysis reagent (Sigma-Aldrich) according to the protocol provided by the 
manufacturer and described in Chapter 2 (sections 2.6.1 and 2.7.5). The concentration 
and purity of the samples were assessed using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific). The cDNA was synthesized from 2.5 µg total RNA using the 
Superscript III First-Strand Synthesis System and oligo (dT)20 as a primer (Invitrogen) 
according to the manufacturer’s protocols (see section 2.6.4 for more details). Gene 
expression was analyzed using TaqMan Gene Expression Assays (Applied Biosystems) 
as described in Chapter 5 (section 5.2.7).  The rat specific assays used were: c-fos 
[Rn02396759_m1], glucose-6-phosphate dehydrogenase (G6pd) [Rn00566576_m1], 
heat shock protein (Hsp)-27 [Rn00583001_g1], Hsp40 [Rn01426952_g1], PGC-1α 
[Rn00580241_m1], PGC-1β [Rn00598552_m1], PAI-1 [Rn01481341_m1] and Sgk-1 
[Rn00570285_m1]. The endogenous control was glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) [Rn99999916_s1]. The Delta–Delta Comparative Threshold 
(CT) method was used to quantify the relative fold change between the samples. 
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Data was analysed using RQ Manager Analysis software, version 1.2.1 (Applied 
Biosystems). 
 
7.2.8 Western blots: rat heart tissue and H9c2 cells 
Total protein was extracted from rat heart tissues and H9c2 cells as described in Chapter 
2 (sections 2.5.2 and 2.7.3) and similarly for western blot procedures described in 
Chapter 2 (section 2.5.3). The primary antibodies were Hsp25/27 (Cayman Chemical, 
Cat # 12215), Hsp40 (Cell Signaling, cat# 4868), Hsp90  (Cayman Chemical, cat# 
19615), c-fos (Abcam, cat# ab7963) and rMR 1-18 1D5 (kindly provided by Prof. 
Gomez-Sanchez).  Antibody binding was detected using HRP-conjugated secondary 
antibodies (1:3000, Dako Cytomation). Membranes were exposed to chemiluminescent 
substrate (Perkin Elmer, Melbourne, Australia) and digital images of the resulting bands 
captured on a LAS4000 (GE Healthcare Life Sciences). 
 
7.2.9 Statistical analysis 
Statistical analyses methods similar to those described in Chapter 2 (section 2.8) were 
used. 
 
7.3 Results 
7.3.1 Low-dose SPIRO restores redox balance during I-R 
To determine whether the cardioprotective effects of low-dose SPIRO are associated 
with a reduction in oxidative stress in the reperfused myocardium, both pro-oxidant and 
antioxidant parameters were measured (Figure 7.1 & 7.2). 
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SPIRO decreases pro-oxidant superoxide: A burst of ROS generation, in particular 
superoxide, occurs during the first minutes after reperfusion of ischemic tissue. NADPH 
oxidase is the major source of pro-oxidant superoxide in cardiomyocytes (Talukder et 
al., 2013; Tsai et al., 2012). Our results from the lucigenin-enhanced 
chemiluminescence assay indicate that NADPH-derived superoxide levels were 
markedly increased in the LV homogenates from the I-R group compared to sham I-R 
(100 ± 7.1% (Sham) vs 165.5 ± 9.6% (I-R), P<0.001, Figure 7.1A). Treatment with 
SPIRO prevented the I-R-induced increase in superoxide levels, reducing the levels to 
those found in sham hearts (Figure 7.1A, P<0.005).  
 
SPIRO maintains antioxidant defense: Further insight into the mechanism by which 
SPIRO reduces oxidative stress in reperfused myocardium were discovered from 
assessing the state of anti-oxidant defense, such as changes in glutathione redox status. 
Under oxidative stress reduced glutathione (GSH) becomes oxidized to the disulfide-
bound form (GSSG). Thus, the ratio of GSH/GSSG decreases as a consequence of 
GSSG accumulation. The GSH/GSSG ratio in LV homogenates was reduced by 53.7 ± 
7.9% in the I-R hearts compared with the Sham I-R group (Figure 7.1B, P<0.005). 
Similarly, reperfusion injury also significantly reduced NAD+ levels (38.8 ± 7.2%; 
Figure 7.1C, P<0.005), similar to previous reports (Hsu et al., 2009).  The loss of NAD+ 
may reflect the loss of reduced glutathione levels in reperfused myocardium (Figure 
7.1B). Pre-treatment with SPIRO prevented the I-R-induced reduction in the 
GSH/GSSG ratio (Figure 7.1B, P<0.001) and the loss of NAD+ levels (Figure 7.1C, 
P<0.05) and maintained levels equivalent to those observed in sham I-R hearts. 
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Figure 7.1: Low-dose SPIRO restores redox balance.  
Measurement of (A) superoxide levels, (B) ratio of reduced-to-oxidised glutathione 
(GSH/GSSG ratio) and (C) NAD+ levels in left ventricular free wall homogenates after 
ischaemia (30 minutes) followed by reperfusion (15 minutes). I-R, ischaemia-
reperfusion; SPIRO, spironolactone. Values are means ± SE; Number in parentheses 
indicate the number of animals in each group; *P<0.01 vs Sham I-R; †P<0.05 vs I-R. 
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SPIRO did not modify G6PD gene expression in reperfused myocardium: G6PD is a 
critical determinant of the intracellular redox state (Leopold et al., 2001).  The activity 
of G6PD has been suggested to be modulated by aldosterone and spironolactone in vivo 
(Leopold et al., 2007). Although, chronic treatment with low-dose SPIRO modulates 
G6PD activity in kidney nephropathy (Pessoa et al., 2012), we did not observe any 
changes in G6PD mRNA expression in LV homogenates with neither I-R injury nor 
SPIRO treatment (Figure 7.2). These data suggest that oxidative stress is rapidly 
activated in response to reperfusion of ischaemic myocardium, independent of cellular 
G6PD transcription. 
 
 
 
Figure 7.2: Low-dose SPIRO did not modify G6PD gene expression.  
mRNA levels of G6PD in left ventricular free wall homogenates of reperfused hearts, 
analysed by qRT-PCR and normailsed by Gapdh level. I-R, ischaemia-reperfusion; 
SPIRO, spironolactone; G6PD, glucose-6-phosphate dehydrogenase. Values are means 
± SE. Number in parentheses indicate the number of animals in each group. 
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7.3.2 Low-dose SPIRO restores PGC-1α and PGC-1β gene expression 
Figure 7.3 shows the mRNA expression of the genes involved in the regulation of 
mitochondrial biogenesis. PGC-1α, and its homolog PGC-1β, with a significant 
reduction  during I-R injury, 39.5 ± 11.2% and 37.9 ± 8.6% respectively (Figure 7.3,  
P<0.02). Perfusion with low-dose SPIRO prevented the loss of PGC-1α and PGC-1β 
mRNA expression in reperfused hearts (Figure 7.3, P<0.05). These alterations are 
consistent with the increased superoxide generation and reduction in antioxidant 
enzymes of the infarcted myocardium (Figure 7.1). 
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Figure 7.3: Low-dose SPIRO restores PGC-1α and PGC-1β gene expression.  
mRNA expression of genes involved in mitochondrial biogenesis and ROS production 
in reperfused hearts. Relative mRNA levels of (A) PGC-1α and (B) PGC-1β in left 
ventricular free wall homogenates analysed by qRT-PCR and normailzed by Gapdh 
level. I-R, ischaemia-reperfusion; SPIRO, spironolactone; PGC-1, peroxisome 
proliferator-activated receptor-γ coactivator 1. Values are means ± SE; Number in 
parentheses indicate the number of animals in each group; *P<0.02 vs Sham I-R; 
†P<0.05 vs I-R. 
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7.3.3 Low dose SPIRO prevents the onset of the immediate early gene 
response in the myocardium after I-R injury 
In response to oxidative stress during I-R, heat shock proteins (Hsp) and immediate 
early response genes are activated (Brand et al., 1992; Webster et al., 1994). We 
examined the expression of Hsp27, Hsp40, Hsp90 and c-fos mRNA (qRT-PCR) and 
protein (western blot). qRT-PCR results demonstrated that mRNA of Hsp27, Hsp40 and 
c-fos were up-regulated in response to I-R injury (2.54 ± 0.32, 3.02 ± 0.40 and 3.18 ± 
0.26 fold changed, respectively; Figure 7.4 A-C, P<0.05, bar graphs). Treatment with 
low-dose SPIRO attenuated the enhanced transcription of these immediate early genes 
in response to I-R-injury (Figure 7.4 A-C, P<0.05, bar graphs). Similarly to qRT-PCR 
results, the expression of Hsp27, Hsp40 and c-fos encoding protein was significantly 
up-regulated during I-R and reduced by low-dose SPIRO (Figure 7.4A-C, 
immunoblots). Although, Hsp90 was not examined at transcriptional level, protein 
levels were markedly up-regulated in response to I-R and SPIRO attenuated this 
expression (Figure 7.4D). The findings of Hsp and c-fos correlated with changes in 
oxidative stress early after I-R (Figure 7.1). Taken together, these data implicate Hsp 
and c-fos rapidly being activated in response to I-R-induced myocardial stress and redox 
imbalance. Treatment with low-dose (10 nM) SPIRO prior to inducing ischaemia 
efficiently attenuates oxidative stress and thus, represses immediate genes and their 
encoding proteins expression in this model. 
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Figure 7.4: Low-dose SPIRO reduces heat shock proteins and immediate early 
genes and proteins expression. 
Top: (A-C) Bar graphs show mRNA expression by qRT-PCR, normalised by Gapdh. 
Below: (A-C) Immunoblots of Hsp27, Hsp40, c-fos in left ventricular free wall 
homogenates. (D) Protein expression of Hsp90 by western blot. I-R, ischaemia-
reperfusion; SPIRO, spironolactone; Hsp, heat shock protein. Values are means ± SE; 
Number in parentheses indicate the number of animals in each group; *P<0.05 vs Sham 
I-R; †P<0.05 vs I-R. 
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7.3.4 Low-dose SPIRO prevents I-R induced MR activation  
Sgk-1 and PAI-1 expression in the reperfused myocardium was investigated to 
determine the role of MR in reperfusion injury-induced oxidative stress (Figure 7.5). 
Sgk-1 and PAI-1 are MR-targeted transcripts and have been used as an index of MR 
activation (Latouche et al., 2010). mRNA levels of Sgk-1 and PAI-1 were significantly 
higher in the I-R hearts compared with sham I-R hearts (1.45 ± 0.08 and 2.17 ± 0.31 
fold change, respectively; Figure 7.5A&B, P<0.02), and treatment with low-dose 
SPIRO attenuated this up-regulation of Sgk-1 (Figure 7.5A&B, P<0.05). The up-
regulation of Sgk-1 and PAI-1 activity correlate with increased oxidative stress during 
I-R (Figure 7.1).  These data collectively imply that MR is activated during I-R injury, 
and that part of the cardioprotective effects of low-dose SPIRO is via preventing 
oxidative stress, and the associated responses, in the reperfused myocardium. To 
determine whether I-R induced changes in the level of MR protein, the same lysates 
from reperfused hearts were immunoblotted for MR protein (Figure 7.5C). There was 
no modification in protein levels between I-R alone and antagonist-exposed hearts 
suggesting that MR blockade reduces oxidative stress through mechanisms that involve 
modulation of MR transcriptional activity but not changes in levels of MR protein nor 
MR protein synthesis. 
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Figure 7.5: Low-dose SPIRO suppresses transcription of MR-responsive genes 
during I-R.  
mRNA expression of Sgk1 (A) & PAI-1 (B) by qRT-PCR, normalised by Gapdh. (C) 
MR protein expression by western blot. I-R, ischaemia-reperfusion; SPIRO, 
spironolactone; Sgk-1, serum/glucocorticoid regulated kinase 1; PAI-1, plasminogen 
activator inhibitor-1. Values are means ± SE; Number in parentheses indicate the 
number of animals in each group; *P<0.02 vs Sham I-R; †P<0.05 vs I-R. 
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7.3.5 BSO induced oxidant stress in H9c2 cells 
The above results indicate blockade of MR with low-dose SPIRO exhibits antioxidant 
effects. To further characterise the protective effects of low-dose SPIRO we decided to 
normalise the oxidant stress to examine whether pathways other than salvage of cellular 
redox mechanisms were involved in the cardioprotective effects of low-dose SPIRO.  
Cellular redox state was altered by using BSO, an inhibitor of glutathione synthesis. 
Dose-response studies in H9c2 cells showed that BSO concentrations above 5 M 
significantly decreased GSH levels after 24 hour incubation, with complete depletion of 
GSH at [BSO] ≥ 20 μM (Figure 7.6). We found that 5 μM BSO depleted GSH levels by 
~50% in vitro (Figure 7.6), which similar to the reduced levels observed with I-R injury 
in our ex vivo heart model (Figure 7.1B). Consistent with the reduction in glutathione 
levels, BSO (5 μM) increased ROS production (1.67 ± 0.14 fold change, Figure 7.7, 
P<0.001), as assessed by NADPH-derived superoxide generation in H9c2 cells. These 
data indicate that the pro-oxidant effects of the ex vivo model could be simulated using 
BSO in vitro. 
 
To determine the concentration of BSO to normalize the anti-oxidant effects of SPIRO 
we repeated the studies this time in the presence of 10 nM SPIRO (Figure 7.6).  
Exposure of H9c2 cells to 10 μM BSO for 24 hours in the presence of SPIRO depleted 
GSH to approximately the same extent as without SPIRO (~84% decrease, Figure 7.6) 
indicating the anti-oxidant effects of SPIRO treatment had been normalised by this 
concentration of BSO. However, we found that the anti-oxidant effects of SPIRO (10 or 
100 nM) were quite potent when used on H9c2 cells treated with 5 M BSO (Figure 
7.7), being equivalent to 100 M tempol (a radical scavenger). These results confirm 
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the findings with ex vivo studies of rat hearts (Figure 7.1). Treatment with SPIRO (10 or 
100 nM) or Tempol (100 μM) alone had no effect on superoxide generation in H9c2 
cells (Figure 7.7). Since the pro-oxidant effects of 5 μM BSO were readily antagonised 
by 10 nM SPIRO we used an increased concentration of 20 μM BSO to determine 
whether the protective effects of SPIRO were independent of anti-oxidant activity as 
this concentration of BSO removes the anti-oxidant activity of SPIRO. 
 
 
 
Figure 7.6: Effects of BSO ± SPIRO (10 nM) exposure on reduced glutathione 
(GSH) levels in H9c2 cells. 
Left: Varying doses of BSO exposure (24 hours) on reduced GSH levels. Right: Effects 
of BSO in the presence of SPIRO (10 nM) on reduced GSH levels. BSO, buthionine 
sulfoximine; SPIRO, spironolactone. Values expressed as means ± SE from two 
independent experiments; *P<0.05 vs No Rx. 
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Figure 7.7: Low-dose SPIRO prevents BSO-induced superoxide generation in 
H9c2 cells.  
Superoxide levels in H9c2 cells after exposure to BSO (5 μM) ± SPIRO (10 or 100 nM) 
or Tempol (100 μM) for 24 hours. BSO, buthionine sulfoximine; SPIRO, 
spironolactone. Values expressed as means ± SE from five independent experiments; 
*P<0.05 vs No Rx; †P<0.05 vs BSO 5 μM. 
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7.3.6 Effects of BSO on SPIRO action in H9c2 cells 
The findings with both ex vivo (rat hearts) and in vitro (H9c2) models indicate that 
oxidative stress causes MR activation in the absence of ligands. To evaluate whether 
oxidant stress modulates the action of low-dose SPIRO, we measured mRNA and 
protein expression of Hsp27, Hsp40, c-fos, PGC-1α and PGC-1β.  Exposure of H9c2 
cells to 20 μM BSO maintained oxidative stress (indicated by GSH depletion) even in 
the presence of SPIRO (Figure 7.6). Treatment with BSO (20 M) induced up-
regulation of the immediate early response genes Hsp27, Hsp40 and c-fos (1.28 ± 0.10, 
1.27 ± 0.04 and 1.42 ± 0.08 fold change, respectively, Figure 7.8).  BSO (20 μM) also 
induced MR activation, as indicated by increase in Sgk-1 and PAI-1 transcripts (1.59 ± 
0.18 and 1.21 ± 0.04 fold change, respectively, Figure 7.8).  These increases was 
prevented by addition of SPIRO (10 nM) even though the anti-oxidant effects had been 
removed (Figure 7.9). Contrary to the data in heart tissue (Figure 7.3), treatment with 
BSO up-regulated expression of PGC-1α and PGC-1β (1.48 ± 0.09 and 1.64 ± 0.19 fold, 
respectively), which was reversed with low-dose SPIRO (Figure 7.9). This could be due 
to the direct effect of oxidative stress alone; however, irrespective of the change (Figure 
7.3 & 7.8), SPIRO ablated these changes of PGC-1α and PGC-1β (Figure 7.3 & 7.9).  
Indeed, the change in MR-mediated transcription was, on average, 59.9% of the values 
obtained with BSO alone (Figure 7.9). These data indicate that only 40% of the 
protective effect of SPIRO is derived from the anti-oxidant effects and ~60% from other 
sources, such as direct genomic effects of MR as a transcription factor or possibly 
through GPR30 activation (See chapter 5). 
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The changes in gene transcription were also mirrored at the protein level.  Treatment 
with BSO (20 M) elevated expression of the proteins encoding for immediate early 
response genes Hsp27, Hsp40, Hsp90 and c-fos (1.21 ± 0.04, 1.17 ± 0.06, 1.24 ± 0.08 
and 1.38 ± 0.06 fold change, respectively; Figure 7.10).  The inclusion of 10 nM SPIRO 
ablated the induction by BSO and returned expression of all proteins to levels observed 
in untreated controls (Figure 7.10).  Thus, the effects of SPIRO on protein expression 
were more complete than that observed on transcription (on average only 60% 
decrease). This indicates that during oxidative stress the protein and transcriptional 
control of these proteins may become unlinked; however, SPIRO blockade of MR 
activation appears to target both aspects of control to bring about normalisation of the 
myocardial response to reperfusion injury. 
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Figure 7.8: BSO-induced various genes expression in H9c2 cells.  
mRNA expression of  PGC-1α, PGC-1β, Hsp27, Hsp40, c-fos, Sgk-1 and PAI-1 in 
H9c2 cells after stimulation with BSO (20 μM), analyzed by qRT-PCR and normalised 
by Gapdh. Bar graphs showing the fold increase of gene expression with [BSO (20 
μM)] treatment compared to No treatment. BSO, buthionine sulfoximine; PGC-1, 
peroxisome proliferator-activated receptor-γ coactivator-1; Hsp; heat shock protein; 
Sgk-1, serum/glucocorticoid regulated kinase 1; PAI-1, plasminogen activator inhibitor-
1. Values expressed as means ± SE from five independent experiments. 
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Figure 7.9: Low-dose SPIRO reduces BSO-induced various genes expression in 
H9c2 cells.  
mRNA expression of  PGC-1α, PGC-1β, Hsp27, Hsp40, c-fos, Sgk-1 and PAI-1 in 
H9c2 cells after stimulation with BSO (20 μM) + SP (10 nM), analyzed by qRT-PCR 
and normalised by Gapdh. Values from [BSO (20 μM)] and [BSO (20 μM) + SPIRO 
(10 nM)] groups were subtracted from [No treatment] group before analysis. Bar graphs 
showing the percentage reduction of gene expression with [BSO (20 μM) + SPIRO (10 
nM)] treatment compared to BSO (20 μM) alone. BSO, buthionine sulfoximine; SPIRO, 
spironolactone; PGC-1, peroxisome proliferator-activated receptor-γ coactivator-1; Hsp; 
heat shock protein; Sgk-1, serum/glucocorticoid regulated kinase 1; PAI-1, plasminogen 
activator inhibitor-1.Values expressed as mean ± SE from five independent 
experiments. 
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Figure 7.10: Low-dose SPIRO reduces BSO-induced stress responsive protein 
expression in H9c2 cells.  
Protein expression of (A) Hsp27, (B) Hsp40, (C) c-fos  and (D) Hsp90 in H9c2 cells 
after stimulation with BSO (20 μM) ± SP (10 nM). Top: Representative immunoblots of 
Hsp27, Hsp40, Hsp90 and c-fos of various treatment groups. Below: Bar graphs 
showing densitometric analysis of protein changes. Values expressed as means ± SE 
from five independent experiments. BSO, buthionine sulfoximine; SPIRO, 
spironolactone; Hsp, heat shock protein. *P<0.05 vs No Rx; †P<0.05 vs BSO. 
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7.3.7 Low-dose SPIRO regulates MR genomic signaling  
The mechanism by which low-dose SPIRO modulates oxidative stress is not known. We 
have shown that MR blockade with SPIRO modifies oxidant stress (Figure 7.1 & 7.7) 
and transcription of a number of genes during the myocardial response to reperfusion 
injury (Figure 7.3-7.5 & 7.9).  To link the observed changes in transcription with low-
dose SPIRO to the observed regulation of oxidative stress (Figure 7.1) we added 
actinomycin D (1 μM) to the perfusate to prevent transcription in response to MR 
activation.  Sgk-1 and PAI-1 mRNA expression were analysed by qRT-PCR from total 
RNA. Actinomycin D suppressed the induction of Sgk-1 and PAI-1 by reperfusion 
injury (Figure 7.11), indicating the transcription in response to MR activation had been 
ablated.  The inhibition by actinomycin D was more complete than that of SPIRO alone 
(combination group, Figure 7.11), suggesting pathways other than MR also regulate 
these genes.  However, under these experimental conditions it is clear that the genomic 
response to MR activation in these hearts was clearly prevented. 
 
When we examined the levels of cardiac damage following I-R, perfusion of rat hearts 
with low-dose (10 nM) SPIRO significantly reduced infarct size (Figure 7.12). 
However, contrary to transcriptional data, actinomycin D did not reverse the protection 
(reduction in infarct size) established by low-dose SPIRO treatment (Figure 7.12). 
These data indicate that low-dose SPIRO modifies oxidative stress and cardiac damage 
through a largely non-genomic signaling pathway. This conclusion is of course 
tempered by the fact that the inhibition of all gene transcription with actinomycin D 
may also suppress signalling pathways that occur during I-R that induce detrimental 
effects. 
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Figure 7.11: Low-dose SPIRO regulates MR genomic signaling.  
Transcription inhibitor, actinomycin D (1 μM) perfused 15 minutes prior to SPIRO (10 
nM) addition. mRNA expression of (A) Sgk-1 and (B) PAI-1 by qRT-PCR, normalized 
by Gapdh. I-R, ischaemia-reperfusion; ActD, actinomycin D; SPIRO, spironolactone; 
Sgk-1, serum/glucocorticoid regulated kinase 1; PAI-1, plasminogen activator inhibitor-
1. Values are means ± SE; Number in parentheses indicate the number of animals in 
each group; †P<0.05 vs I-R; ‡P<0.05 vs SPIRO 10 nM. 
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Figure 7.12: Low-dose SPIRO reduces infarct size and persists in the presence of 
actinomycin D.  
Isolated hearts were subjected to regional ischemia (30 minutes) followed by 
reperfusion (150 minutes). Actinomycin D (1 μM) perfused 15 minutes prior to SPIRO 
(10 nM) addition and maintained throughout I-R. At the completion of reperfusion, 
infarct size measured and expressed as the percentage of infarct area (IA) relative to 
area-at-risk (AAR). I-R, ischaemia-reperfusion; ActD, actinomycin D; SPIRO, 
spironolactone. Values are means ± SE; Number in parentheses indicate the number of 
animals in each group; †P<0.05 vs I-R. 
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7.4 Discussion 
Oxidative stress and ROS formation are key cellular events in myocardial reperfusion 
injury (Raedschelders et al., 2012). Similar to previous reports (Ferrari et al., 1990; Hsu 
et al., 2009; Singh et al., 1989), we found redox imbalance is an early event during 
reperfusion of ischemic hearts (Figure 7.1). Perfusion of isolated rat hearts with low-
dose SPIRO (10 nM), prior to ischaemia, significantly reduced oxidative stress and 
maintained redox balance (Figure 7.1). I-R injury also up-regulates expression of 
immediate-early genes and their encoded proteins (Figure 7.4) (Brand et al., 1992; 
Plumier et al., 1996). However, no reports have linked MR blockade to the expression 
of these genes and associated proteins during myocardial I-R injury. Our study showed 
low-dose (10 nM) SPIRO prevents the up-regulation of immediate-early gene 
transcription by oxidant stress in both ex vivo (Figure 7.4) and in vitro (Figure 7.9 & 
7.10) models. 
 
The effects of MR antagonism on oxidative stress have been previously studied in 
animal models of increased tissue renin-angiotension system (RAS) activation and 
elevated aldosterone levels (Ren2 rats) (Lastra et al., 2008), in diabetic hypertensive rats 
(Pessoa et al., 2012) and myocardial infarction (Sartorio et al., 2007). These studies 
examined the chronic impact of MR blockade and found that both low-dose (0.24 
mg/day) SPIRO and high-dose (100 mg/kg/d) eplerenone reduce NADPH oxidase 
activity and superoxide generation (Lastra et al., 2008; Sartorio et al., 2007). Similarly, 
chronic treatment with SPIRO (50 mg/kg/d) for eight weeks reduces NADPH-mediated 
superoxide generation, maintains glutathione redox balance and increases of G6PD 
activity in diabetic nephropathy tissue (Pessoa et al., 2012). No studies have examined 
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the direct effects of low-dose MR blockade on vascular oxidative stress in the early 
phase post-MI. Our results are novel and show low-dose (10 nM) SPIRO, in the absence 
of other steroids, modifies oxidative stress by attenuating NADPH-mediated superoxide 
generation, reducing NAD+ levels and restoring redox balance (GSH/GSSG ratio) 
during reperfusion injury (Figure 7.1). Contrary to previous studies that have shown 
SPIRO enhances G6PD activity in aorta tissue (Leopold et al., 2007) and in diabetic 
nephropathy (Pessoa et al., 2012), we did not observe any changes with G6PD 
transcripts neither during I-R nor with SPIRO treatment (Figure 7.2). This could be due 
to differences in experimental conditions and tissue-specific effects of G6PD. Other 
reason may be that SPIRO regulated activity of G6PD (Leopold et al., 2007; Pessoa et 
al., 2012) but did not alter its transcription expression as shown in our current studies. 
 
The mechanisms by which treatment with SPIRO restores redox balance are not fully 
identified, however, it likely involves the restoration of key regulators of mitochonrial 
biogenesis such as PGC-1α and PGC-1β and ROS generation. Levels of PGC-1α and 
PGC-1β are usually highly expressed in tissues with abundant mitochondria and 
oxidative metabolism, such as the heart and believed to contribute significantly to 
maintaining baseline mitochondrial and cardiac contractile function in congestive heart 
failure (Garnier et al., 2003) and pressure overload hypertrophy (Riehle et al., 2011). 
Acute MI substantially decreases expression of PGC-1α mRNA (Chen et al., 2012b; 
Sun et al., 2007). Similarly, we found mRNA levels of PGC-1α and PGC-1β rapidly 
decrease in reperfused myocardial tissue which was prevented with low-dose SPIRO 
treatment (Figure 7.3). Our finding is of interest in that low-dose SPIRO can reverse the 
process through an up-regulation of PGC-1α and PGC-1β expression very rapidly 
Results  Chapter 7 
 
Page | 223  
during MI and have not been previously examined. Our results imply that SPIRO 
directly modulates PGC-1α and PGC-1β expression, reducing ROS formation and 
oxidative stress through a mitochondrial pathway. This correlates with our findings in 
the previous chapter, in which, low-dose SPIRO also prevents apoptosis by inhibiting 
mitochondrial apoptotic pathway (see chapter 6). Furthermore, MR blockade with 
SPIRO may impact on the modulation of oxidative stress because PGC-1α and PGC-1β 
are coactivators of MR (Knutti et al., 2000). Additional studies are required to clarify 
the role of MR coactivators PGC-1α and -1β interact with oxidative stress during MI. 
 
Expression of immediate-early genes, and their encoded proteins, play important roles 
in regulating cell survival or death through activating/inhibiting inflammation and 
apoptosis after MI (Dybdahl et al., 2005; Efthymiou et al., 2004; Schenkel et al., 2010; 
Zhang et al., 2013). Immediate redox-sensitive genes are rapidly activated in response 
to oxidative stress-induced by I-R. Similar to previous reports (Nelson et al., 2002; 
Plumier et al., 1996; Zhang et al., 2013), we found I-R injury significantly increased 
expression of Hsp and c-fos genes, which translated to increased protein levels; in 
particular Hsp27, Hsp40, Hsp90 and c-fos. Interestingly, Hsp40 and Hsp90 are co-
chaperones for MR and also involved in regulation of ROS production and apoptosis 
(Chen et al., 2011; Lanneau et al., 2008) while Hsp27 has multiple actions, including 
protection against I-R injury by regulating redox state and mitochondrial-mediated 
apoptosis (Arrigo, 2001; Efthymiou et al., 2004; Tan et al., 2009). Similarly, c-fos is a 
key transcriptional factor involved in regulation of apoptosis or cell survival in MI 
(Gidh-Jain et al., 1998; Preston et al., 1996; Zhang et al., 2013). MR antagonism, with 
low-dose SPIRO, inhibited the effect of oxidative stress on expression of these redox-
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sensitive genes (Figure 7.4). This effect of low-dose SPIRO are maintained under high 
oxidant stress-induced by BSO (Figure 7.9 & 7.10), confirming MR blockade directly 
modulates these redox-sensitive molecules. To our knowledge, no reports have shown 
MR to regulate these immediate redox-sensitive genes in association with I-R stress. 
 
We also found up-regulation of MR-responsive transcripts (Sgk-1 and PAI-1) induced 
by I-R in isolated rat hearts (Figure 7.5) and BSO treatment in H9c2 cells (Figure 7.8). 
What is interesting about these results is that MR activation occurred in the absence of 
ligand since these perfusates (heart) or culture media (H9c2 cells) contain no added 
steroids. MR antagonism with SPIRO blocked the effects of both I-R and BSO 
suggesting MR activation is mediated by oxidative stress and independent of ligand 
binding. Our studies, indicating BSO-induced oxidative stress mediates MR activation 
are supported by previous reports (Nagase et al., 2012). Furthermore, our findings 
suggest that during tissue damage, such as I-R injury, increased oxidative stress (or 
accumulation of ROS) activates MR which, in turn, promotes further ROS generation 
and aggravates tissue damage. Blockade of the receptor with antagonists prevented MR 
activation and thus reduced ROS formation or damage. In support of this hypothesis 
MR antagonism with SPIRO alone significantly reduced apoptosis and tissue damage 
induced by I-R, whereas, the free radical scavenger tempol did not affect apoptosis and 
infarction (Mihailidou et al., 2009). However, both SPIRO and tempol prevent 
aldosterone and cortisol aggravated cell death and tissue damage following I-R 
(Mihailidou et al., 2009), implicating MR signal transduction enhanced by oxidative 
stress. Taken together, this suggests that the cardioprotective effects of SPIRO involve 
both a reduction in ROS formation as well as blockade of MR activation. 
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MR signaling is often linked to the pathogenesis of multiple diseases, including 
hypertension, inflammation and fibrosis. Interestingly, oxidative stress has numerous 
regulatory targets in these same processes (including apoptosis). Therefore it is 
important to further explore the target network of oxidative stress and MR signaling. 
Our findings in the previous chapter showing that the anti-apoptotic protein ARC is a 
target of MR regulation and SPIRO prevents activation of mitochondrial (intrinsic) 
apoptosis signaling pathway during I-R through preservation of ARC expression 
(chapter 6) is a new target network. ARC degradation is promoted by oxidative stress 
(Nam et al., 2007) leading to myocyte death (Ekhterae et al., 1999; Nam et al., 2007b; 
Zhang and Herman, 2006). The exact mechanisms of how low-dose SPIRO prevents 
loss of ARC during I-R is not known; however, we propose the cardioprotective 
mechanism by which low-dose MR blockade protects against reperfusion injury is due 
to both prevention of ROS formation (restoration of redox balance through maintaining 
mitochondrial biogenesis and preventing MR activation) and direct transcriptional 
control over myocardial programming. This, in turn, prevents ARC degradation and 
myocytes apoptosis, leading to reduction in cardiac damage following I-R. 
 
Furthermore, our results indicate an approximately 40% of the protective effect by low-
dose SPIRO is derived from the anti-oxidant effects and ~60% from other sources, such 
as direct genomic effects of MR-mediated transcription (Figure 7.3-7.5, 7.9) or through 
non-genomic effects (ROS, ERK1/2 activation) manifest through different receptors 
such as GPR30 (see chapter 5). The genomic response of SPIRO-mediated MR 
signaling in the ex vivo hearts was suppressed by actinomyocin D (Figure 7.11). 
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However, contrary to transcriptional data, actinomycin D did not reverse the protection 
of low-dose SPIRO treatment on cardiac damage (Figure 7.12), suggesting that low-
dose SPIRO protects against reperfusion injury via other pathways than just MR 
genomic signaling. Previous studies have demonstrated that MR-induced superoxide 
production by the non-genomic activation of NADPH oxidase and Rac1 in endothelial 
cells and cardiomyocytes (Iwashima et al., 2008; Nagase et al., 2012). In addition, our 
results in chapter 5 showed non-genomic effects of aldosterone via a membrane 
receptor, GPR30, resulting in ERK1/2 phosphorylation and ROS production. Increased 
ROS production, in turn, induces MR activation and signal transduction. Importantly, 
we demonstrated that MR genomic signalling is required for mediating cardiac damage 
during MI (see chapter 5). Taken together, these data indicate that the cardioprotective 
action of low-dose SPIRO is mediated through the balance of both non-genomic and 
genomic signaling, by modifying oxidative stress, and controlling transcription and 
protein synthesis, leading to reduced cardiac damage. 
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Advances in treatment strategies have decreased heart disease; however, it still remains 
the leading cause of death globally. Myocardial infarction (MI) is the primary 
contributor to this mortality. Using an experimental model of MI, several novel findings 
have been reported in this thesis, including gender dependent shift in the balance 
between autophagy and apoptosis, leading to cardiomyocyte death and aggravated 
cardiac damage in males.compared to age-matched females. Treatment with low dose 
mineralocorticoid receptor (MR) antagonists significantly reduced cardiac damage 
following MI. The findings in this thesis identify novel mechanisms of action for low 
dose MR antagonists during MI by modulating redox balance and immediate early gene 
transcription, preventing degradation of the anti-apoptotic protein ARC, leading to 
decreased apoptosis and reduce reperfusion damage. These novel mechanisms may 
explain the ability of low dose MR antagonists such as spironolactone and eplerenone to 
reduce mortality observed with clinical studies in patients with heart failure and heart 
failure post-MI (Pitt et al., 2003; Pitt et al., 1999; Zannad et al., 2011).  
 
Our studies to examine the role of androgens in sex differences in cardiac damage 
during MI are novel since they have demonstrated for the first time that sex steroids, 
specifically testosterone, influence the balance between autophagy and apoptosis in the 
heart. These data imply that endogenous testosterone levels represent a critical risk 
factor for IHD in adult males and support previous studies (Bener et al., 2013; 
Papakonstantinou et al., 2013; Tunstall-Pedoe, 1998; Wingard et al., 1983) which show 
higher death rates due to IHD in men than age-matched women. Thus serum 
testosterone levels play an important role in the development of coronary heart disease 
and levels should be monitored. In addition, our results suggest that the severity of IHD 
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should be judged by different markers in males compared to females. Our data highlight 
the importance for future development of new therapies that address male and female 
differences in response to IHD. Moreover, clinical trials should incorporate a higher 
percentage of female patients so that they become sufficiently powered to determine the 
gender differences in treament.  
 
Increasing evidence suggests that hormones such as mineralocorticoids play significant 
role in regulating the adverse outcomes of MI. As such, elevated serum aldosterone 
levels have been associated with adverse outcomes following AMI (Beygui et al., 2006; 
Beygui et al., 2009; Milliez et al., 2005; Napoli et al., 1999; Palmer et al., 2008).  
Although the mechanisms by which aldosterone promotes adverse outcomes of acute 
MI have been well documented, the contribution of aldosterone-mediated non-genomic 
signalling to the enhanced cardiac damage following MI is not known. In chapter 5, we 
demonstrated that the aggravation of cardiac damage by aldosterone during I-R occurs 
via activation of a MR-mediated genomic response. 
 
The physiological role of GPR30 in cardiovascular disease is unclear by the fact that 
multiple ligands activate this receptor. GPR30 is also a membrane-bound oestrogen 
receptor (Prossnitz et al., 2007; Revankar et al., 2005) with low affinity for oestrogen 
(10-7 M). However, this concentration of oestradiol is higher than any concentration 
seen in vivo; thus, GPR30 cannot be a functional physiological receptor for oestrogen. 
Female GPR30 knockout mice display elevated blood pressure resulting in the 
hypothesis that GPR30 mediates the effect on blood pressures (Martensson et al., 2009). 
However, aldosterone promotes hypertension and the data from the GPR30 mice offer 
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an interesting concept of the physiological role of GPR30.  Control of blood pressure by 
aldosterone is thought to occur through MR activation by its ligand. Thus, if GPR30 
acted as a physiological receptor for extracellular aldosterone this would create an 
environment where less aldosterone was available for MR activation. In the GPR30 null 
mice this mechanism would be abolished due to deletion of GPR30, raising free 
aldosterone levels and resulting essential hypertension as observed in these mice 
(Martensson et al., 2009). Clearly further experiments are required to validate this 
hypothesis. 
 
Our results showing treatment with low-dose MR antagonists protects the heart during 
MI which correlate with the large randomised trials where low levels of MR antagonists 
added to standard therapy significantly reduced morbidity and mortality in patients with 
progressive heart failure and heart failure post-MI. What is interesting about these 
clinical studies is that the cardioprotective action of MR antagonists occurred in the 
absence of other steroids, with plasma levels of aldosterone in the low-normal 
physiological range (0.25 – 0.4 nmol/l) (Rousseau et al., 2002) similar to our studies 
described in chapter 6 & 7. The studies in chapter 6 & 7 of this thesis identified 
molecular mechanisms of how low-dose MR blockade protect the heart during MI.  
 
Chapter 6 addressed the effects of MR blockade on apoptosis during MI and we 
discovered a novel mechanism of cardioprotective action of low dose MR antagonists to 
regulate ARC stability and therefore modulate the initiation/inhibition of apoptosis 
during myocardial I-R injury. This is a direct effect of MR interacting with the anti-
apoptotic protein ARC. Hence when levels of aldosterone are elevated, MR activation 
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aggravates cardiac damage and faster progression to failure due to degradation of ARC 
and myocyte loss.  
 
The physiological significance of ARC in MR signalling is unclear, especially in the 
heart where ARC is expressed predominantly in the cardiomyocytes, while MR is 
basally occupied by endogenous glucocorticoids in cardiac myocytes, due to the 
absence of the 11β-HSD2 enzyme. Under normal condition, there is no signalling and 
MR-ARC complex formation is high. Thus, association with ARC may prevent binding 
of other MR co-activators or prevent MR translocation to the nucleus. The second 
hypothesis is that in the SPIRO treatment group, more MR-ARC complexes were 
observed in the nucleus and this would correlate with inhibition of MR transcriptional 
activity and nuclear export. It is possible that a change in the confomational of MR 
through the effects of oxidative stress may promote loss of the binding site for ARC. 
Thus, the hypothesis is that the high level of ARC expression in cardiac tissue may 
prevent basal MR signalling providing a novel level of regulation by which the 
damaging influence of MR activation in the heart is removed; however, further studies 
are required to examine this hypothesis. 
 
Concurrently in chapter 7, we examined whether treatment with low-dose MR 
antagonists modify oxidative stress and immediate early gene transcription during MI. 
In line with effects on apoptosis, perfusion of isolated rat hearts with low-dose (10 nM) 
spironolactone significantly attenuated activation of immediate transcription factors and 
maintained redox balance. Importantly, spironolactone prevented the I-R induced 
activation of PGC-1α and PGC-1β, key regulators of mitochondrial biogenesis and ROS 
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generation. In addition, MR activation was promoted in response to I-R, as indicated by 
increased expression of Sgk-1 and PAI-1 transcripts, even in the absence of exogenous 
ligands.  These results suggest that MR are activated by oxidative stress or redox 
imbalance during I-R, and support previous studies (Nagase et al., 2012; Shibata et al., 
2008) which indicate a ligand-independent pathway of MR activation.  This pathway 
involves the activation of the NADPH oxidase subunit Rac1 by oxidative stress. The 
effects of Rac1 on MR are blocked by MR antagonists. Future studies are needed to 
elucidate the precise mechanisms of how MR is regulated by Rac1 during MI. 
 
Increasing evidence suggests that autophagy plays an important role in controlling cell 
survival during reperfusion injury. Given apoptosis and oxidative stress (mechanisms 
activated during I-R) are regulated by aldosterone (see chapter 5), and protected by low-
dose MR antagonists treatment (see chapter 6 & 7), it would be important to document 
whether the protective action of low-dose MR antagonists is also mediated by alteration 
is autophagy during I-R injury. Currently the effects of MR activation on autophagy 
during I-R are unexplored.  
 
Although the findings in this thesis have defined the mechanisms for cardioprotective 
action by low-dose MR antagonists, these studies were performed only in males 
(chapter 6 & 7). As outlined in chapter 4, there is gender disparity in the modulation of 
cardiac damage during I-R. Therefore, it is important to examine the mechanisms for 
low-dose MR blockade in females, to further our understanding of control mechanisms 
and treatment strategies for IHD in both genders. 
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Another extension of this thesis will be to examine the cardioprotective mechanism(s) 
and novel pathways of low-dose MR antagonists using in vivo models of MI. First, the 
in vivo MI models may include other steroids or factors in the blood that may alter the 
efficacy of low-dose MR antagonists. Since the enzyme 11β-HSD2, which converts 
cortisol into inactive cortisone is not expressed in cardiomyocytes (Sheppard and 
Autelitano, 2002), MR are normally occupied by endogenous glucocorticoids (cortisol 
in human and corticosterone in rodent) which act as MR antagonists (Gomez-Sanchez et 
al., 1990; Sato and Funder, 1996; Young and Funder, 1996). In tissue damage where 
there is increased in oxidative stress or ROS formation, cortisol has similar action to 
aldosterone to aggravate tissue damage (Mihailidou et al., 2009), although the 
mechanisms have not been defined. Future studies need to investigate the mechanisms 
for regulation of cortisol action during MI since clinically elevated levels of cortisol 
have been detected in patients with MI.  
 
An important approach is to determine whether the physiological MR antagonist 
progesterone and the synthetic progestin/potent MR antagonist drosperinone, as well as, 
the potent non-steroidal MR antagonists SM-368229 and BAY 94-8862, show 
protective responses similar to that of spironolactone and eplerenone during MI. 
Examining the protective mechanism(s) of various MR antagonists offer therapeutic 
options for the treatment of hypertension, acute myocardial infarction and heart failure. 
 
Overall, the findings from this thesis provide valuable insights into the molecular 
mechanisms of myocardial I-R injury and beneficial effects of treatment with low-dose 
MR antagonists during MI. The translation from this work is that guidelines recommend 
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MR antagonists are administered to patients with heart failure with or without 
myocardial infarction. Given the novel findings in this thesis, MR antagonists may be 
extended to other disease states (such as hypertension, obesity and diabetes) where there 
is increased oxidative stress, decreased ARC protein levels and increased apoptosis. 
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Appendices 
Buffer formulations 
Krebs-Henseleit Buffer 
- 118.0 mM NaCl 
- 4.7 mM KCl 
- 1.5 mM CaCl2.H2O 
- 1.2 mM KH2PO4 
- 1.6 mM MgSO4.7H2O 
- 24.9 mM NaHCO3 
- 11.1 mM glucose 
10x PBS (Phosphate Buffer Saline) 
- NaCl   80 g 
- KCl   2 g 
- Na2HPO4 14.4 g 
- K2HPO4  2.4 g 
- Make up to 1 L with milli-Q water 
- Check pH 7.6 
10X TBS (Tris Buffer Saline) 
- Tris Base  24.2 g 
- NaCl   80 g 
- pH 7.6 with HCl 
- Make up to 1 L with milli-Q water 
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RIPA Buffer 
- 50 mM Tris (pH 8.0) 
- 150 mM NaCl 
- 1% (v/v) TritonX-100 
- 1% (w/v) Na deoxycholate 
- 0.1% (w/v) sodium dodecyl sulphate (SDS) 
- 1 mM phenylmethyl sulfonyl fluoride (PMSF) 
- Protease inhibitor cocktail (Roche Applied Science) 
2x SDS Loading Buffer 
 Prepare loading buffer in milli-Q containing the following: 
- 125 mM Tris (pH 6.8) 
- 4% (w/v) SDS 
- 20% (v/v) Glycerol 
- 10% (v/v) 2-mercaptoethanol 
- 0.01% (w/v) Bromophenol Blue 
5x SDS (sodium dodecyl sulphate) Loading Buffer 
 Prepare loading buffer in milli-Q containing the following: 
- 312.5 mM Tris (pH 6.8) 
- 10% (w/v) SDS 
- 50% (v/v) Glycerol 
- 25% (v/v) 2-mercaptoethanol 
- 0.05% (w/v) Bromophenol Blue 
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Tris-Glycine running buffer 
- 25 mM Tris 
- 192 mM Glycine 
- 0.1 % (w/v) SDS 
- pH 8.3 
Tris-Glycine transfer buffer 
- 25 mM Tris 
- 192 mM Glycine 
- 10 % (v/v) Methanol 
TBST Washing Buffer 
- 1x TBS 
- 0.1% (w/v) Tween-20 
Blocking buffer 
- 1x TBS 
- 0.1% (w/v) Tween-20 
- 5% (w/v) non-fat milk powder 
Coomassie Blue staining for SDS-PAGE Gels 
Prepare staining solution in milli-Q water containing the following: 
- 0.25% (w/v) Coomassie Brilliant Blue R250 
- 40% (v/v) Methanol 
- 10% (v/v) Glacial Acetic Acid 
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Coomassie Blue destain solution 
Prepare destain solution in milli-Q water containing the following: 
- 40% (v/v) Methanol 
- 10% (v/v) Glacial Acetic Acid 
Stripping Buffer (for reprobing western blots) 
- 10% SDS    20 ml 
- 0.5 M Tris (pH 6.8)  12.5 ml 
- β-mecaptoethanol  0.8 ml 
- Milli-Q water   67.5 ml 
- Incubate membrane at 50°C for up to 45 minutes with some agitation 
50x TAE (Tris-acetate) 
- Tris Base      242 g 
- Glacial acetic acid   57.1 ml 
- 0.5 M EDTA (pH 8.0)  100 ml 
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Table A1: Details of primary antibodies and concentrations used in western blots 
(WB) and immunohistochemistry (IHC) 
Primary Antibody Manufacturer Cat # Dilution (IHC) 
Dilution 
(WB) 
α-Tubulin Santa Cruz Biotechnology Sc-5286 - 1:1000 
Actin Sigma A3853 - 1:2000 
Acinus p23 (NT) Santa Cruz Biotechnology Sc-5430 1:50 - 
Acinus (CT) AnaSpec 53206 1:50 1:500 
Annexin V Abcam Ab14196 1:50 - 
ARC Cayman Chemical 160737 1:100 1:1000 
AR Santa Cruz Biotechnology Sc-816 - 1:500 
Atg5-Atg12 Sigma-Aldrich A2859 - 1:1000 
Bcl-2 Santa Cruz Biotechnology Sc-7382 - 1:1000 
Bcl-xL Santa Cruz Biotechnology Sc-634 - 1:1000 
Beclin-1 Cell Signaling 3738 - 1:1000 
Caspase-2 Abcam Ab18737 - 1:500 
Caspase-3 (active) Abcam Ab2302 1:50 - 
Caspase-3 Cell Signaling 9662 - 1:500 
Capase-8 Abcam Ab15552 - 1:200 
Caspase-9 Cell Signaling 9506 - 1:500 
c-fos Abcam Ab7963 1:50 1:1000 
Desmin Abcam Ab8592 1:50 - 
ERα Santa Cruz Biotechnology Sc-542 - 1:500 
ERβ Santa Cruz Biotechnology Sc-8974 - 1:500 
ERK1/2 Cell Signaling 9102 - 1:1000 
Phospho-ERK1/2 
(Thr202/Tyr204) Cell Signaling 9101 - 1:1000 
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GPR30 Santa Cruz Biotechnology Sc-48524 - 1:500 
HSP25/27 Cayman Chemical 12215 - 1:5000 
HSP40 Cell Signaling 4868 - 1:1000 
HSP90 Cayman Chemical 19615 - 1:1000 
ICAD (CT) Santa Cruz Biotechnology Sc-6866 - - 
ICAD (NT) AnaSpec 28043 - 1:500 
LC3A/B Cell Signaling 4108 - 1:1000 
MR Santa Cruz Biotechnology Sc-11412 - 1:500 
MR1-18 1D5 Prof. Gomez-Sanchez’s Lab - 1:20 1:100 
MR1-18 6G1 Prof. Gomez-Sanchez’s Lab - 1:20 1:100 
mTOR Cell Signaling 2972 - 1:500 
Phospho-mTOR 
(Ser2448) Cell Signaling 2971 - 1:500 
RAGE Abcam Ab3611 1:100 1:1000 
XIAP Cell Signaling 2042 - 1:500 
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Table A2: Formulation for sodium dodecyl sulphate (SDS) - separating and 
stacking gels 
Components 
Separating gel Stacking gel 
7 % 10 % 12 % 4 % 
30% Acrylamide:bis (29:1) 5.83 mL 8.3 mL 10 mL 1.3 mL 
1.5 M Tris, pH 8.8 6.25 mL 6.25 mL 6.25 mL - 
1.0 M Tris, pH 6.8 - - - 2.5 mL 
10% (w/v) SDS 0.25 mL 0.25 mL 0.25 mL 0.1 mL 
MilliQ Water 12.53 mL 10.01 mL 8.36 mL 6.04 mL 
10% (w/v) AMPS 125 μL 125 μL 125 μL 50 μL 
TEMED 12.5 μL 12.5 μL 12.5 μL 10 μL 
Total Volume 25 mL 25 mL 25 mL 10 mL 
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